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ABSTRACT 
Hypoxanthine-guanine phosphoribosyltransferase (HPR T) catalyses the first step in purine 
salvage. A complete deficiency of the enzyme results in the devastating neurological 
symptoms of the Lesch-Nyhan syndrome. The Lesch-Nyhan syndrome is characterised by 
purine overproduction leading to , hyperuricemia and gout and a central nervous system 
disorder characterised by severe , spasticity, choreoathetosis, mental retardation and 
compulsive self-mutilatory behaviour, A partial deficiency of the enzyme results in purine 
overproduction , gout and occasionally, mild neurological symptoms. Patients are spared 
the compulsive self-mutilation of the Lesch-Nyhan syndrome. 
The major part of the thesis consists of the characterisation of the molecular defects in 
nine patients with the Lesch-Nyhan syndrome. The polymerase chain reaction was used to 
amplify reverse transcribed HPRT mRNA. The coding region of the amplified HPRT 
cDNA was either directly sequenced, or cloned and sequenced. All the mutations 
characterised were insertion or deletion events which resulted in premature termination of 
the predicted protein. Three patients were found to have a deleti9n of exon 7, two 
patients had single base insertions, while two patients appeared to have a complete 
deletion of the HPR T gene. An insertion in one patient was the result of a mutation within . 
intron 6 which created a new splice donor site. The new splice donor site in concert with 
a cryptic splice acceptor resulted in the creation of a new exon. A deletion of exons 2, 3 
and 4 in another patient was found to lead to the alternative splicing of exon 5. These 
unusual splice junction mutations provided in viva support for the exon definition model 
of pre-mRNA splicing. 
Four patients with partial HPRT deficiency were characterised at the biochemical and 
molecular levels. An Alal61 to Ser and a similar Ala161 to Gly substitution were identified 
in two patients with partial HPRT deficiency. These HPRT variants showed normal 
substrate affinities, but marked thermal instability. A substitution of Aspm by Asn was 
defined in HPRTcape Town, a variant HPRT enzyme characterised by purine base inhibition. 
The carboxylate residue is located at the center of the PRPP binding motif within the 
active site of the enzyme and is proposed to interact with the pyrophosphate moiety of 
PRPP during catalysis. No defect within the HPRT cDNA of a fourth patient with 
apparent partial HPRT deficiency could be detected. 
The incorporation by cultured cells of [14C] hypoxanthine relative to a [3H] control 
substrate such as phenylalanine, is a rapid method for the diagnosis of complete HPRT 
deficiency. However, the major physiological variation in the incorporation of purine base 
substrates shown by cells in culture has led us to question the validity of double label 
methods in the diagnosis of partial HPRT deficiency. The incorporation by cultured 
lymphoblasts of the label pairs, [14C] hypoxanthine and [3H] phenylalanine, or 
[14C] hypoxanthine and [3H] adenine, were analysed in a nested analysis of variance. 
Large between experiment variation in the incorporation of the label pair [14C] 
hypoxanthine and [3H] phenylalanine masked differences between control and partially 
HPRT deficient cell lines. Due to large variation between individual cell lines within an 
experiment for the ratio [14C] hypoxanthine/[3H] adenine, it was necessary to pool data 
from repeated experiments in order to correctly identify cell lines as partially deficient in 
HPRT. The unexpected large variation in purine label incorporation by cultured 
lymphoblasts suggests that a diagnosis of partial HPRT deficiency should not be made on 
the basis of a single double label experiment. 
The rate of PRPP accumulation in erythrocytes of patients with gout was measured under 
conditions of pathophysiologically low pH and non-physiologically high external inorganic 
phosphate. Preliminary evidence suggests that three of four patients identified with 
overproducing gout had increased rates of erythrocyte PRPP accumulation in vitro. An 
unexpected finding was a significant decrease in the rate of PRPP accumulation in 
erythrocytes of patients with gout due to urate underexcretion. These results suggest that 
a generalised defect in anion transport across membranes cannot be excluded. 
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1. INTRODUCTION. 
1.1 Overview of the Thesis. 
The thesis is divided into three broad sections. The first deals with the molecular genetics 
of hypoxanthine-guanine phosphoribosyltransferase (HPR T) deficiency in nine patients 
with the Lesch-Nyhan syndrome. The biochemistry and the molecular genetics of four 
partially deficient HPRT variant enzymes in patients with gout comprises the second 
portion of the thesis. In the third section, the biochemical basis of primary overproducing 
gout is investigated. 
1.2 Overview of Purine Metabolism. 
1.2.1 De Novo Purine Synthesis. 
The pathways of purine de novo synthesis, salvage, interconversion and degradation have 
been comprehensively reviewed by Pallela and Fox (1989) and are shown in Figure 1.1. 
The compound 5-phosphoribosyl-a-1-pyrophosphate (PRPP) plays a central role in purine 
metabolism. PRPP condenses with L-glutamine to form B-phosphoribosylamine in the 
first committed step of de novo purine synthesis and PRPP is also the phosphoribosyl 
donor in the purine base salvage reactions catalysed by hypoxanthine-guanine 
phosphoribosyltransferase and adenine phospho-ribosyltransferase (APRT). In subsequent 
reactions of the de novo pathway, the purine ring is built in a stepwise fashion with 
contributions of a formyl unit from N10 -formyl tetrahydrofolic acid (Benkovic, 1984 ), an 
amide group from glutamine, contributions from bicarbonate and aspartate, and the further 
donation of a one-carbon unit from N10 -formyl tetrahydrofolic acid. Finally, the purine 
ring is closed by the exclusion of a water molecule and inosine monophosphate (IMP) is 
formed. IMP can be converted to either adenosine monophosphate (AMP) or guanosine 
monophosphate (GMP) in two-step energy requiring reactions. 
APRT, 
PRPP 
Ribose-5-P + ATP 
+ PRPP Synthetase 
PRPP 
Gin ~ AmidoPRT 
5-Phosphoribosyl-1-amine 
ATP, Gly ""-
formate ""-
ATP, Gin ""-
ATP ""-
CO2 
ATP ATP, Asp GTP 
t! formate H 
ADP AMP DA GDP 
A~P~ IMP 1~ XMP~ GU P 
AK ll S'NT ADA S'NTl [ s·Nr 
Adenosine ---- lnosine Guanosine 
l PNP PNP l HPRT 
Adenine Hypoxanthine PRPP Guanine 
: XO 
I 
' 2- 0H-Adenine 
x~~ 
Xanthine 
I 
: XO 
I 
I 
' 2,8-diOH-Adenine Uric Acid 
2 
Figure 1.1: An overview of purine metabolism. Only the first committed step of de 
novo purine synthesis catalysed by amidophosphoribosyltransferase (amidoPRT) is shown. 
Abbreviations for the enzymes, adenylosuccinate synthetase (ASS), adenylosuccinate lyase 
(ASL), adenylic acid deaminase (AMP DA), IMP dehydrogenase (IMP-D), GMP 
synthetase (GMPS), adenosine kinase (AK), 5'-nucleotidase (5'NT), purine nucleoside 
phosphorylase (PNP), adenosine deaminase (ADA), adenine phosphoribosyltransferase 
(APRT), hypoxanthine-guanine phosphoribosyltransferase (HPRT), guanase (GA) and 
xanthine dehydrogenase (XO) are indicated at the point of the reactions they catalyse. 
Substrates: adenylosuccinate (AS), 2-hydroxy-adenine (2-0H-adenine), 2,8-dihydroxy-
adenine (2,8-diOH-adenine ). 
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1.2.2 Purine Catabolism. 
Mononucleotides are converted to nucleosides by 5'-nucleotidases located on cell 
membranes and in the cytosol. Normal intracellular purine catabolism proceeds via 
various cytosolic 5' -nucleotidases, each with preferred activity towards a certain class of 
nucleoside monophosphates (Bontemps, 1988). Purine nucleoside phosphorylase (PNP) is 
able to cleave, in a reversible reaction, the purine nucleosides (guanosine, inosine and to a 
lesser extent xanthosine) to the purine bases (guanine, hypoxanthine and xanthine 
respectively) and ribose-1-phosphate. Adenosine is converted to inosine by adenosine 
deaminase. Any hypoxanthine which escapes salvage is converted to xanthine and then 
uric acid by xanthine oxidase. 
1.2.3 Purine Salvage Pathway. 
The phosphoribosyltransferase pathways are the most active in the salvage of preformed 
purine bases. The purine bases hypoxanthine, guanine and much less efficiently, xanthine, 
are salvaged by HPRT to form IMP, GMP and xanthosine monophosphate (XMP) 
respectively, while APRT salvages adenine. Under normal conditions, the two-step 
nucleoside phosphorylase-nucleoside kinase salvage pathway does not appear to be very 
active in most tissues. 
1.3 The Biochemistry of HPRT. 
Hypoxanthine-guanine phosphoribosyltransferase (HPRT EC 2.4.2.8, McKusick 25890), 
more commonly abbreviated to HPRT, catalyses the magnesium dependent transfer of a 
phosphoribosyl moiety from PRPP to the N9 nitrogen of the purine bases hypoxanthine or 
guanine, to form IMP or GMP respectively. In humans, up to 90% of purines are 
salvaged by HPRT (Stout and Caskey, 1989) resulting in a saving, compared to de novo 
purine synthesis, of 4 ATP molecules for each purine base salvaged. 
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1.3.1 Kinetics ofHPRT. 
Henderson et al (1968) performed kinetic studies on HPRT using dialysed haemolysates. 
Initial velocity experiments produced parallel double reciprocal plots when substrate 
concentrations of hypoxanthine and PRPP were mutually varied, which provided evidence 
for a ping pong mechanism in which the two substrates are not present on the enzyme 
simultaneously. They speculated that the reason for parallel double reciprocal plots in 
their initial rate experiments was a low ( <O .1) Ki to Km ratio for PRPP, which implies that 
any deviation from parallel lines in double reciprocal plots would be virtually impossible to 
detect. However, product inhibition patterns by inorganic pyrophosphate (PPi) as well as 
the observed PPi stimulation of IMP-hypoxanthine exchange suggested an ordered bi-bi 
reaction mechanism in which PRPP binds first and IMP leaves last, rather than a ping pong 
mechanism. 
Krenitsky et al (1969) purified HPRT fifty-fold from human erythrocytes and suggested 
that PRPP in the form of a di-magnesium salt rather than a mono-magnesium salt was the 
preferred substrate of the enzyme. The kinetic studies of Krenitsky and Papaioannou 
(1969) on purified HPRT showed features of both ping pong and ordered reaction 
mechanisms, depending on the magnesium concentration. They showed that the Ki to Km 
ratio for PRPP was greater than O. 1 and that initial velocity curves at low magnesium 
concentrations were non-parallel. Product inhibition by PPi was markedly influenced by 
the concentration of magnesium. PPi was an ineffective inhibitor at high concentrations of 
magnesium (5 mM) but at low magnesium concentrations (0.05 mM), PPi showed marked 
inhibition. As a result, they argued that data based on the use of PPi in inhibition studies 
such as those of Henderson et al (1969) were unsuitable for mechanistic interpretation. 
After preincubation of HPRT with PRPP, the addition of hypoxanthine resulted in an 
initial burst of IMP synthesis and this was taken as evidence for the existence of an 
enzyme-ribosylphosphate intermediate. They also showed that some nucleotide-base 
exchange could occur in the absence of PPi, and that PPi stimulation was non-hyperbolic, 
evidence against an ordered reaction mechanism. Inhibition by mononucleotides was 
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competitive with respect to Mg2PRPP and non-competitive with respect to hypoxanthine 
and provided evidence in agreement with Henderson et al (1968) that Mg2PRPP was the 
first substrate to add to the enzyme and IMP the last product to leave. Krenitsky and 
Papaioannou (1969) however postulated alternate reaction sequences, depending on 
magnesium salt concentration. At high magnesium concentrations, the predominant 
reaction sequence involves an enzyme-phosphoribosyl intermediate compatible with a ping 
pong reaction mechanism. At low magnesium concentrations, they suggested that the 
mono-magnesium salt of PRPP participates in an ordered reaction, but the di-magnesium 
salt of PRPP entered a ping pong reaction. 
Giacomello and Salemo, (1978) have provided the most definitive study of the kinetics of 
human HPRT to date. They studied the reaction catalysed by HPRT in the reverse 
direction. They proposed a sequential mechanism where the monomagnesium complexes 
of IMP and PPi bind to the enzyme in a rapid equilibrium random fashion, while the 
products of the reverse reaction, PRPP and hypoxanthine, then dissociate in an ordered 
sequence with first the purine base and then the magnesium complex of PRPP being 
released. MgPPi and MgIMP are competitive with respect to Mg2PRPP and non-
competitive with respect to hypoxanthine. Their results thus strongly supported an 
ordered bi rapid equilibrium random bi mechanism in good agreement with Henderson et 
al (1968). In summary, available evidence suggests that the substrates hypoxanthine and 
PRPP bind to human HPRT in an ordered sequence, with PRPP binding first. The 
products of the reaction, PPi and IMP are released from the enzyme in a random manner. 
It is possible that HPRT in other organisms may be characterised by different kinetic 
mechanisms, for example, Yaun et al (1992) have proposed an ordered bi-bi mechanism 
for schistosomal HPR T. 
Human erythrocyte HPRT has a reported true Km value for hypoxanthine and PRPP of 9. 9 
µM and 240 µM respectively (Henderson et al, 1968; Krenitsky and Papaioannou, 1969). 
A true Km value of 4 µM has been reported for guanine (Henderson et al, 1968). It should 
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be noted that the true Km for the two substrate reaction catalysed by HPRT is calculated 
from data generated by mutually varying the concentrations of both substrates, 
hypoxanthine and PRPP. The apparent Km is an estimate of the true Km and is more easily 
determined from substrate velocity curves, where one substrate is kept constant at a single 
saturating concentration, while the concentration of the other substrate is varied. 
1.3 .2 Enzyme Structure. 
Native human HPRT is a multimeric enzyme and exists predominantly as a tetramer of 
identical subunits (Holden and Kelley, 1978; Smithers and O'Sullivan, 1984). Under 
certain non-physiological conditions, the enzyme can exist as catalytically active dimers 
(Johnson et al, 1979). Wilson et al (1982b) have determined the complete amino acid 
sequence of the enzyme purified from human erythrocytes. After cleavage of the 
N-terminal methionine, the N-terminal alanine is acetylated, a feature characteristic of 
many soluble cytoplasmic enzymes. Each subunit is thus 217 amino acids long with a 
molecular weight of24 470. 
In 1994, Eads et al solved the three-dimensional structure of recombinant human HPRT 
with bound GMP using X-ray diffraction data to 2.5 A resolution. The enzyme monomer 
is composed often 8 strands and six a. helices. The enzyme contains a core region (amino 
acid residues 37-189, the amino acid sequence is numbered with the N-terminal alanine as 
residue 1) with a twisted parallel B sheet consisting of five B strands surrounded by four a. 
helices. The core region resembles a dinucleotide binding fold (Argos et al, 1983) and is 
equivalent to the core region observed by Scapin et al (1994) in the crystal structure of the 
related enzyme orotate phosphoribosyltransferase (OPRT). A long disordered loop of 
residues ( 103-117) is referred to as the flexible loop by the authors and is believed to 
move during catalysis. The sequences flanking the core region form a separate 
substructure which differs between HPRT and OPRT and appears to confer substrate 
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specificity. Above the core is a lobe that contains residues Glu-13 to Pro-37 and Asp-184 
to Ala-217. 
The interface between monomers in dimer formation involves interactions between 27 
residues on each subunit, contributed from strand B3, helix A3 and residues 196-200 and 
24-26. 
Eads et al (1994) described interaction between the conserved PRPP binding motif (amino 
acid residues 129-140) identified by Wilson et al (1983d) and Hershey and Taylor (1986) 
and bound GMP. The motif starts with hydrophobic residues which have no direct 
interactions with the active site. The side chains of Glu-133 and Asp-134 are located on 
the floor of the active site cleft below the ribose group. The 8 strand makes a sharp tum 
at Asp-134 to lead into a loop composed of the residues Asp-137 to Thr-141 which are 
involved in binding the 5'-phosphate group ofGMP. 
1.3 .3 Posttranslational Modification ofHPRT. 
Johnson et al (1982) identified three isoenzymes in erythrocytes, the relative quantities of 
which change as the cell ages. Modification of HPR T appears to be initiated in the 
reticulocyte and continues throughout the life span of the erythrocyte. Johnson et al 
pointed out that various combinations of modified and unmodified subunits in the native 
multimeric enzyme could account for the electrophoretic heterogeneity seen in 
preparations of erythrocyte HPRT. In contrast, only one electrophoretic form of the 
enzyme was present in lymphoblasts. At least three charge variant forms of HPR T 
purified from human brain have also been distinguished by Smithers and O'Sullivan (1984). 
These findings suggest that HPRT is subject to at least one posttranslational modification. 
One such modification defined in erythrocyte HPR T appears to be the time dependent 
deamination of asparagine at position 106 (Wilson et al, 1982a). 
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1. 3. 4 Tissue Distribution. 
HPR T is expressed in all tissue at relatively low levels, with the exception of the brain and 
testes. Testes had the highest specific activity of all tissues studied by Adams and 
Harkness (1976), with values almost a third higher than HPRT activity in cerebral cortex 
grey matter. Although high compared to most other tissue, HPR T activity in the basal 
ganglia was lower than in cerebral cortex grey matter, a result in conflict with an earlier 
study (Rosenbloom, 1967). It seems likely that high levels ofHPRT activity in a tissue are 
inversely correlated with a lower capacity to synthesize purines de novo (Stout and 
Caskey, 1989). 
1.4 The HPRT Gene. 
Jolly et al (1983) cloned and sequenced HPRT cDNA. The cDNA is just under 1350 
nucleotides long with a single open reading frame of 654 base pair (bp). The cDNA 
predicts a polypeptide of 218 amino acids (including the N-terminal methionine) with an 
amino acid sequence identical to that found by Wilson et al (1982b ). 
The human HPRT locus is located on the X-chromosome at Xq26-q27 (Pai et al, 1980). 
Edwards et al (1990) sequenced 57 kilobases (kb) of the human HPRT locus, including 
1676 bp upstream of the start codon and 15238 bp downstream of the termination codon. 
The gene is organised into 9 exons and 8 introns (Patel et al, 1986) and is shown in Figure 
1.2 Four HPRT-like non-functional pseudogenes have been localised to chromosomes 3, 
5 and 11 (Patel et al, 1984). 
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HPRT GENE STRUCTURE 
EXON (no . ) 2 3 4 5 6 7 8 9 
EXON ( b p) 1 4 5 106 184 66 18 82 46 76 637 
INTRON (kb) 13,8 1,8 13,4 3,9 3,0 4,0 0,2 1 , 6 
INTRON (no.) 2 3 4 5 6 7 8 
Figure 1.2: Structure of the HPRT gene. The nine exons are shown as rectangles 
with sizes in base pair (bp) shown above the cartoon and introns are shown as lines 
connecting the exons. The sizes of the 8 interconnecting introns in kilobases (kb) are 
shown below the cartoon. 
1.4.1 Regulation ofHPRT Gene Expression. 
The 5'-noncoding region of the HPRT gene is GC rich and lacks a TATA box and a 
CAAT sequence, two elements which play a regulatory role in transcription of most 
eukaryotic mRNAs. The 5'-flanking region does, however, contain three copies of the 
sequence 5'-CCGCCC-3', which is characteristic of the promoters of many housekeeping 
genes, as well as many viral promoters (Patel et al, 1986). There are 46 CpG sequences 
within 400 bases upstream of the translation start site and these CpG clusters are under 
methylated when the gene is active, and extensively methylated when the gene is inactive. 
This correlates with transcriptional silencing on the inactive X chromosome in female 
mammals (Wolf and Migeon, 1985). Homstra and Yang (1994) analysed the methylation 
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of individual cytosines in the 5'-CpG island of human HPRT on the active and inactive X 
chromosomes. The inactive allele is methylated at nearly all CpG nucleotides, except in a 
68 bp region containing 4 adjacent GC boxes which are unmethylated or partially 
methylated. This is in contrast with the gene for human phosphoglycerate kinase which 
shows complete methylation of all CpG sites in the 5' CpG island. 
A cis acting element from nucleotide (nt) -219 to nt -122 relative to the initiating codon is 
necessary for maximal expression of the gene and functions in both normal and reverse 
orientations, while a negative regulatory cis acting element is present in the region nt -570 
to nt -388 (Rincon-Limas et al, 1991). This suppresser element is also orientation 
independent, but appears to be distance dependent. It is interesting that not all the 
regulatory elements are located 5' to the coding region. An element in intron 2 was found 
to be required for effective expression of HPRT minigene constructs in embryonic stem 
cells and an element in intron 1 acts as an enhancer ofHPRT expression (Reid et al, 1990). 
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2. DEVELOPMENT OF MOLECULAR METHODS. 
2.1. Introduction. 
Total RNA was extracted from cultured fibroblasts or Epstein Barr virus transformed 
lymphoblasts and reverse transcribed using AMV reverse transcriptase in a reaction 
primed by an oligo dT 1s primer. The polymerase chain reaction (PCR) was used to 
amplify the coding region of HPRT cDNA using HPRT specific oligonucleotide primers. 
PCR products were directly sequenced or, when this did not give easily readable 
sequences, the PCR products were cloned and sequenced. 
2.1. 1 The Polymerase Chain Reaction. 
The polymerase chain reaction, first devised by Mullis and Faloona and described in detail 
in 1987, has simplified the detection and characterisation of mutations. Synthetic 
oligonucleotide sequence specific primers are annealed to heat denatured singled stranded 
target DNA in a buffer containing all four deoxynucleotide triphosphates (dNTPs). Mullis 
and Faloona (1987) used the thermolabile Kienow fragment of Esherichia coli (E coli) 
DNA polymerase I to extend the annealed primers. The newly synthesised DNA duplex 
was then denatured by heating, the reaction mixture cooled to allow the primers to anneal, 
more Kienow added to extend the annealed primer, recreating a double stranded DNA 
molecule. Each cycle of denaturing, annealing and extension results in a doubling of the 
number of double stranded DNA molecules present and a geometric accumulation of a 
primer defined segment of the target DNA. In 1988, Saiki et al substituted a thermostable 
DNA polymerase, Taq DNA polymerase, isolated from a thermophilic bacterium, Thermus 
aquaticus for Kienow. The use of a thermostable DNA polymerase enabled annealing and 
extension of the primer to occur at higher temperatures, increasing the specificity of the 
reaction and obviating the need to add more polymerase after each denaturing step. 
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2.1.2. Screening for Unknown Mutations. 
Two PCR based approaches were considered for determining the molecular defect 
responsible for HPRT enzyme deficiency: exon by exon screening and cDNA screening. 
Exon by Exon Screening. 
Each exon is amplified by a unique set of primers located in the 5' and 3' introns. The 
marked heterogeneity of mutations reported at the HPR T gene locus would necessitate the 
synthesis of nine primer pairs to screen each of the nine HPRT exons. Splice junction 
mutations would be detected and defined as a change in the sequence of the splice 
junction. Mutations within an intron, outside of the sequence defined by the primer pair 
would not, however, be detected. Structural deletions of all or part of the gene would not 
be detected directly, being seen rather as a failure to amplify one or more exons. 
A major advantage of exon by exon screening is that genomic DNA can be readily isolated 
from peripheral leukocytes and a source of preserved mRNA is not necessary. 
Screening at the cDNA level. 
Total RNA is extracted from nucleated cells, mRNA is reverse transcribed to cDNA using 
a reverse transcriptase and an oligo dT 1s primer and the coding region of the cDNA 
amplified using HPRT gene specific primers. The reverse transcribed mRNA represents a 
"summary" of the gene. The size of the amplified cDNA can sometimes serve as an 
indicator to the nature of the mutation. Mutations affecting splice donor and acceptor 
sites are detected as smaller or larger than normal PCR products caused by exon skipping 
or an insertion of an intron derived sequence respectively. These mutations however, 
would still need to be defined at the gene level. A PCR product of the predicted size 
suggests a small deletion or insertion event, or a point mutation. Mutations affecting the 
primer binding domains or mutations deleting the whole gene (null mutations) would be 
seen as a failure to amplify HPRT cDNA 
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A major disadvantage of screening cDNA is that a source of mRNA needs to be available. 
However, HPRT is ubiquitously expressed (Section 1.2.4.) and the availability of tissue 
culture material from all patients in this study, the greater sensitivity of cDNA screening 
compared to exon by exon screening in detecting a variety of mutational types, as well as 
the greater cost of synthesising nine primer pairs for exon by exon screening, suggested 
that the most efficient approach to screening for mutations at the HPR T gene locus was by 
cDNA screening. 
2.2 Materials. 
AMV reverse transcriptase, oligo dT 1s primer, deoxynucleotide triphosphates, proteinase 
K, restriction endonucleases and pUC 18 were purchased from Boehringer Mannheim 
GmbH, Germany. RNAsin, a ribonuclease inhibitor was obtained from Promega, 
Madison, Wisconsin, USA. Taq DNA polymerase was purchased from BRL, 
Gaitherburg, Maryland, USA, Stratagene, La Jolla, California, USA or Boehringer 
Mannheim GmbH, Germany. Vent DNA polymerase was obtained from New England 
Biolabs, Beverly, Massachussets, USA. DH5a E. coli cells were from GIBCO BRL, 
Gaitherburg, Maryland, USA. [35S] dATP was purchased from the Radiochemical Centre, 
Amersham, UK. 
Ultrafree-MC 30,000 and 100,000 NMWL filter units were obtained from Millipore 
Corporation, Bedford, Massachussets, USA. All other chemicals were of reagent or 
molecular biology grade. 
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2.2.1. PCR and Sequencing Primers. 
DNA oligonucleotide primers were synthesised on an automated DNA synthesiser by the 
Departments of Biochemistry or Medical Biochemistry, University of Cape Town, Cape 
Town, South Africa. 
The primers were designed using the computer software programme Oligo 3.4 (National 
Biosciences Inc, Plymouth MN, USA) and numbered according to the sequence shown in 
Figure 2.1 with the A of the ATG start codon numbered as base 1. A schematic 
representation of the position of the primers within the HPRT cDNA and the HPRT gene 
are shown in Figure 2.2, while the Tm and sequence for each primer are shown in Tables 
2.1, 2.2 and 2.3. 
The Tm in °C for each PCR and sequencing primer was calculated according to the 
formula: 
Tm= 4(G+C) + 2(A+T) 
where (G+C) is the number of guanines and cytosines in the primer sequence and (A+T) is 
the number of adenines and thymines in the sequence. 
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-90 -80 -70 
TCTTG CTGCGCCTCC GCCTCCTCCT 
-60 -50 -40 -30 -20 -10 
CTGCTCCGCC ACCGGCTTCC TCCTCCTGAG CAGTCAGCCC GCGCGCCGGC CGGCTCCGTT 
1 11 21 31 41 51 
ATGGCGACCC GCAGCCCTGG CGTCGTGATT AGTGATGATG AACCAGGTTA TGACCTTGAT 
61 71 81 91 101 111 
TTATTTTGCA TACCTAATCA TTATGCTGAG GATTTGGAAA GGGTGTTTAT TCCTCATGGA 
121 131 141 151 161 171 
CTAATTATGG ACAGGACTGA ACGTCTTGCT CGAGATGTGA TGAAGGAGAT GGGAGGCCAT 
181 191 201 211 221 231 
CACATTGTAG CCCTCTGTGT GCTCAAGGGG GGCTATAAAT TCTTTGCTGA CCTGCTGGAT 
241 251 261 271 281 291 
TACATCAAAG CACTGAATAG AAATAGTGAT AGATCCATTC CTATGACTGT AGATTTTATC 
301 311 321 331 341 351 
AGACTGAAGA GCTATTGTAA TGACCAGTCA ACAGGGGACA TAAAAGTAAT TGGTGGAGAT 
361 371 381 391 401 411 
GATCTCTCAA CTTTAACTGG AAAGAATGTC TTGATTGTGG AAGATATAAT TGACACTGGC 
421 431 441 451 461 471 
AAAACAATGC AGACTTTGCT TTCCTTGGTC AGGCAGTATA ATCCAAAGAT GGTCAAGGTC 
481 491 501 511 521 531 
GCAAGCTTGC TGGTGAAAAG GACCCCACGA AGTGTTGGAT ATAAGCCAGA CTTTGTTGGA 
541 551 561 571 581 591 
TTTGAAATTC CAGACAAGTT TGTTGTAGGA TATGCCCTTG ACTATAATGA ATACTTCAGG 
601 611 621 631 641 651 
GATTTGAATC ATGTTTGTGT CATTAGTGAA ACTGGAAAAG CAAAATACAA AGCCTAAGAT 
661 671 681 691 701 711 
GAGAGTTCAA GTTGAGTTTG GAAACATCTG GAGTCCTATT GACATCGCCA GTAAAATTAT 
721 731 741 751 761 771 
CAATGTTCTA GTTCTGTGGC CATCTGCTTA GTAGAGCTTT TTGCATGTAT CTTCTAAGAA 
781 791 801 811 821 831 
TTTTATCTGT TTTGTACTTT AGAAATGTCA GTTGCTGCAT TCCTAAACTG TTTATTTGCA 
841 851 861 871 881 891 
CTATGAGCCT ATAGACTATC AGTTCCCTTT GGGCGGATTG TTGTTTAACT TGTAAATGAA 
901 911 921 931 941 951 
AAAATTCTCT TAAACCACAG CACTATTGAG TGAAACATTG AACTCATATC TGTAAGAAAT 
961 971 981 991 1001 1011 
AAAGAGAAGA TATATTAGTT TTTTAATTGG TATTTTAATT TTTATATATG CAGGAAAGAA 
1021 1031 1041 1051 1061 1071 
TAGAAGTGAT TGAATATTGT TAATTATACC ACCGTGTGTT AGAAAAGTAA GAAGCAGTCA 
1081 1091 1101 1111 1121 1131 
ATTTTCACAT CAAAGACAGC ATCTAAGAAG TTTTGTTCTG TCCTGGAATT ATTTTAGTAG 
1141 1151 1161 1171 1181 1191 
TGTTTCAGTA ATGTTGACTG TATTTTCCAA CTTGTTCAAA TTATTACCAG TGAATCTTTG 
1201 1211 1221 1231 1241 
TCAGCAGTTC CCTTTTAAAT GCAAATCAAT AAATTCCCAA AAATTT 
Figure 2.1: Nucleotide sequence of HPRT cDNA. The nucleotide sequence of the HPRT cDNA 
is according to Jolly et al (1983). The coding region is in bold print, with the A of the ATG start codon 
numbered as base 1. 
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HPRT cDNA PRIMERS 
NPF 
OPF P1 b P3 
r 
ATG 312 471 TAA 663 696 
P5 P4 NPR OPR 
HPRT INTRON PRIMERS 
EXON (no.) 1 2 3 4 5 6 7 8 9 
H7 LN2 
H6 LN1 
INTRON (no . ) 2 3 4 5 6 7 8 
Figure 2.2: Position of PCR and sequencing primers within the HPRT cDNA 
and gene. The cDNA is represented as a rectangle in the upper panel, with the coding 
region defined by the start codon ATG and ending at the stop codon TAA. The forward 
or reverse direction of the primers is indicated schematically by the direction of the arrow, 
while the nucleotide position of the 3'-terminal base of each primer is indicated by the 
number within the rectangle. The lower panel shows the position of primers in the HPRT 
gene which were used to amplify a section of intron 6 (primers H6 and H7) and across 
exon 7 (primers LN I and LN2). 
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Table 2.1: cDNA PCR primers. 
PRIMER POSITION Tm SEQUENCE 
Pla F -12 14°c 5'-aatctGCAGTCAGCCCGCGCGCCGG-3 
cDNA PCR primer. Incorporates a 
Pstl site at the non-complementary 5' end 
Plb F -14 66°C 5'-aatctGCAGTCAGCCCGCGCGCC-3' 
cDNA PCR primer. Differs from Pla 
by lack of the GG at the 3' end 
P2 R+663 62 °C 5'-tGcgaaTTCCAAACTCAACTTGAACTC-3' 
cDNA PCR primer. Incorporates an 
EcoRI site at the non-complementary 5' end. 
OPF F-57 66°C 5'-CCTCCGCCTCCTCCTCTGC-3' 
cDNA outer forward PCR primer. 
OPR R+696 76°C 5'-TTGAT AATTTTTACTGGCGATGTC 
AATAG-3' 
cDNA outer reverse PCR primer. 
NPF F-33 68°C 5'-CCACCGGCTTCCTCCTCCTG-3' 
cDNA nested forward PCR primer. 
NPR R+663 64°C 5'-tGcgGaTcCCAAACTCAACTTGAACTC-3' 
cDNA nested reverse primer, same as P2 except for 
a BamHI site at the 3' end. 
Forward primers are designated F and reverse primers R The 3' terminal base of each primer used for 
cDNA amplification and sequencing is numbered according to the HPRT cDNA sequence published by 
Jolly et al, 1983, with the A of the initiation codon ATG numbered as base 1. Restriction endonuclease 
sites incorporated into the 5'-end of primers Pla, Plb, and P2 are underlined. Non-complementary bases 
at the 5'-end of primers Pla, Plb and P2 are shown as lower case letters and were not used in calculating 
the Tm using the formula shown in the text. 
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Table 2.2: cDNA sequencing primers. 
PRIMER POSITION Tm SEQUENCE 
P3 F+312 42°c 5'-TCAGACTGAAGAGC-3' 
P4 R+471 48°C 5'-CTTGCGACCTTGACC-3' 
PS R+300 42°c 5'-AGCTCTTCAGTCTG-3' 
Forward primers are designated F and reverse primers R. The 3' terminal base of each primer used for cDNA 
sequencing is numbered according to the HPRT cDNA sequence published by Jolly et al, 1983, with the A of the 
initiation codon ATG numbered as base 1. The Tm of each primer was calculated according to the formula shown in 
the text. 
Table 2.3: Primers for the amplification and sequencing of genomic DNA. 
PRIMER POSITION Tm SEQUENCE 
H6 F 36154 78°C 5'-TTGCTTATTTTTCTACATGCTCTTTAGGG-3' 
Forward primer for amplification of a segment 
of intron 6. 
H7 R 36385 66°C 5'-AAGCAGCACTGACGTGGGGTTC-3' 
Reverse primer for amplification of a segment of 
intron 6. 
LNl F 39634 10°c 5'-GTAGTGTCAACTCATTGCTGCCC-3' 
Forward primer located in intron 6 for amplification 
of exon 7. 
LN2 R 40187 68°C 5'-TCTGTTCAAATTATGAGGTGCTGG-3' 
Reverse primer located in intron 7 for amplification 
of exon 7. 
The 3' terminal base of each primer is numbered according to the numbering and sequence of the HPRT 
gene published by Edwards et al, 1990. Forward primers are designated F and reverse primers R. The Tm 
of each primer was calculated according to the formula shown in the text. 
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2.3. Methods. 
2.3 .1. DNA Extraction. 
High molecular weight genomic DNA was extracted from tissue culture material using a 
standard proteinase K-SDS method as described in Ausubel et al, 1994. 
2.3.2. RNA Extraction. 
Total RNA was extracted from cultured fibroblasts or lymphoblasts using the single step 
acid guanidinium thiocyanate - phenol - chloroform method modified from Chomzynski 
and Sacchi, 1987. All aqueous reagents which did not contain guanidinium thiocyanate 
were treated with diethylpyrocarbonate (DEPC) to destroy ribonuclease activity (Ausubel 
et al, 1994). 
Cells in an intact fibroblast monolayer or in a saline washed cell pellet were lysed in 1 ml 
of a denaturing solution containing 4 M guanidinium thiocyanate, 25 mM sodium citrate, 
pH 7, 0.5% N-lauroyl sarcosine and 0.1 M 2-mercaptoethanol. The lysate was passed 
through a 21 gauge needle several times to shear high molecular weight DNA and 
transferred to a polypropylene centrifuge tube. An equal volume ( 1 ml) of water saturated 
phenol and 0.2 ml of chloroform:isoamyl alcohol ( 49: 1) were then added. The suspension 
was then shaken vigorously for 10 s and cooled on ice for 15 min. The organic phase 
containing DNA and protein was then separated from the RNA containing aqueous phase 
by centrifugation at 10000g for 15 min at 4°C. RNA was recovered from the aqueous 
phase by the addition of 2 volumes of I 00% ethanol followed by precipitation at -80°C for 
30 min. The precipitate was pelleted by centrifugation at 10000g for 20 min, washed with 
75% ethanol made up with DEPC treated water and dried under vacuum. The dry pellet 
was then resuspended in 200 µl DEPC treated water, 400 µl I 00% ethanol was added and 
the RNA stored at -80°C. The RNA was recovered for cDNA synthesis by centrifugation 
after the addition 0.1 the original volume (20 µl) DEPC treated 3 M sodium acetate 
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pH 5.2, washed in 1 ml 75% ethanol, the pellet dried under vacuum and resuspended in 
200 µl DEPC treated water. The absorbance of a 10 µl aliquot in 490 µl water was 
measured at 260 nm and 280 nm. The 260 nm/280 nm ratio was used to detect the 
presence of contaminating proteins. A conversion factor of 1 absorbance unit = 40 µg 
RNNml was used to quantify the amount of RNA present. 
The quality of the RNA isolate was checked by electrophoresis on 1 % formaldehyde-
agarose gels using standard techniques (Ausubel et al, 1994). 
2.3.3. First Strand cDNA Synthesis. 
First strand cDNA was synthesised by a method modified from Ausubel et al, 1994. A 
typical reaction volume of 100 µl contained the following: 10 µg of total RNA annealed to 
5 µg oligo dT 1s primer or a HPRT cDNA specific primer (P2), 80 U AMV reverse 
transcriptase, 50 mmol/1 Tris-HCL pH 8.3, 60 mmol/1 KCL, 3 mmol/1 MgCL2, 10 µg 
bovine serum albumin, 5 U ribonuclease inhibitor, 5 mmol/1 dithiothreitol and 500 µmol/1 
of each of the four dNTPs. The reaction mixture was incubated at 42°C for 60 min, and 
stored at -20°C. 
2.3.4. Polymerase Chain Reaction. 
The standard PCR 100 µl reaction volume contained the following: 50 pmole of each 
PCR primer, 200 µM of each of dATP, dGTP, dCTP and dTTP, in a buffer containing 10 
mM Tris-HCL pH 8.3, 50 mM KCL, 0.01% gelatine and an appropriate amount of 
MgCL2 in the range 1. 5 mM to 5. 0 mM, as established for each primer pair by a MgCL2 
titration. The equivalent of 1 µg of total reverse transcribed RNA or 1 µg of genomic 
DNA was used for each reaction. cDNA synthesis or DNA extraction blanks were 
amplified for each patient to control for contamination during template preparation. 
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A PCR blank containing all the components of the reaction, except the template, was used 
as a control for contamination of the amplification reaction components. The reaction was 
overlaid with 70 µl mineral oil to prevent evaporation during 30 to 40 cycles of 
amplification. 
Primers. 
Primers were diluted to a concentration of 50 pmol/µl in TE buffer, divided into aliquots 
and stored at -20°C. 
Deoxynucleotide triphosphates. 
Each dNTP was prepared in sterile distilled water to a concentration of 20 mM and the pH 
adjusted to 8. Equal volumes of the four dNTPs combined to yield a final concentration 
of 5 mM for each dNTP. The combined dNTPs were then divided into aliquots and stored 
at -80°C. 
1 OX PCR Buffers. 
Two buffers at a lOx concentration were used: a lOX Tris/KCL/gelatine buffer was 
prepared from autoclaved stock solutions and contained 100 mM Tris-HCL pH 8.3, 
500 mM KCL, 0.1 % gelatine and a variable amount of MgCL2 in the range 15 to 50 mM. 
A second lOX buffer contained 1% Triton X-100 in 700 mM Tris-HCL pH 8.8 with 15 to 
50 mM MgCL2. The buffers were filter sterilised, divided into aliquots and stored at 
-20°C. A proprietary lOX detergent based buffer containing 15 mM MgCL2 supplied by 
some Tag polymerase vendors was also used. 
Thermostable DNA polymerase. 
Tag DNA polymerase from a variety of vendors was used at 2.5 U per standard 100 µl 
reaction volume. Vent DNA polymerase was used at 2 U per 100 µl reaction volume in a 
buffer supplied by the manufacturer. 
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Thermocyclers and Temperature Profile. 
Initially, an in house thermocycler, designed and manufactured by L. Purves and J. 
Thomthwaight of the Department of Chemical Pathology, University of Cape Town, was 
used. The instrument consisted of a carbon block with an array of holes drilled into the 
top to accommodate the PCR reaction vessels. The block was heated by the resistance of 
the carbon to the passage of an electrical current and cooled by allowing water to flow 
through a channel drilled through the center of the block. The machine was later replaced 
by two commercial thermocyclers: a Techne PHC-2 and a Techne Gene-E (Techne, 
Cambridge, UK). 
A typical temperature profile for the amplification of cDNA using primers Pla and P2 
consisted of: 
denaturation: 94°C 45 s to 1 min 
annealing: 
extension: 
57°C 45 s to 1 min 
72°C 2 min 13 cycles 
3 min 13 cycles 
4 min 13 cycles 
10 min 1 cycle 
A temperature 5 to 10°C below the lowest Tm of the pnmer pair being used in 
amplification was used as the annealing temperature. Stepped extension times were used 
to allow for degradation ofTaq polymerase during thermocycling. Generally, a 1 to 2 min 
extension time was allowed per 1000 bases of template to be amplified. 
NestedPCR. 
Primers OPI and OP2 were used to amplify cDNA in 40 cycles of amplification. One 
microliter of the PCR reaction served as template for a further 30 cycles of amplification 
using nested primers NPI and NP2. One microliter of a cDNA synthesis blank was 
carried through both amplification systems to control for contamination. 
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2.3.5. Agarose Gel Electrophoresis and Visualisation ofPCR Products. 
PCR products were separated by agarose gel electrophoresis in 1 X T AE buffer and 
visualised on a long wavelength UV light box after ethidium bromide staining. The 
concentration of agarose was varied between 1. 5% and 2% for standard agarose, 
depending on the size of the PCR products to be separated. Low melting point agarose or 
MetaPhor agarose (FMC BioProducts, Rocklands, ME, USA) was used at a concentration 
of2% to 3%, as appropriate for the size of the amplified product. 
Molecular Weight Markers for Gel Electrophoresis. 
Lambda DNA was digested to completion ( overnight at 3 7°C) with Hindl 11 or Dra 1, in a 
buffer supplied by the restriction endonuclease manufacturer. Hindl 11 digestion yielded 
fragment sizes of 23130, 9415, 6557, 4361 , 2322, 2027, 564 and 125 bp. Digestion with 
Dral produced fragment sizes of 8596, 8370, 7834, 6816, 6038, 3599, 2303, 2152, 1075, 
696, 533, 228, 174 and 90 bp. A commercial DNA marker, Bio Marker Low, with DNA 
fragment sizes 1000, 700, 500, 400, 300, 200, 100 and 50 bp, was purchased from Bio 
Ventures Incorporated, Murfreesboro, Tennessee, USA. 
2.3.6. Purification of PCR Products. 
2.3.6.1. Filtration Methods. 
Millipore Ultrafree-MC 30,000 and 100,000 NMWL filter units were used to separate 
high molecular weight PCR products from low molecular weight primers and primer 
dimers. Five I 00 µl PCR reactions were extracted with an equal volume of TE buffered 
phenol:chloroform:isamyl alcohol (25 :24:1). DNA in the aqueous phase was precipitated 
by the addition of 0.2 volumes 10 M ammonium acetate and 2 volumes of 100% ethanol. 
After incubation for 20 min at -80°C, the precipitate was recovered by centrifugation, 
washed with 70% ethanol and then dried under vacuum. The pellet was resuspended in 
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300 µI TE buffer and loaded into the cartridge of the filter unit and spun for 2 min at 
7500g in a variable speed fixed angle microfuge. The filtrate was discarded and the high 
molecular weight DNA retained by the membrane was then washed twice more with 
300 µl of TE. The DNA was r~overed from the membrane by rinsing with 20 µl TE 
buffer. 
2.3.6.2. Gel Purification Methods. 
Five 100 µl PCR reactions were combined, the mineral oil overlay removed by extraction 
with an equal volume of chloroform and the DNA in the aqueous phase ethanol 
precipitated. The DNA pellet was resuspended in 20 µl TE buffer and loaded into a single 
lane of an agarose gel. After electrophoresis, the gel was stained with ethidium bromide 
and the position of the DNA band to be isolated, visualised under UV light. Care was 
taken to avoid damaging DNA during UV visualisation by using a hand held, long 
wavelength, low intensity UV lamp. 
Electrophoresis onto DEAE Cellulose. 
Strips of DEAE cellulose were placed in two slits cut on either side of the DNA band. 
The DNA band was electrophoresed onto one strip of DEAE cellulose, while non-specific 
high molecular weight smearing, if present, was blocked by the other strip. DNA bound 
to the cellulose strip was then washed free of inhibitors present in the agarose using a high 
salt buffer and eluted in a low salt buffer as described in Ausubel et al, 1994. 
Electro-elution from agarose gel slices. 
Excised DNA containing agarose gel slices were tied into dialysis tubing containing 400 µl 
T AE buffer. The dialysis tubing was placed into the buffer tank of an electrophoresis 
apparatus and the DNA electrophoresed out of the gel slice at 100 volts for 10 min. The 
DNA containing buffer was then transferred to a microfuge tube, extracted with an equal 
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volume of phenol:chloroform:isoamyl alcohol and the DNA recovered by ethanol 
precipitation. 
Extraction of DNA from Agarose Gel Slices Using Commercially Available Kits. 
Two commercially available kits, Promega Magic or Wizard Prep (Promega, Madison, 
Wisconsin, USA) and Qiaex gel extraction kit (Qiagen, Hilden, Germany), both based on 
the binding of DNA in solubilised agarose gel slices to a proprietary DNA binding matrix, 
were also used. 
2.3.7. Re-amplification of PCR Products. 
Gel purified PCR fragments were serially diluted ( 1 : 100, 1 : 1000 and I : 10000) and I µl of 
the dilution was amplified for 30 cycles.. Care was taken to avoid contamination with 
other PCR products by washing the buffer tank of the electrophoresis apparatus prior to 
electrophoresis. Only one PCR product was loaded per gel to avoid cross contamination 
between PCR products. 
2.3.8. Cloning PCR products. 
Competent DH5a cells were prepared to a competency of 106 to 107 by a rubidium 
chloride/calcium chloride method as described in Ausubel et al (1994). PCR products 
were gel purified to remove unincorporated primers, primer dimers and non-specific 
amplification products prior to cloning into the plasmid pUC 18. Generally, 50 ng of 
plasmid was ligated to a 10 fold molar excess of PCR product 
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2.3.8.1. Klenow-Kinase-Ligase Method (Sorens, 1991). 
This method was used to clone PCR products generated by primers with restriction 
endonuclease sites at the 5' -ends (primer sets Pla/P2, and Plb/P2). Briefly, the PCR 
products were blunt ended with the Klenow fragment of E. coli DNA polymerase 1 to 
remove the single 3' terminal A added by the terminal transferase activity of Taq 
polymerase (Clarke, 1988), phosphorylated at the 5'-end using T4 polynucleotide kinase, 
which allowed T4 DNA ligase to concatenate the PCR products. The concatenated PCR 
products were then digested with Pstl and EcoRI. The sticky ended PCR products were 
gel purified and ligated into Pstl/EcoRl digested pUC 18, using standard protocols, as 
described in Ausubel et al (1994). A portion of the ligation was transformed into 
competent E. coli DH5(a) cells and plated onto LB plates coated with 5-bromo-4-chloro-
3-indolyl-B-D-galactoside (Xgal) and isopropyl-1-thio-B-galactoside (IPTG) and 
containing 100 µg ampicillin. Recombinants ( clones unable to metabolise Xgal due to 
insertional inactivation of the a-peptide coding region of the enzyme B-galactosidase after 
induction with IPTG) were selected, grown to saturation in 2X TY medium, and plasmid 
DNA prepared by a modified alkaline lysis miniprep method as described by Kraft et al, 
1988. The presence of an insert was confirmed on a 0.8% agarose gel by either releasing 
the cloned fragment from the multiple cloning site by Pstl/EcoRl digestion, or by 
comparing the mobility of the intact recombinant plasmid to that of a plasmid containing 
no insert. 
2.3.8.2. Blunt Ended Cloning. 
pUC 18 was linearised with Smal and dephosphorylated using shrimp alkaline 
phosphatase as described in Ausubel et al (1994). Purified PCR products amplified by 
Vent DNA polymerase were ligated directly into the vector. PCR products amplified with 
Taq DNA polymerase were blunt ended with Klenow prior to ligation. 
27 
2.3.8.3. Smal Cloning (Lui and Schwarz, 1992). 
Blunt ended PCR products were ligated to Smal linearised pUC 18 vector in the presence 
of Smal. Vector self-religation reconstitutes a Smal site, which was then re-digested by 
Sma l thereby reducing the background of religated vector. The Sma l site was destroyed 
in plasmids which ligated to a PCR product. 
2.3.8.4. TA Cloning. 
The single 3'-A added by Taq (Clark, 1988) is complementary to a single 3'-T present at 
each end of the linearised vector pGEM-T. This enables cloning of Taq generated PCR 
products without having to blunt end the PCR products. PCR products were cloned into 
pGEM-T (Promega, Madison, Wisconsin, USA) following the manufacturers 
recommended protocol. 
2.3.9. DNA Sequencing. 
DNA was sequenced using the Sanger dideoxy method (Sanger et al, 1977) with the 
Sequenase Version 2.0 kit purchased from United States Biochemical, Cleveland, Ohio, 
USA. 
2.3.9.1. Direct Sequencing of Double Stranded PCR Products. 
Four 100 µl PCR reaction volumes where combined and gel purified by one of the 
methods described. The basic Sequenase protocol (United States Biochemical 
Corporation, 1987) as suggested by the manufacturer, was modified according to 
Casanova et al (1990) and Bachman et al (1990). The protocol differed from the standard 
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Sequenase protocol by the method of annealing primer to template and the inclusion of 
detergents in all the sequencing steps. Tween 20 and NP 40 at 0.5% were included in all 
steps of the Sequenase protocol (Bachman et al, 1990). Primers were annealed to heat 
denatured template by snap cooling on ethanol/dry ice (Casanova et al, 1990). The 10 µl 
annealing reaction contained 3 to 5 µg of purified PCR product, 5 pmole of the 
sequencing primer, 2 µl sequencing buffer (USB) and 0.5% Tween 20 and MP40 
detergent. After annealing, the following were added on ice: Tween 20 and MP40 to 
0.5%, 2 µl dGTP labelling mix diluted 1 :4 (USB), 1 µl 0.1 M dithiothreitol (USB) and 0.5 
to 1 µl [35S] dATP. The manganese containing Mn buffer (USB) was included when 
sequencing close to the primer. The labelling reaction was started with 2 µl diluted 
Sequenase enzyme (USB) and incubated for 3 min at 18°C. 3.5 µl of the labelling mix was 
transferred to tubes containing 2.5 µl of each of ddA, ddG, ddC, ddT termination mixes 
(USB) at 37°C. The extension/termination reaction was terminated after 5 min by the 
addition of 4 µl stop solution (USB). 
2.3.9.2. Sequencing of Cloned PCR Products. 
Recombinant plasmids were prepared for sequencing using a modified alkaline lysis 
miniprep method which incorporated a PEG 8000 precipitation step (Kraft et al, 1988). 3 
to 5 µg of purified plasmid was alkaline denatured, and sequenced without detergents 
using the basic Sequenase protocol (United States Biochemical Corporation, 1987). 
2.3 .9.3. Denaturing Polyacrylamide Gel Electrophoresis. 
Sequencing reactions were separated on 6% polyacrylamide gels (19: 1 acrylamide to bis-
acrylamide) containing 8 M urea as a denaturant, using 1 X TBE as the electrophoresis 
buffer. Dried gels were autoradiographed against B-Max film (Radiochemical Centre, 
Amersham, UK) for periods of 24 hr to 2 weeks. 
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2.4. Results and Discussion. 
2.4.1. RNA extraction and cDNA Synthesis. 
Total RNA extraction from confluent fibroblast monolayers cultured in 250 ml tissue 
culture flasks consistently yielded between 25 and 40 µg of RNA with a 260 nm / 280 nm 
ratio > 1. 9. Visualisation of the isolated RNA on formaldehyde agarose gels showed that 
the RNA was undegraded, with sharp 28s and 18s rRNA bands (data not shown). RNA 
stored as an ethanol precipitate was stable for at least a year when stored at -80°C. 
First strand cDNA synthesis was primed using either an oligo dT1s primer, or a HPRT 
cDNA specific primer P2 and the results of cDNA amplification using these differently 
primed templates are described below. A 100 µl cDNA reaction volume proved useful in 
optimising PCR, but was subsequently reduced to 25 µl, with a proportional reduction in 
the amount of template reverse transcriptase and the other components of the reverse 
transcription reaction. First strand cDNA preparations were stable for at least a year at 
-20°C. Second strand cDNA synthesis was primed by primer Pla during the first round of 
the polymerase chain reaction. 
2.4.2. HPRT cDNA Amplification. 
Initial attempts at amplification of a 721 bp fragment encompassing the coding region of 
HPRT cDNA using primers Pla and P2 were unsuccessful at a range of MgCL2 
concentrations (1 .5, 2, 3, 4, and 5 mM), with an annealing temperature of 57°C and a 
1 min extension time at 72°C. Primer degradation was eliminated as possible cause of 
amplification failure by analysing primers P 1 a and P2 on a 20% acrylamide gel. The 
primers were undegraded with most of the primer concentrated in a single band. 
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Low molecular weight primer dimers were massively amplified during PCR. Adding Taq 
polymerase after a 3 min incubation at 94°C to start amplification (a hot start) did not 
significantly decrease the amount of primer dimers amplified, nor yield a detectable PCR 
product of the predicted size. Decreasing primer Pla concentration from 50 pmole/100 µl 
reaction to 1 pmole had no effect. In an attempt to destabilise primer dimer formation and 
improve the specificity of amplification, formamide was added to the PCR reaction at 
concentrations of 2.5%, 5% and 10% (Sarkar et al, 1990), but also had no effect on 
reducing primer dimer formation. Incrementally decreasing or increasing the annealing 
temperature of 57°C in the range 50 to 60°C was unsuccessful in generating a PCR 
product. 
Altering the extension time profile at 72°C to 2 min extension for the first 13 cycles, 
followed by 3 min extension for 13 cycles, 4 min for 13 cycles and a final extension of 
10 min for one cycle, while keeping denaturing and annealing temperatures constant at 
94°C and 57°C respectively, resulted in the successful amplification of a PCR product of 
the predicted size. 
It is interesting that amplification ofHPRT cDNA was only possible when extension times 
were increased in a stepped system of 2, 3 and 4 minutes. P 1 a dimer formation is 
probably low at an annealing temperature of 57°C however, some primers will anneal to 
themselves. Once dimers are primed and amplified, they will amplify efficiently and 
increase geometrically with each PCR cycle. The amount of Taq polymerase becomes 
limiting as the amount of primer dimer template increases and is compounded by the 
cumulative loss of enzyme activity due to heat denaturation during 40 cycles of 
amplification. Increasing the extension time is then necessary to allow time for limiting 
Taq polymerase to bind to and extend specific HPRT cDNA products. 
In retrospect, primer Pla is an example of how not to design a PCR primer. The GC rich 
nature of the 5'-noncoding end of the Hl>RT gene sequence is a constraint on choosing a 
primer sequence with a balanced GC-AT content. However, lack of experience when 
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designing this first PCR primer resulted in choosing a primer sequence with inter-primer 
self-complementarity at the 3'-end (Figure 2.3a). Ten out of twelve bases at the 3'-end of 
the primer were complementary, and all of these bases where G or C resulting in stable 
dimer priming and extension. In addition, the 3'-end of the primer was also 
complementary to a sequence within itself (Figure 2.3a), and intra-primer annealing and 
extension could result in some of P 1 a being effectively destroyed, especially at the low 
temperatures used during sequencing. The GC richness of the self-complementary regions 
and the resultant stability of the primer Pla - primer Pla complex resulted in primer 
dimers being efficiently amplified at the expense of specific HPRT cDNA sequences. 
Primer P2 is a "good" PCR primer, with a balanced GC-AT content and no significant 
propensity to dimer formation, either with itself, or with primer PI a. 
Primer Pia also proved to be a "bad" sequencing primer due to dimer formation. A new 
primer, Plb was synthesised to overcome the problem of dimer formation. The 3'-end of 
the primer PI a sequence was shortened by the removal of the terminal GG eliminating 
complementarity at the 3'-terminal base (Figure 2.3b), and resulted in reduced dimer 
formation. However, between primer complementarity still remained a problem. 
(a) Primer P1 a - in s trastrand priming. 
/GCCGG 3' 
c"'-GcbJ!cGACTGACGTCTAA 5' 
(b) 
Primer P1 a - dimer formation. 
5' AATCTGCAGTCAGCCCGCGCGCCGG 3' 
II 111111 11 
3' GGCCGCGCGCCCGACTGACGTCTAA 5' 
Primer P 1 b - dimer formation. 
5' AATCTGCAGTCAGCCCGCGCGCC 3' 
1111 11 
3' CCGCGCGCCCGACTGACGTCTAA 5' 
Figure 2.3: Predicted dimer formation and primer secondary structure of primers 
Pla and Plb. (a) Possible intra--primer priming conformation and dimer formation in 
primer Pia. (b) Reduced between primer complementarity of the modified primer, Plb. 
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The composition of the PCR buffer was also a factor contributing to the efficiency and 
success of amplification. Two PCR buffers were assessed (Figure 2.4). A detergent based 
buffer containing 0.1% Triton X-100 in 70 mM Tris-HCL pH 8.8 produced optimal 
amplification at 2 mM MgCL2. However, amplification yields as estimated on ethidium 
bromide stained gels, were consistently lower and often, use of this buffer resulted in 
failure to amplify a cDNA PCR product. A detergent free buffer containing 50 mM KCl, 
10 mM Tris-HCI pH 8.3 and 0.01% gelatine had a broader MgCL2 requirement with 
optimal amplification at 2 mM and at 4 and 5 mM. Amplification yields at 4 to 5 mM 
MgCL2 were generally higher than at 2 mM MgCL2. 
Although Eckert and Kunkel (1991) reported that Taq polymerase errors occur at a higher 
frequency when MgCL2 concentration is in large excess to dNTP concentration, yields of 
PCR products were sufficiently greater at 5 mM MgCL2 compared to 2 mM MgCL2 to 
justify the use of the higher MgCL2 concentration. 
1234 56 78 
2027 bp 
564 bp 
Figure 2.4: A comparison of detergent based and detergent free PCR buffers used 
in cDNA amplification. Primers Pla and P2 were used to amplify the equivalent of 1 µg 
of total RNA from the same I 00 µl volume oligo dT 1s primed reverse transcription 
reaction, using a KCl - Tris-HCI - gelatine buffer or a detergent - Tris-HCI buffer as 
described in the text. 15 µl of 100 µl each PCR reaction was loaded onto a 2% agarose 
gel and visualised under UV after ethidium bromide staining. Lanes 1 to 3: amplification 
in a detergent free buffer at MgCL2 concentrations of 2, 4 and 6 mM. Lanes 5 to 8: 
amplification using a detergent containing buffer with MgCh concentrations at 1.5, 2, 4, 
and 6 mM. Lane 4: molecular weight marker, lambda phage DNA digested with Hindlll, 
the 564 bp and 2027 bp bands are indicated 
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The optimal amplification conditions for primer pair Plb-P2 were thus established as being 
a function of the thermocycling profile and the PCR buffer composition. A detergent free 
buffer containing 10 mM Tris-HCL pH 8.3, 50 mM KCL, 0.01% gelatine and 5 mM 
MgCL2, with 200 µM of each dNTP and 50 pmoles of each of primers P 1 a and P2 in a 
100 µl reaction volume was used. The thermocycler profile was: 
denaturation: 94°c 1 min 
annealing: 51°c 1 min 
extension: 12°c 2 min 13 cycles 
3 min 13 cycles 
4min 13 cycles 
10 min 1 cycle 
Amplification of HPRT cDNA from control cell lines using 0.3 to 1 µg of reverse 
transcribed total RNA as template was routinely achieved. 
2.4.2.1. Oligo dT vs Primer P2 Primed Reverse Transcribed Total RNA as PCR 
Template. 
Amplification of oligo dT 15 primed cDNA under the optimal conditions defined above, 
produced a single PCR product of the predicted size with minimal background smearing. 
Conversely, amplification of cDNA primed with PCR primer P2, although yielding a PCR 
product of expected size, also resulted in significant high and low molecular weight 
smearing (Figure 2.5). This background smearing is probably a consequence of 
mispriming at the low primer annealing temperature (0°C) and extension temperature 
( 42°C) at which reverse transcription occurs. These miss-primed templates are linearly 
amplified through 40 PCR cycles. The use of oligo dT 15 to prime cDNA synthesis and an 
internal, upstream sequence specific primer P2 in PCR, is a semi-nested primer system and 
results in increased specificity. 
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1 2 3 4 5 6 
2027 bp 
564 bp 
Figure 2.5: Amplification of oligo dT15 primed or P2 primed cDNA. Amplification of 
oligo dT15 primed and P2 primed cDNA. The equivalent of 1 µg of oligo dT15 or P2 
primed reverse transcribed total RNA, isolated from a control cell line (lanes 1 and 2) and 
a patient cell line F45 (lanes 5 and 6), was amplified for 40 cycles using primer pair Pla 
and P2 under optimal PCR conditions as described in the text. 16 µl of the amplification 
reaction was separated on a 2% agarose gel. Lanes 1 and 5: oligo dT 1s primed cDNA. 
Lanes 2 and 6: P2 primed cDNA. Lane 4 is a PCR blank which have been carried 
through both the RNA extraction protocol and cDNA synthesis. Lane 3: DNA molecular 
weight marker, HindIJJ. digest of lambda DNA, the 546 bp and 2027 bp bands are 
indicated. The low molecular weight bands visible below the 564 bp band of the marker 
are primer dimers. 
2.4.2.2. Re-amplification of PCR Products. 
The cDNA templates were a limited resource, and in order to generate sufficient PCR 
product for direct sequencing, it was necessary to re-amplify PCR products. Direct re-
amplification of 1 µl of unpurified PCR product resulted in primer dimers being efficiently 
re-amplified and the system became rapidly saturated with non-specific amplification 
products. Amplification of a gel purified PCR product was optimal at 1 : 1000 or 1 : 10000 
dilution as judged by the presence of a single, bright band of the predicted size on 
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ethidium bromide stained agarose gels. The diluted purified PCR fragment provided an 
effectively unlimited template stock for re-amplification. 
2.4.2.3 . Nested Primer Amplification ofHPRT cDNA. 
A nested primer HPRT cDNA amplification system was developed for convenience and 
for added sensitivity. The first amplification reaction using OPl and OP2 to amplify 
cDNA, serves as a "stock" of template for re-amplification using primers NPl and NP2. 
Gel purification of PCR products with the associated risk of cross-contamination, is no 
longer necessary. The system is extremely sensitive and specific: any non-specific PCR 
products amplified during the first, outer round of amplification, would not be amplified 
during the second, nested, round of amplification. The leverage of an additional 30 cycles 
of amplification enables rare cDNA transcripts to be amplified with sometimes spectacular 
success (Figure 2.6). Primer pairs OP1/0P2 and NP1/NP2 produced optimal 
amplification at a MgCL2 concentration of 1. 5 mM. 
To reduce the risks of contamination, the following precautions were taken: 
1. All reagent stocks were aliquotted in a laminar flow cabinet and stored separately 
from cDNA templates and PCR products. Any contamination could then be 
eliminated by discarding the PCR "kit" in use without great expense. 
2. PCR reactions were set up at a different bench to where PCR products were 
processed. 
3. An RNA extraction blank was carried through cDNA synthesis and amplified in 
parallel with cDNA templates to control for contamination during template 
preparation. 
4. A PCR reaction blank was included with each series of PCR reactions. 
5. If two or more different templates were to be amplified simultaneously, an 
additional PCR reagent blank was used. The first blank was set up and closed 
before the template was brought to the bench and served as a true reagent blank. 
The second PCR blank controlled for cross-contamination during PCR reaction 
preparation and was the last PCR reaction tube to be closed. 
6. All PCR products in a series with a positive blank were discarded. 
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Rigorous adherence to these precautions resulted in only occasional PCR contamination 
during this study. 
2.4.3. DNA Sequencing. 
The sequencing primers were located so as to allow sequencing of both strands of the 
PCR product in overlapping segments (Figure 2.2). Compressions were resolved by 
running the sequencing gel at 90 watts so as to increase the temperature of the gel and aid 
denaturation of DNA secondary structure, or by using the dITP labelling mix supplied 
with the sequencing kit (USB), or by sequencing the complementary strand. Where 
necessary, sequences close to the PCR primers were obtained by sequencing cloned PCR 
products using vector sequencing primers. 
2.4.3 .1. Direct Sequencing of PCR Products. 
Successful direct sequencing of PCR products depended on the preparation of 2 to 5 µg 
of pure, primer free, PCR product. The following methods of PCR fragment purification 
were assessed in terms of ease, efficiency of product recovery and the quality of the 
sequence generated. 
(a) 
(b) 
E 
2027 bp 
564 bp 
MgCl 2 mM 
~ 0 0 ~ ~ 0 00 
L{) 
N ,0 "St - N ,0 "St 
MgCl 2 mM 
0 L{) 
N -
0 
N 
CD 
u 
CD 
a... 
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Figure 2.6: Nested amplification of HPRT cDNA. (a) HPRT cDNA from 2 
normal fibroblast cell lines was amplified for 40 cycles with outer primers OPl and OP2 
with MgCh concentration varied from 1. 5 mM to 4 mM. (b) 1 µl of the outer primer PCR 
reactions at 1.5 mM and 2.0 mM MgCh were amplified at the corresponding MgCh 
concentrations with the nested primers NPl and NP2 for an additional 30 cycles. A PCR 
blank (MgCh at 1.5 mM) carried through from cDNA synthesis is shown in the lane CB 
and a PCR blank carried through both outer and nested PCR is shown in lane PB. Both 
PCR blanks confirm the absence of contaminating HPRT cDNA in the PCR system. Lane 
m is a DNA molecular weight marker (HindIIJ. digest of lambda DNA), with the 564 bp 
and 2027 bp bands indicated. 15 µl of each 100 µl reaction volume was loaded onto a 
1.5% agarose gel. 
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a) Direct Purification of PCR Products Using Millipore Ultrafree-MC filter Units. 
The 30,000 NMWL filter unit retained primer dimers and PCR fragments prepared using 
this unit were unsuitable for sequencing. The 100,000 NMWL unit efficiently removed 
primer dimers, but at -the cost of some loss of high molecular weight PCR product. As a 
result, it was necessary to autoradiograph sequencing gels for up to 2 weeks. The DNA 
sequences generated were, however, of excellent quality. This purification method was 
quick and easy, but the yield of purified PCR product was low. This method could not be 
used if any high molecular weight non-specific amplification products or background 
smearing in the PCR products were present, as these DNA species would be co-purified 
with the specific amplification product. The constraints of a single specific PCR product 
in the PCR reaction and the relatively high losses of PCR product during purification, 
meant that this method was not suitable for large scale direct sequencing of multiple 
templates. 
b) Recovery of DNA from agarose gel slices after electrophoresis. 
Agarose gel electrophoresis efficiently separates PCR products from non-specific 
amplification products or primer dimers in the PCR reaction. PCR fragments can then be 
recovered from agarose gel slices. 
Electro-elution of PCR products from agarose gel slices proved to be unsuitable for 
purifying DNA for direct sequencing. DNA recovery was poor and the DNA co-purified 
with inhibitors present in the agarose gel slice. 
Electrophoresis onto DEAE cellulose provided purified DNA variable in quality with fair 
yields. The method was time consuming and did not lend itself to the simultaneous 
preparation of multiple PCR fragments. An unavoidable consequence of accurately 
placing the DEAE cellulose strips and checking whether transfer was complete, was the 
exposure of the DNA in the agarose gels to damaging amounts of ultra violet light. As a 
result, the quality of DNA sequences varied, depending on how long the DNA had been 
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exposed to UV light. Readable sequences were obtained after 2 weeks exposure to 
autoradiographic film. 
Commercial gel purification kits, such as the Magic/Wizard Prep and Qiaex kits, are based 
on the recovery of DNA from solubilised agarose gel slices using a proprietary DNA 
binding matrix. Recovery of DNA was better than 80% and readable sequences of high 
quality were attainable after a 24 hour exposure of the gel to autoradiographic film. Most 
of the direct sequencing in this study used PCR product template prepared with these kits. 
The Promega Magic and Wizard Prep kits are cartridge based and were quick and easy to 
use. Solubilised agarose gel contaminants were removed by washing with 80% 
isopropanol, which is not as volatile as ethanol and can be difficult to remove completely, 
before DNA elution from the binding matrix. This was an occasional cause of failure to 
obtain a readable sequence. A disadvantage of the kit is that DNA is recovered in a 50 µl 
volume and further concentration was occasionally necessary before the DNA could be 
used for direct sequencing. 
The Qiaex kit methodology is tube based and not as convenient to use. The wash steps 
are, however, with ethanol based buffers which are easier to evaporate prior to DNA 
elution. DNA could be eluted from the silica binding matrix in buffer volumes as small as 
20 µl, which was a major advantage over the Magic/Wizard Prep kit, as no further 
concentration of DNA prior to direct sequencing was usually necessary. 
2.4.3.2 Sequencing of Cloned PCR Products. 
To Clone or Not to Clone ... 
Taq DNA polymerase lacks a 3'-5' exonuclease proof reading activity and is as a result, 
error prone. An error rate of2x104 was reported by Saiki et al (1988), while an error rate 
of 2.6x10-5 is reported by one Taq polymerase manufacturer (Boehringer Mannheim). 
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Eckert and Kunkel ( 1991) reported an error rate of 10-4 to 10·5, depending on dNTP and 
MgCL2 concentration, and the pH of the PCR buffer. When PCR products are sequenced 
directly, these random errors are averaged out and the consensus sequence is read. When 
PCR generated DNA molecules are cloned, a single PCR amplified molecule is sequenced. 
Any errors due to lack of fidelity of Taq polymerase will then be seen as a change in the 
DNA sequence of that particular cloned PCR fragment and two clones would need to be 
sequenced and compared to the reference sequence in order to distinguish between Taq 
errors and true mutations. If the sequences of two clones differs, those sequences 
differences are a result of Taq errors. If two or more clones have the same sequence 
change, the sequence change is accepted as a genuine mutation. In autosomal recessive 
conditions, mutations in compound heterozygotes may be difficult to detect by sequencing 
of cloned PCR products. Two alleles, both different from the normal sequence would be 
present. Mutations on each allele would have to be found in more than one clone to 
confirm that the change is not the consequence of a Taq error. Fortunately, HPRT is X-
linked with only one allele in affected males. 
There are a number of advantages to cloning and then sequencing PCR products: 
1. Milligram quantities of cloned PCR product can be generated in an overnight 
culture. For large PCR fragments requiring multiple sequencing reactions, this is 
particularly useful. 
2. PCR products of similar size are sometimes difficult to separate during gel 
purifying for direct sequencing. Cloning PCR fragments allows easy sequence 
differentiation between similarly sized PCR products. 
3. Sequences within a few bases of the primer may be difficult to read. Sequencing 
of cloned PCR products using vector sequencing primers enables sequencing of 
the entire PCR product. 
4. Some PCR primers are "bad" sequencing primers as is the case with primer Pla, 
and to a lesser extent, Plb. Both are GC rich primers with a high degree of self-
complementarity. Sequencing cloned PCR products with a vector sequencing 
primer avoids this problem. 
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Single stranded conformational polymorphism (Orita et al, 1989), heteroduplex analysis 
and chemical cleavage of mismatched heteroduplexes (Cotton et al, 1988) have been used 
as preliminary mutation screening methods to detect the presence of mutations in 
amplified DNA segments prior to DNA sequencing. These methods are particularly useful 
where a mutation in more than one candidate gene may be responsible for a specific 
biochemical defect. The clinical and biochemical profile of HPR T deficiency is however, 
sufficiently clear to justify sequencing HPR T cDNA without a preliminary mutational 
screen. 
A combination of direct PCR sequencing and sequencing of cloned PCR products was 
used in this study to define the mutations responsible for HPRT deficiency. 
3. 
3.1 
MOLECULAR BASIS OF THE LESCH-NYHAN 
SYNDROME. 
Introduction. 
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The Lesch-Nyhan syndrome (Lesch and Nyhan 1964) is a clinical condition consequent to 
a complete HPRT deficiency. The syndrome is characterised by purine overproduction 
leading to hyperuricemia and a central nervous system disorder, which includes severe 
spasticity, choreoathetosis, mental retardation and compulsive self-mutilatory behaviour. 
3.1.1 Pathogenesis ofHPRT Deficiency. 
3.1.1.1 Biochemical basis of Purine Overproduction. 
Fibroblasts cultured from Lesch-Nyhan patients have increased rates of de novo purine 
synthesis and an increased intracellular pool of PRPP (Rosenbloom et al, 1968). It is 
generally accepted that the rate limiting step of de novo purine biosynthesis is catalysed by 
amidophosphoribosyltransferase ( amidoPR T), the enzyme that catalyses the formation of 
13-phosphoribosylamine from glutamine and PRPP (Pallela and Fox, 1989). The enzyme is 
cumulatively inhibited by mono-, di- and trip hosp hate adenine and guanine nucleotides. 
Inhibition is relieved by binding ofPRPP. Intracellular levels ofPRPP are governed by the 
rate of PRPP synthesis by PRPP synthetase and by the rate of PRPP utilisation. HPR T 
deficiency results in decreased utilisation of PRPP and a rise in intracellular PRPP levels 
which drives de novo synthesis by relieving inhibition on amidoPR T. In addition, the Km 
for amidoPRT (0.1-0.5 mM) is several-fold above the physiological concentration of 
PRPP (in the micromolar range). An increase in PRPP concentration will thus directly 
lead to an increase in the activity of amidoPRT (Holmes, 1978). Increased PRPP 
availability, rather than a deficiency in the nucleotide pool is mainly responsible for 
increased de novo synthesis in HPRT deficient cells (Becker et al, 1987, 1989). 
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3.1.1.2 Purine Nucleotide Pools in HPRT Deficiency. 
There is a three to fourfold elevation in hypoxanthine and xanthine in plasma and a four to 
tenfold increase in the excretion of total purines in patients with the Lesch-Nyhan 
syndrome (Harkness et al, 1988; Mateos and Puig, 1993). This loss of purines appears to 
be adequately compensated in most tissues by an increase in de nova purine nucleotide 
synthesis and no major changes in the intracellular nucleotide pool profile have been 
observed in cultured human fibroblasts (Becker, 1987) and a rat neuroma cell line (Zoref-
Shani et al, 1993). Erythrocytes lack the capability to synthesize purines de nova and 
disturbances in intracellular nucleotide pools are detectable. ATP and GTP nucleotide 
pools may be depleted in erythrocytes of some Lesch-Nyhan patients with the effect on 
GTP pools being more marked (Simmonds et al, 1988; Harkness and McCreanor, 1991). 
NAD levels are increased two to three fold (as a result of increased PRPP levels) and may 
be a reliable marker of severe HPRT deficiency (Simmonds, 1988; Simmonds, 1994). 
ZTP (5-amino-4-imidazole-carboxamide ribotide triphosphate) and other Z-nucleotides 
may be detectable in erythrocytes of patients with the Lesch-Nyhan syndrome (Simmonds, 
1988), however this is not a specific consequence ofHPRT deficiency since Z-nucleotides 
are also found in purine nucleoside phosphorylase deficiency and in some patients with 
PRPP synthetase superactivity (Sidi and Mitchell, 1985). 
APRT activity has been reported to be increased in erythrocytes of Lesch-Nyhan patients 
due to stabilisation of APRT by increased PRPP pools (Kelley et al, 1969; Seegmiller et 
al, 1967). 
3.1.1.3 Pathogenesis of Neurological Symptoms and Self-Mutilation. 
The accumulation of hypoxanthine, xanthine and to a lesser extent uric acid, reported in 
the CNS of patients with the Lesch-Nyhan syndrome (Harkness et al, 1988) are unlikely to 
be a direct cause of the neurological symptoms in these patients. Similar levels of 
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oxypurine metabolites are found in neurologically normal patients with partial HPR T 
deficiency (Harkness et al, 1988; Puig and Mateos, 1993). 
Amino acid pools in the brains of Lesch-Nyhan patients are generally markedly decreased. 
However, levels of glutamine and urea are increased (Rassin et al, 1982, Harkness et al, 
1988). However, blood and urine amino acid levels are normal (Harkness et al, 1988), 
which would appear to exclude severe nutritional deprivation as a cause of the brain amino 
acid pool changes. 
The brains of Lesch-Nyhan patients are morphologically normal (Stout and Caskey, 1989). 
One of the earliest neurological signs of the Lesch-Nyhan syndrome are movement 
disorders, which points to involvement of the basal ganglia of the brain, the major site of 
dopaminergic neurones and an area of the brain with high levels ofHPRT activity. Lloyd 
et al (1981) reported a general deficit in dopamine-neurone function (low dopamine and 
homovanillic acid levels and low activities of dopa decarboxylase and tyrosine hydroxylase 
activities) in the brains of Lesch-Nyhan patients. Their results indicated a functional loss 
of between 65% and 90% of nigrostriatal and mesolimbic dopamine terminals. Recently, 
Ernst et al (1996) demonstrated abnormally few dopaminergic nerve terminals and cell 
bodies using positron-emission tomography to measure the accumulation of flourodopa F 
18 tracer in the brains of Lesch-Nyhan patients. The dopaminergic deficits were pervasive 
and appeared to be developmental in origin. Since guanine nucleotides participate in the 
regulation of dopamine receptor binding, it is possible that decreased GTP pools which 
may result from HPR T deficiency in tissues with a low capacity for purine de novo 
synthesis, could affect dopaminergic function (Stout and Caskey, 1989, Puig and Mateos, 
1993). Watts (1985) has explored the link between possible GTP depletion due to HPRT 
deficiency and disturbances in pterin metabolism. GTP-cyclohydrolase catalyses the rate 
limiting step of pterin de novo synthesis and a decrease in the GTP pool could affect the 
production of tetrahydrobiopterin, leading to impaired synthesis of norepinephrine, 
dopamine and serotonin. This would in tum lead to disturbed neurotransmission in the 
basal ganglia and may contribute to the pathogenesis of the neurological symptoms of the 
Lesch-Nyhan syndrome. 
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Reduced GTP levels have also been reported to occur in erythrocytes of patients with 
PRPP synthetase superactivity and purine nucleoside phosphorylase deficiency (Sidi and 
Mitchell, 1985; Simmonds et al, 1988). The presence of neurological symptoms in these 
patients (Simmonds et al, 1988) supports a link between GTP depletion due to HPRT 
deficiency and dopaminergic function. Moreover, the observed GTP depletion in 
erythrocytes correlates closely with the severity of the CNS involvement. 
There is some evidence from animal models to support the involvement of dopaminergic 
neurones in the pathogenesis of the Lesch-Nyhan syndrome. The administration of a 
dopamine agonist to rats rendered hypersensitive to dopamine by unilateral intracerebral 
injection of 6-hydroxydopamine into the nigrostriatal region, caused an incessant biting of 
limbs and tail (Ungerstedt, 1971). 
Transgenic HPR T deficient mice show no overt neurobehavioral abnormalities and HPR T 
deficiency has no notable affect on the content of brain purines (Jinnah et al, 1993). 
Purine synthesis de novo was however increased four to fivefold. The mice are not 
entirely neurologically normal and dopamine levels have been reported to be reduced by 
up to 50% (Finger et al, 1988; Jinnah et al 1992). The mouse model may be less 
dependant on HPRT for purine salvage, which may make it a poor model for the human 
condition. The reported ratio of HPR TI APR T enzyme activities is 1. 86 in whole brain 
extracts of neonatal rats, and 11.66 to 51.38 in human brain obtained on autopsy (Brosh et 
al, 1990). The relative importance of APRT activity in mice suggests that doubly (APRT 
and HPRT) deficient mice may be a better animal model of the Lesch-Nyhan syndrome. 
Wu and Melton (1993) used an adenine analogue 9-ethyladenine to block APRT activity in 
9 to 12 month old HPRT deficient mice. Treated mice showed a high frequency of self-
injurious behaviour which resulted principally from excessive stereotypic grooming, rather 
than from the appearance of a new pattern of self-mutilatory behaviour. Genetically 
APRT and HPRT deficient mice may thus be an appropriate animal model for the study of 
the Lesch-Nyhan syndrome. The link between HPRT deficiency and the neurochemical 
changes apparent in the brains of Lesch-Nyhan patients still needs to be defined. 
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3 .1 .2 Genetic Basis of the Lesch-Nyhan Syndrome. 
HPRT is an X-link:ed gene, hence hemizygous males with the Lesch-Nyhan syndrome may 
inherit a mutant allele though the maternal lineage, or the defective gene may result from a 
de novo germ line mutation. About one third of cases are the consequence of new 
mutations. The Lesch-Nyhan syndrome is rare in females and is usually the result of non-
random X chromosome inactivation of the normal chromosome in a carrier female 
(Ogasawara et al, 1989; Aral et al, 1996). 
Mutations at the HPRT locus show marked genetic heterogeneity in vivo (Wilson et al, 
1986a; Davidson et al 1989a; Davidson et al, 1991 ; Tarle et al, 1991 ; Sege-Peterson et al, 
1992; Sculley et al, 1992; Cariello and Skopek, 1993) and provide an opportunity to gain 
insight into the molecular basis of inborn errors of metabolism. 
In this thesis, nine Lesch-Nyhan patients were investigated at the molecular level to 
determine the nature of the molecular defects in the HPRT gene. 
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3.2 Materials and Methods. 
3 .2.1 Origin of Patients. 
Patients (P) are coded in the text by cell line reference numbers (Cell Bank, Department of 
Chemical Pathology, University of Cape Town, South Africa). Cell line numbers prefixed 
by "L" are Epstein Barr virus transformed lymphoblast cultures and cell line numbers 
prefixed by "F" are fibroblast cultures derived from forearm skin biopsies. 
Patient JM (F526) 
This male patient presented at Red Cross Children's Hospital, Cape Town, South Africa, 
at the age of 1 month with severe vomiting and diarrhoea leading to shock, renal failure, 
and hypotonia, progressing to spastic quadriplegia with marked irritability. At 18 months, 
the patient presented with macroscopic haematuria and a worsening of the neurological 
symptoms. Urinary calculi, composed of uric acid, were passed. Plasma urate was 
markedly elevated at 0.97 mmol/1. 
HPRT enzyme activity assayed in haemolysates prepared from P526 using the method of 
Steyn and Harley (1984) described in Section 4.2.3.2., showed less than 0.1% residual 
activity compared to a control haemolysate. Doubling the amount of haemolysate in the 
assay to 200 µg protein and increasing the incubation time to 1 hour did not lead to a 
detectable increase in HPRT activity. The ratio of [14C] hypoxanthine to [3H] 
phenylalanine incorporation by fibroblasts cultured in a Hanks balanced salt based labelling 
medium (See Section 4.2.3.5.) was less than 0.01% of control values (Section 4.3.2. and 
Table 4.2), confirming a virtually complete deficiency of the enzyme in the patient. 
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The following HPRT deficient cell lines derived from Lesch-Nyhan patients were kindly 
supplied by John Duley and Anne Simmonds of the Purine Research Laboratory, Guy's 
Hospital, London. 
Cell Line Patient Origin 
F748 MJ Italy 
F749 pp UK 
F750 MP UK 
F751 AB UK 
F764 DT UK 
F765 JR UK 
F766 LW UK 
F768 LH Brazil 
3.2.2 Materials. 
Dulbecco's Modified Eagle Medium was purchased from Gibco BRL, Gaithersburg, 
Maryland, USA or from Highveld Biological, Kelvin, South Africa. Foetal calf serum was 
purchased from Highveld Biological, Kelvin South Africa. Sterile plastic pipettes, 
centrifuge tubes, flasks and petri dishes were of tissue culture grade. 
[8-14C] Hypoxanthine and L-[2,3,4,5,6-3H] phenylalanine were purchased from Amersham 
International plc, UK. Hionic-Fluor was from Packard, Downers Grove, Illinois, USA. 
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3.2.3 Methods. 
3.2.3.1 Tissue Culture Methods. 
Fibroblast cultures were established from forearm skin biopsies using standard methods. 
Cultures were grown in 250 ml tissue culture flasks in an atmosphere of 10% CO2 at 37°C 
and fed twice weekly with Dulbecco's Modified Eagles medium (DMEM) supplemented 
with 10% foetal calf serum. No antibiotics were used in the medium as this reduced the 
risks of undetected Mycoplasma infection. The cultures were screened at intervals for 
Mycoplasma infection using bisbenzamide fluorochrome stain (Hoechst No. 33258), 
(Chen, 1977). 
3.2.3.2 Fibroblast Double Label Experiments. 
A confluent fibroblast monolayer in a 250 ml flask was trypsinised and seeded in triplicate 
into a six well tissue culture plate to give a level of confluency of approximately 80%. 
The plates were incubated overnight in DMEM supplemented with 10% foetal calf serum 
to allow the cells to recover. The medium was then replaced by 1 ml labelling medium 
containing 1 µCi [3H] phenylalanine and 0.3 µCi [14C] hypoxanthine in DMEM with no 
foetal calf serum. After a 3 hr incubation at 3 7°C in an atmosphere of 10% CO2, the cells 
were treated with 1 ml ice cold 5% trichloroacetic acid (TCA) and the precipitate washed 
three times with 2 ml ice cold 5% TCA to remove unincorporated radiolabelled substrate. 
The washed precipitate was dissolved in 1 ml 0.1 M NaOH and neutralised by the addition 
of 100 µl 6.6% acetic acid. The dissolved precipitate was added to 10 ml Hionic-Fluor 
and counted in a Beckman LS6001 C scintillation counter using windows of O to 200 ke V 
for [3H] and 400 to 1000 ke V for the [ 14C] label. 
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3.2.3 .3 Molecular Methods 
The molecular methods have been described in detail in Section 2. Initially, HPRT cDNA 
prepared from F526 was amplified using primers Pla and P2. In subsequent experiments, 
nested primers were used in the amplification of HPRT cDNA from all the Lesch-Nyhan 
patients investigated. Amplified PCR products were blunt end cloned into pUC 18 using 
the Sma l method or sequenced directly as indicated in the results. The coding region of at 
least two independent clones was completely sequenced. 
HPRT genomic DNA was amplified as indicated in the results using the primers and PCR 
conditions described in Section 2.3.4. 
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3.3 Results. 
3.3.1 Double Label Studies. 
A marked decrease in the incorporation of [ 14C] hypoxanthine relative to normal 
[3H] phenylalanine incorporation was observed in all the cell lines derived from the Lesch-
Nyhan patients (Table 3. I). The results are consistent with the virtually complete absence 
ofHPRT activity in these patients. 
Table 3.1: Incorporation of [14CJ hypoxanthine relative to [3H] phenylalanine by 
8 Lesch-Nyhan and 3 control cell lines. 
Cell Line L 14C] Hx ( cpm) f3Hl Phe (cpm) 
F747* 915 
F734* 743 
F735* 1537 
F748 73 
F749 82 
F750 84 
F751 105 
F764 70 
F765 91 
F766 40 
F768 49 
* control cell lines. 
Values are the means of triplicate determinations. 
Abbreviations: hx, hypoxanthine 
1026 
1115 
1737 
1276 
1016 
1443 
1455 
1424 
1697 
727 
1150 
Ratio f14Cl/f3H] 
0.89 
0.67 
0.89 
0.06 
0.08 
0.06 
0.07 
0.05 
0.05 
0.06 
0.04 
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3.3.2 Results of the Molecular Investigations. 
Amplification of 1 µg of reverse transcribed total RNA extracted from F526 using primers 
Pla and P2, yielded PCR products of a smaller size and with a lesser band intensity than 
PCR products from a control preparation amplified under identical conditions (Figure 3 .1). 
However, low amplification yields due to with primer dimer formation necessitated the 
design of the nested primer system described in Section 2.3.4. 
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Figure 3.1: Amplification of HPRT cDNA using primers Pla and P2 from F526 
and a control cell line. The DNA molecular weight marker in lane m is lambda DNA 
digested with Hindi.IT. The 564 bp and 2027 bp bands are indicated. The low molecular 
weight bands visible below the 564 bp band of the marker are primer dimers. 
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700 bp 
300 bp 
Figure 3.2: Nested primer amplification of HPRT cDNA from 7 Lesch-Nyhan cell 
lines. HPRT cDNA was amplified with the outer primers OPl and OP2. 1 µl of the outer 
primer PCR reaction was then amplified using the nested primers NPl and NP2. Lanes m; 
DNA molecular weight marker (Bio Marker Low) with DNA fragment sizes 1000, 700, 
500, 400, 300, 200, 100 and 50 bp. Lane B; an amplification blank carried through both 
the outer and nested amplification systems. PCR products were resolved on a 2% 
MetaPhor agarose gel. 
The results of the nested primer amplification are shown above in Figure 3.2. Abnormally 
sized PCR products were amplified with the nested primers NPF and NPR from five cell 
lines, F526, F749, F751 , F764 and F765. HPRT cDNA amplified from F766 and F768 
were consistent with a predicted size of 7 41 bp and of equivalent size to the PCR products 
amplified from a control. HPRT cDNA could not be amplified from two cell lines, F748 
and F750. 
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Figure 3.3: Amplification of a control cDNA (cystathionine-8-synthase) from 
cDNA preparations of F748 and F750 using a nested primer system. Cystathionine-B-
synthase cDNA was amplified in two segments. Outer primers CBS 1 and CBS2 were used in the initial 
40 cycle amplification reaction (Lane CBSl-2), only low molecular weight non-specific amplification 
products are visible. In order to amplify the 5' end of the cDNA, 1 µl of the outer primer PCR reaction 
was amplified with nested primers NPl and NP3 (lane NPl-3) and yielded a PCR product of 
approximately the predicted size of 1289 bp. An overlapping segment of the 3' end of the cDNA was 
amplified using primers NP2 and NP4 (Lanes NP2-4) and yielded a PCR product of approximately the 
predicted size of 1075 bp. Lane m; DNA molecular weight marker, lambda DNA digested with Dral, the 
696 bp and 1075 bp bands are indicated. Position of PCR primer pairs: CBSl nt -109 to -93 (forward) 
and CBS2 nt 1741 to 1766 (reverse); NPl nt -58 to -33 (forward) and NP3 nt 1212 to 1231 (reverse); NP2 
nt 665 to 684 (forward) and NP4 nt 1714 to 1739 (reverse). Numbering is according to the sequence and 
convention of Kraus et al (1993), with the A of the ATG start codon numbered as base 1. 
3.3.2.1 Null Mutations. 
HPRT cDNA could not be amplified from three independent RNA and cDNA preparations 
of F748 and F750. A control mRNA (cystathionine-B-synthase EC 4.2.1.22) could 
however be amplified from the same preparations (Figure 3.3), suggesting that the failure 
to amplify an HPRT mRNA did not lie in the experimental system, but was a true 
reflection of the defect responsible for the Lesch-Nyhan syndrome in these two patients. 
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Figure 3.4: Genomic amplification of a segment of HPRT intron 6 from genomic 
DNA of F748, two control cell lines, F749 and the exon 7 deletion mutants F526, 
F764 and F765. 
In order to determine whether the absence of an amplifiable HPR T cDNA was a 
consequence of a deletion of all or part of the HPRT gene, a 281 hp segment of intron 6 
(nt 36127 to nt 36407) of the HPRT gene was amplified from genomic DNA preparations 
using primers P6 and P7. A segment of intron 6 could be amplified from controls, but not 
from F748 and F750 (Figure 3.4). These results suggest that a large structural deletion of 
all or part of the HPRT gene, affecting one or both of the 5' and 3' PCR primer binding 
sequences, is responsible for the absence of an amplifiable HPRT mRNA in F748 and 
F750. 
3.3.2.2 Single Base Insertion Events. 
Amplification of HPRT mRNA from F766 and F768 yielded PCR products which 
migrated in the same position as PCR products amplified from a control cell line (Figure 
3.2). DNA sequencing of cloned PCR products showed different single base insertions in 
both patients. In the cell line F766, a single T was inserted within a run of four T 's. 
between nucleotides 294-T to 297-T within exon 3 (Figure 3.5a). 
(a) G Control F766 
~ ~ GATC GATC 
A 
297-T 
T 
T 
294-T 
~/ 
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T 
T 
T 
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G 
56 
(b) Control F768 
i~ 
G ATC GA TC / ~ 
G C 
24-C T 
T 
- T 
22-G G 
C C 
G 
~ ! ~/ 
C 
Figure 3.5: Single base insertions identified in the coding region of HPRT cDNA 
amplified from F766 and F768. (a) F766: insertion of a T between 294-T and 297-T. 
(b) F768: insertion of a T between 22-G and 24-C. The HPRT cDNA sequence is 
numbered with the A of the ATG start codon numbered as nucleotide 1. 
In the cell line F768, a single Twas inserted within the sequence 21-CGTCG-25 in exon 1, 
creating the sequence 21-CGTTCG (Figure 3.5b). 
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3.3.2.3 Large Insertion or Deletion Events. 
Similarly sized PCR products, which were smaller than control PCR products, were 
amplified from three Lesch-Nyhan patient cell lines F526, F764 and F765. DNA 
sequencing of cloned PCR products showed an exact 4 7 bp deletion of exon 7 in all three 
patients (Figure 3.6). The lower molecular weight band present in F526 (Figure 3.2) was 
reproducibly amplified from three independent cDNA preparations. This low molecular 
weight PCR product was cloned and sequenced, but proved to be a non-HPRT specific 
amplification product with no sequence homology to either the HPRT cDNA or gene. 
In order to determine whether the deletion of exon 7 in F526, F764 and F765 was due to a 
splice junction mutation or due to a deletion within the HPRT gene, primers LNl and LN2 
located within intron 6 and intron 7 respectively were synthesised. The predicted 599 bp 
segment included the whole of exon 7 and the flanking intron sequences. Amplification 
with the LNl and LN2 primer pair proved difficult to optimise. PCR product yields from 
5 control templates were variable, ranging from complete failure to amplify the target 
fragment to easily visualised PCR products. Varying the annealing temperature of the 
PCR reaction between 50°C and 60°C, well below the predicted primer Tm of 68°C and 
70°C, did not improve PCR product yields. Yields of PCR products were greatest at a 
MgCh concentration of 1. 5 mM. Varying the MgCh concentration within the PCR 
reaction in the range 1. 5 to 5 mM did not result in an increase in the efficiency of the 
amplification reaction. The reasons for the poor amplification efficiency of the LN1-LN2 
primer pair are not clear. There is no obvious intra- or inter- primer complementarity 
which can potentially reduce PCR efficiency. It is unlikely that the problem lay in the 
degradation of the DNA preparations, as a segment of intron 6 could be easily amplified 
using primers H6 and H7 from all the DNA preparations (Figure 3.4). 
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Figure 3.6: The 47 base pair cDNA deletion of exon 7 in F526, F764 and F765 . . 
The HPRT cDNA sequence is numbered with the A of the ATG start codon numbered as 
nucleotide 1. 
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F526 /~ G-39821 G A T C T C I"--G C 
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Figure 3.7: Splice junction mutation in F526. A 39815-G to T transversion in the 
invariant AG of the intron 6 splice acceptor results in a cDNA deletion of exon 7. 
Nucleotides within intron 6 are shown in lower case. The HPRT gene reference sequence 
and numbering is according to Edwards et al (1990). 
Nevertheless, PCR products of approximately the predicted size could be amplified from 
genomic DNA preparations ofF526. The PCR products were cloned and the intron/exon 
boundary of exon 7 sequenced using primer LNl. A 39815-G to T transversion in the 
invariant AG of the intron 6 splice acceptor was found (Figure 3.7). 
Exon 7 could not be amplified from genomic DNA preparations ofF764 and F765. These 
results suggest that the deletion of exon 7 in HPRT cDNA of these two HPRT variants is 
most likely to be the result of a deletion spanning exon 7 within the HPRT geny. 
However, in view of the difficulties experienced in amplification of exon 7 with the primer 
pair LNl and LN2, this interpretation of the results is speculative and these two patients 
require further investigation in order to define the defects at the gene level. 
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A single, larger than expected PCR product was amplified from F749. Direct sequencing 
of the amplified cDNA showed a 60 bp insertion between the boundaries of exon 6 and 7 
(Figure 3.8). A search of the HPRT gene sequence showed that the inserted sequence was 
derived from intron 6 with the 5'-end of the insert located at nt 36223 (1204 bp from the 3' 
boundary of exon 6) and the 3'-end of the insert at nt 36282 (3533 bp from the 5' 
boundary of exon 7). 
In order to examine the flanking sequences of the insert in more detail, genomic DNA 
prepared from F749 was amplified using primers P6 and P7. These primers are located on 
either side of the intron 6 derived insertion and yielded a PCR product of approximately 
the predicted 281 bp size in both the patient and a control. Direct sequencing of PCR 
products revealed a 36221-T to A transversion in the genomic 5'-flanking sequence of the 
60 base insertion (Figure 3.9). 
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Figure 3.8: Sequence of the 60 
base pair cDNA insertion 
identified in F749. The insertion is 
derived from intron 6 and is inserted 
between exon 6 and exon 7 of the 
HPRT cDNA. The inserted sequence 
is numbered according to Edwards 
et al (1990). 
Reference F749 
T-36228 
~""-
A GA T C 
T 
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Figure 3.9: A 36221-T to A G G 
transversion in intron 6 of the g g 
HPRT gene of F749 creates a 3' t a 
splice site. Nucleotides flanking the C C C C 
insertion are shown in lower case. t t 
t !/ t 
c-36215 C 
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Amplification ofHPRT cDNA from F751 yielded two low molecular weight bands (Figure 
3.3). Initial attempts at directly sequencing the lower molecular weight PCR product was 
complicated by the difficulty in separating the two bands completely on standard agarose 
gels. Direct sequencing of the low molecular weight PCR product showed a deletion of 
exons 2, 3, 4, and 5. However, it was possible to read a superimposed shadow sequence 
which appeared to be HPRT cDNA derived (data not shown). 
For this reason, both PCR products were separately excised, cloned and sequenced. The 
lower molecular weight band, or Type A cDNA transcript, showed a 375 bp deletion of 
. 
exons 2, 3, 4 and 5 (Figure 3.10). The higher molecular weight band (Type B transcript) 
showed a 357 bp deletion of exons 2, 3, and 4 (Figure 3.10). The two HPRT cDNA 
transcripts identified in F751 thus share a deletion of exons 2, 3 and 4, but differ in the 
presence or absence of exon 5. A total of 10 clones, 6 of the low molecular weight PCR 
products and 4 derived from the higher molecular weight species, were sequenced. All the 
clones proved to be either Type A or Type B transcripts. 
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Figure 3.10: The two HPRT cDNA transcripts isolated from F751 share a deletion 
of exons 2, 3 and 4, but differ in the presence or absence of exon 5. Type A 
transcripts are characterised by a deletion of exons 2, 3, 4 and 5. Type B transcripts are 
characterised by a deletion of exons 2, 3 and 4. The HPRT cDNA sequence is numbered 
with the A of the ATG start codon numbered as nucleotide 1. 
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3.4 Discussion. 
A review of mutations reported in Lesch-Nyhan patients (Table 3.2) shows remarkable 
genetic heterogeneity which is in accordance with Haldane's principle (Haldane, 1935). 
Haldane predicted that lethal X-linked mutations that confer no advantage to 
heterozygotes, would frequently arise as spontaneous new mutations. Complete selection 
against 50% of a carrier female's male offspring would result in a rapid loss of the 
deleterious mutation from the population and as a result, about one third of mutations at 
an X-linked locus are likely to have arisen de novo. 
The neurological features of the Lesch-Nyhan syndrome are a consequence of severely 
impaired HPRT activity of usually less than 1 % of control values. It is not surprising that 
nearly 50% of the reported mutations in the Lesch-Nyhan syndrome are insertion or 
deletion events (based on a survey of in vivo HPRT mutations shown in Tables 3.2 and 
4.4). The effect of a DNA insertion or deletion on protein structure is not restricted to a 
single amino acid and in two thirds of cases, would result in an alteration of the reading 
frame. Termination codons account for 3 of 64 codons and a termination codon would be 
expected to occur in a random sequence once every 21 codons. A cDNA insertion or 
deletion event is thus likely to result in incorrectly coded amino acids as well as premature 
termination of the amino acid sequence. This would lead to total disruption of protein 
structure and function. Even without sequencing, the size of the HPRT cDNA amplified 
from the nine patients investigated gives an indication of the nature of the mutation. Three 
classes of mutations were distinguished: 
1. Null mutations: no amplifiable HPRT mRNA. 
2. Single base substitutions and small deletion/insertion events: mutations 
which do not significantly alter the size of the amplified cDNA. 
3. Large deletion/insertion events: mutations resulting in a detectable change 
in the size of the amplified HPRT cDNA. 
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Table 3.2: Survey of in vivo mutations in HPRT which result in an altered 
protein size. 
Variant cDNAChange Predicted Change Comment Reference 
in Protein 
Female nocDNA no translation entire gene deleted, Ogaswara et al, 
non-random X- 1989 
inactivation 
RJK 853 (McA) nocDNA no translation entire gene deleted, Yang et al, 1984; 
nomRNA, Wilson et al, 1986a 
noCRM 
P748 no amplifiable no translation deletion not defined this study 
(MJ) cDNA 
P750 no amplifiable no translation deletion not defined this study 
{MP) cDNA 
HPRT Illinois 13 bp deletion cannot predict partially deficient, Wilson et al, 
(RKJ 951 , RT) nt -12 to 1 A of ATG start 1986a; Gibbs et 
codon deleted, al, 1989; 
normal mRNA Davidson et al, 
levels, 0.8% CRM 1994 
1151 G3toA cannot Eredict start codon altered Tarle et al, 1991 
P768 insertion single T 10 amino acids this study 
(LH) between nt 22 and 
24 
RJK 1760 deletion exon 2 10 amino acids Gibbs et al, 1990 
{CB} {nt 23 to 134) 
GM1662, 25 duplication of 315 amino acids noCRM Yang et al, 1988 
(OM) exons 2 and 3 partial activity, Sege-Peterson et al, 
1.6% 1992 
P751 deletion exons 2, 3, 93 and 99 amino deletion of exons 2, this study 
(AB) and 4 or deletion of acids 3, and 4. Exon 5 
exons 2, 3, 4, and 5 alternatively 
liced 
HPRTCbicago insertion single T 19 amino acids normal mRNA, Wilson et al, 1986; 
(OM) (run of 2 Ts, nt 56 noCRM Davidson et al, 
and 57} 1989a 
1423 deletion 217 amino acids Tarle et al, 1991 
ATI nt 80 to 82 Tyr 28 deleted 
RJK 1939 (BB) deletion single T 51 amino acids Gibbs et al, 1990 
(either nt 125 or 
126) 
TH C 151 to T Arg 51 to Stop same mutation in 5 Fujimori et al, 
HPRT Shelford 50 amino acids different patients 1990; Davidson et 
754-4 al, 1991; Tarle et 
AS al, 1991; 
MS Sege-Peterson et al, 
1992 
RJK.2108 deletion nt 155 to 71 amino acids Gibbs et al, 1990 
(RK) 195 
HPRT eoorparoo insertion T 171 25 amino acids nomRNA, Keough et al, l 98S; 
{JG} noCRM Gordon et al, 1991 
66 
Variant cDNAChange Predicted Change Comment Reference 
in Protein 
RJK.866 insertion of a G in 72 amino acids same mutation in 2 Gibbs et al, 1989; 
(CW) run of 6 G between different patients Tarle et al, 1991 
1650 nt 207 and 212 
Family 10 insertion T288 106 amino acids same mutation in 2 Gibbs et al, 1986; 
HPRT Codicote (run of 2 T nt 288 different patients Davidson et al, 
and 289) 1991 
RJK 1322 (RC) deletion GT 289, 105 amino acids same mutation in 3 Gibbs et al, 1989; 
Patient 3 290 different patients Watts et al, 1982; 
HPRT Cheltenham Davidson et al, 
1991 
P766 insertion of a T in a 106 amino acids this study 
(LW) run of 4 T between 
nt 194 and 297 
RJK 1747 deletion GT 317, 105 amino acids Gibbs et al, 1990 
( 318 
Case4 deletion 5 bp 5 ' - 112, 196 and 215 splice junction Yamada et al, 1992 
endofexon 4 amino acids altered, multiple 
~nt 319-322) mRNA transcriEts 
1052 deletion exon 4 196 amino acids same mutation in Tarle et al ,1991 
1757/1758 (nt 319-384) different patients 
(sibs) 
HPRT Bamberi~e Davidson et al, 
1991 
RT Sege-Peterson et al, 
1992 
RJK 1930 C 325 to T Gln 109 to Stop Gibbs et al, 1991 
PW C 368 to G Ser 123 to Stop Lesch-Nyhan Sege-Peterson et al, 
1992 
TL insertions between additional amino A 32863 to G Sege-Peterson et al, 
exon 5 and6 acids added creates 5' splice 1992 
site, multiple 
transcripts, partial 
activity, 50% 
activi 
RJK 2019 deletion single T, 130 amino acids Gibbs et al, 1990 
either nt 391 or 392 
HPRTCbemside deletion exon 6 146 amino acids splice junction Keough et al, 1988; 
(RW) (nt 402 to 484) mutation, no RNA Gordon et al, 1991 
0.5%CRM 
RJK 984 deletion exons 6, 7, 7989 bp genomic Fuscoe and Nelsen, 
8 and 9 deletion from nt 1994 
34612 to 42600 
MiG deletion nt 403 to Asp 135 to Val 150 abnormal splicing, Sege-Peterson et al, 
452 deleted, premature multiple 1992 
termination transcripts, cryptic 
splice site in exon 6 
utilised 
Eartial, 9% activi~ 
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Variant cDNAChange Predicted Change Comment Reference 
in Protein 
RW Insertion GCA at 219 amino acids partial activity Sege-Peterson et al, 
nt 429 insertion of Ala 7.5% 1992 
after Met 143 
1656 insertion single T 153 amino acids Tarle et al, 1991 
in run of T's 
nt 435-437 
HPRTParis T 459 to G Tyr 153 to Stop Female Lesch- Aral et al, 1996 
Nyhan, non-
randomX-
inactivation 
P749 insertion 60 nt 177 amino acids T 36221 to A in this study 
(PP) between exon 6 and intron 6 creates 3' 
exon 7 splice site for a new 
"exon" 
P526 deletion exon 7 165 amino acids same mutation in 7 this study 
(JM) (nt 485 to 532) different patients this study 
P764 this study 
(DT) Mckeran et al, 
P765 1975; Watts et al, 
(JR) 1982; ; Gibbs et al, 
HPRT eou1sc1en 1986; Davidson et 
(Family 4) al, 1991 ; 
Family 8 Gibbs et al ,1986; 
(DAG25) Davidson et al, 
DAG33 1991 
Sege-Peterson et al, 
DL 1992 
HJ duplication of 315 amino acids Lesch-Nyhan Marcus et al, 1993 
exons 7 and 8 Alu-Alu 
recombination 
RJK 974 C 508 to T Arg 169 to Stop same mutation in 5 Gibbs et al, 1989; 
169 amino acids different patients Watts et al, 1982; 
Patient 4 Gibbs et al, 1986; 
(Family 3 Davidson et al, 
HPRTNorth Mymms) 1991; 
1321 Tarle et al, 1991 
NB family Marcus et al, 1992; 
GS normal mRNA Burgemeister et al, 
2.2% activi!l'. 1995 
1266 insertion GT in 189 amino acids Tarle et al, 1991 
repeat sequence 
between nt 511 and 
517 
RJK 1894 (PK) deletion 217 amino acids Gibbs et al, 1990 
GTT 514-517 
RJK 1210 deletion of 5 bases 153 amino acids Gibbs et al, 1989 
insertion of 6 bases 
HPRT Chemside deletion exon 6 146 amino acids splice junction Keough et al, 1988; 
(RW) (nt 402 to 484) mutation, no RNA Gordon et al, 1991 
0.5%CRM 
Variant 
HPRT Conne,sville 
(HD) 
RJK.888(GM 
7092) 
HPRTMichiJ7,ll]l 
(DA, RJK 855) 
RJK 906 
(GM 1899) 
Case 5 
HPRT Brierly Hill 
HPRT Evansville 
(BS, RJK 894) 
Japan 3 
cDNAChange Predicted Change 
in Protein 
deletion exon 8 182 amino acids 
(nt 533 to 609) 
deletion 217 amino acids 
GTI 535-537 or 
TIG 536-538 
deletion 17 bp, 203 amino acids 
cryptic splice site 
deletion 58 bp 5' - 233 amino acids 
end of exon 9 (nt 
610 to 567). 
Insertion of 26 bp 
of3 ' -end of 
intron 8 
deletion GT 617, 127 amino acids 
618 
deletion 242 amino acids 
(nt 643 to 663 
deletion nt 648-698 216 amino acids 
68 
Comment Reference 
nonnalm.RNA Wilson et al, 
noCRM 1986a; Davidson et 
Same mutation in 2 al 1989a; Gibbs et 
patients al, 1989; Gibbs et 
al, 1990 
nonnalm.RNA Wilson et al, 
noCRM 1986a: Davidson et 
al, 1989a; 
Gibbs et al, 1989 
normalm.RNA Wilson et al, 
1.3%CRM 1986a; Gibbs et al, 
1989; Gibbs et al, 
1990 
7 4 bp genomic Yamada et al, 1992 
deletion from 
intron 8 to exon 9 
Alternative splice 
site utilisation 
Davidson et al, 
1991 
normal m.RNA Wilson et al, 
noCRM 1986a; Davidson et 
al, 1989a; 
Gibbs et al, 1990 
partially deficient lgarashi et al, 1989 
The amino acid sequence is numbered with the methionine coded by the ATG start codon as residue 1. 
The HPRT cDNA sequence is numbered with the A of the ATG start codon numbered as nucleotide 1. 
The sequence of the HPRT gene is numbered according to Edwards et al (1990). 
Abbreviations: nt , nucleotide; crm, HPRT immunoreactive material. 
All of the mutations described in the patients investigated in this study resulted in cDNA 
insertion or deletion events. Premature termination of the translated sequence due to an 
early encounter with a nonsense codon resulted in a change in the predicted size of the 
protein in those cell lines with an amplifiable HPRT mRNA (Figure 3.10). Premature 
translation termination has been reported to trigger deadenylation-independent mRNA 
decapping and consequently, an increased rate of mRNA degradation (Muhlrad and 
Parker, 1994). The qualitative decrease in the levels of HPRT mRNA noted in the 
amplification of HPRT cDNA from F526 using primers Plb-P2 and the low levels of 
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HPRT mRNA reported in many Lesch-Nyhan patients (Table 3.2), may well be an 
illustration of this phenomenon. 
3. 4 .1 Null Mutations. 
The defect in two of the Lesch-Nyhan cell lines, F748 and F750, appears to be the result 
of structural deletions affecting either one or both of the PCR primer binding sequences 
located in exons 1 and 9. Although the extent of the deletion has still to be determined, 
the experimental evidence suggests that the defect is not confined to a local area about 
either exon 1 or exon 9. A segment of intron 6 near the center of the HPR T gene could 
not be amplified in these two cell lines which indicates that the deletion is very large. 
Complete deletions of the HPRT gene appear to be relatively rare mutational events, with 
only two such mutations having been previously reported (see Table 3.2). However, a 
deletion of exons 6, 7, 8 and 9 has been reported. 
3.4.2 Single Base Insertions. 
The single base insertions found in F766 and F768 are novel mutations which result in a 
shift in the reading frame and premature termination of the predicted amino acid sequence 
(Figure 3.11). 
In F766, the frame shift due to the insertion of a T within the sequence 293-ATTTTA-
298, results in a predicted protein of 106 amino acids (Figure 3.10) compared to the 
normal predicted protein of 218 amino acid residues. A review of in vivo somatic and 
germinal mutations at the HPRT locus by Cariello and Skopek (1993b), showed that 23 of 
34 single base insertions or deletions shifts were found in runs of two or more identical 
nucleotides. The data presented in Table 3 .2 shows that single base pair insertions 
previously reported in the Lesch-Nyhan syndrome are more common than single base pair 
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deletions (5 single base deletions compared to 2 insertions). Four of these mutations 
occur within two or more mononucleotide runs and 6 of the 7 mutations involve the 
insertion or deletion of a single T. 
The insertion found in F766 is consistent with the Streisinger strand slippage model of 
frameshi:ft mutagenesis (Streisinger and Owen, 1985). Streisinger proposed that during 
DNA replication, should the polymerase stall at a run of identical nucleotides, the DNA 
strands could misalign. When DNA replication resumes, an insertion or deletion of a 
single nucleotide would result. 
The single base insertion defined in F768 results in a predicted protein of 11 amino acids 
(Figure 3.11). The insertion of a T between nucleotides 22-G and T-23 or 23-T and 24-C 
occurs within the context of the sequence 21-CGTCG-25, which has the potential to form 
a small hairpin loop. Two to seven base repeats have been associated with spontaneous 
deletions in E. coli (Nalbantoglu et al, 1986), in human HPRT (Cariello and Skopek, 
1993b) and human mitochondrial DNA (Mita et al, 1990) and are associated with two of 
the GT deletions (GT2s9,290 and GT311,31s) previously described in Lesch-Nyhan patients 
(Table 3.2). Insertions within hairpin loops have not previously been reported in Lesch-
Nyhan syndrome patients. It is likely that the sequence context of the insertion defined in 
L768 is fortuitous and the presence of a hairpin loop does not imply a particular 
mutational mechanism. 
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10 20 30 40 
HPRT MATRSPGWI SDDEPGYDLD LFCIPNHYAE DLERVFIPHG 
F751-B MATRSPGW- ---------- ---------- ----------
F751-A MATRSPGW- ---------- ---------- ----------
F749 MATRSPGWI SDDEPGYDLD LFCIPNHYAE DLERVFIPHG 
F526 MATRSPGWI SDDEPGYDLD LFCIPNHYAE DLERVFIPHG 
F766 MATRSPGWI SDDEPGYDLD LFCIPNHYAE DLERVFIPHG 
F768 MATRSPGVRD * 
50 60 70 80 
HPRT LIMDRTERLA RDVMKEMGGH HIVALCVLKG GYKFFADLLD 
F751-B ---------- ---------- ---------- ----------
F751-A ---------- ---------- ---------- ----------
F749 LIMDRTERLA RDVMKEMGGH HIVALCVLKG GYKFFADLLD 
F526 LIMDRTERLA RDVMKEMGGH HIVALCVLKG GYKFFADLLD 
F766 LIMDRTERLA RDVMKEMGGH HIVALCVLKG GYKFFADLLD 
F768 
90 100 110 120 
HPRT YIKALNRNSD RSIPMTVDFI RLKSYCNDQS TGDIKVIGGD 
F751-B ---------- ---------- ---------- ----------
F751-A ---------- ---------- ---------- ----------
F749 YIKALNRNSD RSIPMTVDFI RLKSYCNDQS TGDIKVIGGD 
F526 YIKALNRNSD RSIPMTVDFI RLKSYCNDQS TGDIKVIGGD 
F766 YIKALNRNSD RSIPMTVDFY QTEELL* 
F768 
130 140 150 160 
HPRT DLSTLTGKNV LIVEDIIDTG KTMQTLLSLV RQYNPKMVKV 
F751-B --------NV LIVEDIIDTG KTMQTLLSLV RQYNPKMVKV 
F751-A ---------- ----DIIDTG KTMQTLLSLV RQYNPKMVKV 
F749 DLSTLTGKNV LIVEDIIDTG KTMQTLLSLV RQYNPKMVKV 
F526 DLSTLTGKNV LIVEDIIDTG KTMQTLLSLV RQYNPKMVKV 
F766 
F768 
170 180 190 200 
HPRT ASLLVKRTPR SVGYKPDFVG FEIPDKFWG YALDYNEYFR 
F751-B ASLLVKRTPR SVGYKPDFVG FEIPDKFWG YALDYNEYFR 
F751-A ASLLVKRTPR SVGYKPDFVG FEIPDKFWG YALDYNEYFR 
F749 ARYMLWN* 
F526 ASCWI* 
F766 
F768 
210 
HPRT DLNHVCVISE TGKAKYKA* 
F751-B DLNHVCVISE TGKAKYKA* 
F751-A DLNHVCVISE TGKAKYKA* 
Figure 3.11: A comparison of the predicted amino acid sequence due to the 
insertion or deletion events defined in HPRT cDNA of 7 Lesch-Nyhan patients. 
HPRT, normal predicted HPRT amino acid sequence with methionine coded by the ATG 
start codon numbered as residue 1. F751-A and F75 1-B, Type A and Type B cDNA 
transcripts respectively. The predicted amino acid sequence in F526 is identical to that of 
F764 and F765. 
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3.4.3 Large Deletion or Insertion Events. 
3.4.3.1 Deletions ofExon 7. 
The 47 bp deletion of exon 7 in three patient cell lines F526, F764 and F765 cause a shift 
in the reading frame and premature termination, resulting in each case, in a predicted 
protein of 165 amino acids (Figure 3 .11 ). The cDNA deletions in F764 and F765 have not 
been defined at the gene level. It is possible that a genomic deletion including one or both 
of the splice junctions defining exon 7 is responsible for the deletion in these two patients. 
Preliminary results suggesting that the cDNA deletions of exon 7 in F764 and F765 are 
due to & genomic DNA deletion of exon 7, are not totally convincing. The technical 
difficulties experienced in amplifying exon 7 from genomic DNA of controls points to the 
need for alternative PCR primers to reliably amplify exon 7. Only then can it be 
determined whether the cDNA deletions of exon 7 defined in F764 and F765 are due to 
splice junction mutations, or due to deletions of the exon at the gene level. 
The dinucleotide AG at the intron-exon boundary of a 3' splice site or splice acceptor is 
highly conserved (Mount 1982). The A of the dinucleotide is not invariant and a 
pyrimidine in this position has been occasionally reported in the non-consensus splice 
acceptors of some alternatively spliced exons (Jackson, 1991). The G of the AG 
dinucleotide is however, absolutely conserved and is necessary for splicing to occur. The 
cDNA deletion of exon 7 in F526 is the result of a 39815-G to T transversion in the 
invariant G of the terminal AG of the intron 6 splice acceptor. The mutation destroys the 
intron 6 splice acceptor and results in the skipping of exon 7 during HPRT pre-mRNA 
splicing. 
Four cDNA deletions of exon 7 have been reported in the literature (see Table 3.2) and 
together with the three apparently unrelated patients reported in this study, represent the 
largest single group of deletion mutants in the Lesch-Nyhan syndrome. Until the 
mutations responsible for the deletion of exon 7 in the patients in this study and those 
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reported in the literature have been defined at the genomic level, it is not possible to 
determine whether the cDNA deletion of exon 7 represents a mutational hot spot. 
3.4.3.2 The Creation of a New Exon. 
The 36221-T to A single base transversion in intron 6 defined in F749 effectively creates a 
new exon. The detection of this mutation is an illustration of the power of screening for 
mutations at the cDNA level as opposed to genomic exon by exon screening. The 
amplification of a larger than predicted PCR product from HPRT cDNA is an indication 
from the outset that an insertion has occurred. DNA sequencing of the amplified cDNA 
provides the information necessary to determine the origin of the inserted fragment. PCR 
primers for exon by exon screening of genomic DNA are usually located within 200 bp of 
the intron-exon boundaries and are unlikely to be positioned so as to amplify a segment of 
DNA located thousands of bases from any exon boundary. In essence, if an exon by exon 
screening strategy had been used to screen HPRT genomic DNA from this patient, no 
mutation would have been detected. 
Although the insert is in-frame, stop codons within the intron derived sequence result in 
premature termination after coding for 6 incorrect amino acids. A shortened protein of 
167 amino acids is predicted (Figure 3.11). The T to A transversion occurs within a 
pyrimidine rich region bounded by TGG at the 3' end (Figure 3.12). 
A number of cis acting sequence elements and trans acting factors are required for the 
splicing of an intron (see reviews by Aebi and Weissman, 1987; Smith et al, 1989; 
Horowitz and Krainer, 1994; Norton 1994). The 5' splice site consensus sequence is 
exon-(C or A)AG/GTRAGT-intron with the vertical line indicating the exon-intron 
boundary. The GT dinucleotide at the exon-intron boundary is strictly conserved. The 3' 
splice site is composed of 3 elements: the conserved splice sequence intron-Y AG/G-exon, 
a stretch of pyrimidines typically found immediately adjacent and upstream of the 3' splice 
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site and a loosely defined branch point with the consensus sequence YNYTRA Y, typically 
found 20-40 nucleotides upstream from the 3' splice site. The only highly conserved bases 
are the AG at the intron-exon boundary of the 3' splice site. 
In addition, downstream purine-rich exonic enhancer elements may act as cis acting 
modulators of intron splicing efficiency (Dirksen et al, 1995; Chiara and Reed, 1995; 
Takeshima et al, 1995). G rich sequences present in the 5' part of introns may also 
enhance the splicing reaction (Sirand-Pugnet et al, 1995). 
36010 36020 36030 36040 36050 
ATAGATTTGG GACAGGTACT ATGAGAGTAT ATAAGTGATA CGTTATAGGA 
36060 36070 36080 36090 36100 
CACTAACTAG TATCCTATGA AATGGCAAAA ACTGCAATCA CTTTTGCACC 
36110 36120 36130 36140 36150 
AACCAAATAG AAACTAATCA GTGCACTTGC TTATTTTTCT ACATGCTCTT 
36160 36170 36180 36190 36200 
TAGGGTTTTA AATGTCAACC TACTGTGGCA TAGACTTTAA TCCTCTGGGT 
36210 36220 + 36230 36240 36250 
ATTCTTTTGT TGTTCTTTCC AGpTATATGC TGTGGAATTG AGATAGACTGI 
36260 36270 36280 36290 36300 
!GTTCGTGAGC GAGAGATTTT GTGTTGCCAC AGi:;TAGGACA TGCTCAAACA 
36310 36320 36330 36340 36350 
ATACTTGGGT CATTTCTTGA CCCAAGTCAT CTATTCACCA TAGTTTTGTA 
36360 36370 36380 36390 36400 
GCACCGATCT TGCATACATT TCATGTATCT TCTTTGAACC CCACGTCAGT 
Figure 3.12: The sequence context of the T to G transversion at nucleotide 36221 
within intron 6 which creates a new exon in F749. The mutation is indicated by an 
arrow. The sequence inserted within HPRT cDNA is shown in the rectangle. 
Components of the 3' splice site and downstream 5' splice site are double underlined. A 
cryptic upstream 3' splice site and possible branch site, which are not used in splicing are 
shown single underlined. The sequence and numbering are according to Edwards et al 
(1990). 
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Within this context, the mutation creates an AG dinucleotide at bases -2 and -1 from the 
insert boundary, which is characteristic of the highly conserved 3' splice site or splice 
acceptor. The insert is bounded at the 3' end by a sequence with homology to the 
consensus sequence for a 5' spli~e site or splice donor. Only one abnormally large species 
of HPRT cDNA could be amplified from F749 in a highly sensitive nested primer 
amplification system and direct sequencing showed only one sequence. This evidence 
suggests that both the newly created splice acceptor and cryptic splice donor brought into 
use are "tight", in the sense that only a single mRNA species is spliced. In addition, the 
clinical features of the Lesch-Nyhan syndrome reported in the patient and the 
demonstration of severely impaired [14C] hypoxanthine incorporation by the cell line F749, 
argue against the synthesis of any detectable amount of normal HPRT mRNA in F749. 
A sequence 36130-CTTATTTTTCTACATGCTCTTTAG GGT-36156 with good 
homology to a splice acceptor already exists 48 bases 5' to the newly created splice 
acceptor. While this sequence has less homology to the consensus splice acceptor than the 
new splice acceptor, it is a better fit to the consensus sequence than the true intron 6 
acceptor (sequence intron 6-TTTTGTAATTAACAG/CTT-exon 7). This raises the 
question: why is the existing cryptic splice acceptor sequence at nt 36130 to nt 36154 not 
used in splicing HPRT pre-mRNA, considering that the sequence 36280-CAG/GTAGGA-
36288 is shown as able to act as a splice donor in the variant HPRT pre-mRNA ofF749? 
Splicing of an intron from a pre-mRNA is thought to occur in two steps involving 
successive transesterification reactions ( see reviews by Smith et al, 1989; Horowitz and 
Krainer, 1994). The first step involves cleavage at the 5' exon and creation of a lariat 
intermediate by an attack of the 2'0H of the internal branch site adenosine on the 5' splice 
site. The second step is thought to involve an attack of the 3'0H of the 5' exon on the 3' 
splice acceptor, ligation of the exons and the release of the lariat intron from the mature 
mRNA. 
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The mechanisms by which splice site pairs are recognised and distinguished from cryptic 
splice sites are not clear. A number of trans-acting factors are involved in the recognition 
of a splice site and assemble into a highly ordered spliceosome. Initial recognition of the 5' 
splice site is primarily by base pairing and binding of Ul small nuclear ribonucleoprotein 
(snRNP). Identification of the 5' splice site takes place early in the splicing pathway and 
may occur in parallel with recognition of the 3' splice site (Horowitz and Krainer, 1994). 
Recognition of the 3' splice site and branch site is promoted by the binding of several 
proteins, including U2AF which directs U2 snRNP towards the 3' splice site. The U2 
snRNP base pairs with the branch site, although often these RNA sequences have limited 
complementarity. U2 binding is mediated by Ul snRNP but does not depend strictly on 
the presence of a 5' splice site. Interaction ofUl snRNP with a downstream splice site or 
exonic enhancer may target components to the 3' splice site (see references in Tam and 
Steitz, 1995). The pre-spliceosome composed of Ul and U2 snRNPs and other proteins 
then binds to a complex of U4, U5, and U6 snRNPs to form the spliceosome. In 
mammalian systems, Ser/ Arg rich (SR) proteins may be involved in recruiting Ul snRNP 
to the 5' splice site and are also involved in promoting the binding of U2 snRNP to the 3' 
splice site, even in the absence ofUl snRNP (Tam and Steitz, 1995). 
There is still uncertainty as to whether recognition of the 5' splice site of an intron occurs 
first and then directs recognition of the downstream 3' splice site of the intron. There is 
however, accumulating evidence that 3' splice site choice can occur first and direct across 
an exon, the choice of a downstream 5' splice site. In many pre-mRNAs, the closest 
downstream 5' splice site to a 3' splice site is used in preference to more distant candidate 
5' splice sites (Horowitz and Krainer, 1994). This is in line with the exon definition model 
of splice site choice (proposed by Roberson et al (1990) and reviewed by Stephens and 
Schneider, 1992; Horowitz and Krainer, 1994; Norton, 1994) which proposes that the 
spliceosome binds the 3' splice site first and then searches 5' to 3' across the adjacent 
downstream exon for the next 5' or donor splice site. Once two exons have been located, 
the intervening intron is removed. However, the model cannot be generalised to all 
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pre-mRNAs (Horowitz and Krainer, 1994) and other factors are likely to play a role in 
defining both exons and introns. 
Nevertheless, there is accumulating evidence that 3' splice site choice may direct 5' splice 
site choice across an exon. Interactions mediated by SR proteins between Ul snRNP and 
components assembled at the 3' splice site may direct 5' splice site selection (Tam and 
Steitz, 1995), while Chiara and Reed (1995) provided further evidence from trans splicing 
experiments that selection of the 5' splice site can occur after assembly of the 3' splice site 
complex, if the 3' splicing substrate contains a downstream exonic enhancer or 5' splice 
site. 
The cryptic 5' splice site 36280-CAG/GTAGGA-36288 used in splicing of the insertion in 
F749 HPRT pre-mRNA, has reasonable homology to the consensus 5' splice site sequence 
exon-(C or A)AG/GTRAGT-intron. An identical cryptic splice site is located 160 
nucleotides downstream. The absence of any amplifiable mRNA transcripts utilising the 
second downstream cryptic 5' splice site suggests that the splice site sequence has 
sufficient strength to avoid alternative use of this downstream cryptic 5' splice site. The 
use of the closest downstream 5' splice site in preference to other splice sites located 
further downstream is consistent with the observations of other investigators ( see 
references in Horowitz and Krainer, 1994). 
The selection of the new pair of splice sites which define the insert in F749, may be the 
result of the creation of a 3' splice site which is "stronger" than a nearby upstream cryptic 
3' splice site. The first component of this added "strength" is the greater homology to the 
consensus sequence of the newly created 3' splice site. Only 2 purines are present in the 
19 nucleotide polypyrimidine tract compared to 4 purines in the 21 nucleotide 
polypyrimidine tract of the upstream cryptic 3' splice site. Although the intrinsic strength 
of a splice site sequence is not absolutely related to the degree of homology to the 
consensus sequence (Lear et al 1990; also see review by Smith et al, 1989), Dirksen et al 
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(1995) have shown that mutating splice sites towards the consensus sequence can lead to 
complete splicing of introns which are normally alternatively spliced. 
A second element adding to the strength of the new 3' splice site is the potential branch 
site sequence 36185-CTTTAAT-36191 located within 30 bases of the 3' splice site which 
has 100% homology to the consensus sequence YNYTRA Y. In contrast, the potential 
branch point sequence 36112-AACTAAT-36118 located 34 nucleotides upstream of the 
cryptic 3' splice site, differs from the consensus branch sequence by the presence of a 
purine at the 5' end. Sub-optimal branch site sequences have been shown to decrease the 
intrinsic strength of a 3' splice site (Champion-Arnaud et al, 1995) and have been 
implicated in mechanisms of alternative splicing (Dirksen et al, 1995; Andreadis et al, 
1995). 
It is interesting that the insertion contains a 10 nucleotide purine-rich sequence, 36257-
GAGCGAGAAGA-36266. It is possible that this sequence could act as an exonic 
enhancer element. Although this element would be included in the "exon" were the cryptic 
3' splice site to be used, the element could be a contributor to raising the strength of the 
newly recognised splice site pair above a splicing threshold. 
The defining of the new exon in the variant HPRT pre-mRNA is consistent with a splicing 
mechanism which depends on the initial recognition of the 3' splice site, followed by 
scanning downstream across the exon and identification of the 5' splice site. The creation 
of a 3' splice site which leads to pre-mRNA splicing of a new exon thus provides further in 
vivo evidence in support of the exon definition model. 
In summary, a single nucleotide substitution within intron 6 has led to the creation of a 
new 3' splice site. The good homology of the polypyrimidine tract and branch point 
sequence of the new 3' splice site in F749 to the consensus sequence, are likely to 
contribute to committing the variant HPRT pre-mRNA to the splicing pathway. 
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3.4.3.3 A Deletion of Exon 2, 3, 4 and 5. 
Both HPRT cDNA transcripts sequenced in F751 share a deletion of exons 2, 3 and 4. 
Exon 5 is spliced out in the lower molecular weight transcript or Type A transcript, but is 
included in the higher molecular weight cDNA or Type B species. It would thus appear 
that a deletion of exons 2, 3, and 4 modulates the splicing of exon 5. 
Alternative splicing of an exon is dependent on the interplay between the splicing elements 
defining the exon, the intrinsic strength of the exon inherent in the exon nucleotide 
sequence and the splicing context of the exon. 
The relative strength of elements of the splice junctions is an important determinant of 
whether an exon will be alternatively spliced. The majority of alternatively spliced exons 
have suboptimal or unusually placed splicing elements (Norton, 1994). Donor splice sites 
tend to have poor complementarity to Ul snRNA, while 3' splice sites feature unusually 
long polypyrimidine tracts and multiple or unusual branch sites. 
lfit is assumed that the deletion ofexons 2, 3 and 4 in HPRT cDNA is the result of a large 
deletion in the HPRT gene which encompasses these exons, then exons 1 and 5 will be 
joined by an intervening hybrid intron derived from intron 1 and intron 4. Splicing of the 
hybrid intron will be dependent on the recognition of the intron 1 splice donor and the 
intron 4 splice acceptor. In terms of the exon definition model, exon 5 is defined by the 
upstream hybrid intron splice acceptor and the downstream intron 5 splice donor 
sequences (Figure 3. 13). 
The intron 5 splice donor (downstream of exon 5) has the sequence 31633-ANGTAAGT-
31641 , which differs from the consensus donor sequence at nt 3163 3-G and nt 3 163 5-A in 
the exonic nucleotides of the splice site. The last nucleotide of the exon (31635-A) is 
probably the more important of the two nucleotides in influencing splice site strength. The 
G at this position in the consensus sequence is well conserved. 
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31510 31520 31530 31540 31550 
GCATCTAAAA ACAAGAGTTT GGATAATTCC TTAGGGTTGT TATGATGTG8 
51560 31570 31580 31590 31600 
TTTGACTTAT AATTGGAAAT ACCGTTTTAT TCATTGTACT GATTTTCATT 
31610 31620 31630 31640 31650 
TCTCTTTTTC TTCTAqAATG TCTTGATTGT Gaj.GTAAGT TCACATTTAC 
31660 31670 31680 31690 31700 
TTTTAATATA ACATTTATGA CTTTTCTAAC TTAGTATGCA CCATCCTAAA 
31710 31720 31730 31740 31750 
GGTAAGCCAG GGAGAGAAAT TCCTCTGCAT CAGTTTTAAT GGTGGGCTTG 
Figure 3.13: The sequence context of exon 5. Nucleotides of exon 5 are shown within 
the rectangle. Components of the 3' splice site and downstream 5' splice site are double 
underlined. A potential branch site located close to the polypyrimidine tract, but with 
poor homology to the consensus branch site sequence, is shown single underlined. The 
sequence and numbering are according to Edwards et al (1990). 
An analysis of 1800 authentic splice donor sequences by Stephens and Schneider (1992) 
showed only 169 splice donor sequences with an A in this position. 
The intron 4 splice acceptor which is used in splicing the hybrid intron in F751 has the 
sequence 7294-TTTTCATTTCTCTTTTTCTTCTAG/ A-7318, which with the exception 
of the first nucleotide of the exon, compares favourable to the consensus splice acceptor 
intron-Y nAG/G-exon. The 22 nucleotide polypyrimidine tract has only one purine within 
the sequence. The only difference between the authentic splice acceptor and the 
consensus sequence is at the first nucleotide of the downstream exon. This position is not 
particularly conserved and 25% of the 1800 authentic splice acceptors analysed by 
Stephens and Schneider (1992) had an A nucleotide in this position. The consensus 
branch site sequence is YNYTRAC. Two potential branch site sequences exist upstream 
of the 3' splice site. The sequence 7285-ATTGTAC-7290 has poor homology to the 
consensus branch site sequence and is located within 40 base pairs of the splice junction. 
The second sequence, 7251-ATTTGAC-7257, has 100% homology to the consensus 
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branch site sequence and is located within 60 base pairs of the splice site. The cis acting 
splicing elements identified which could potentially effect alternative splicing have, with 
the exception of the exonic components of the elements, good homology to the consensus 
sequences. This is to be expected as exon 5 is constitutively included in the normal mature 
HPRTmRNA. 
It is possible that intrinsic features of the nucleotide sequence of exon 5 contribute to 
alternative splicing in F751. In this regard, it may be significant that at 18 bp, exon 5 is 
the smallest of the HPRT exons . Alternatively spliced short cassette exons are usually 
excluded in default pre-mRNA splicing, but are constitutively spliced if the exon is 
lengthened (Black, 1992). Exon 5 also lacks an identifiable purine rich element which may 
promote constitutive splicing (Dirksen et al, 1995; Chiara and Reed, 1995; Takeshima et 
al, 1995). The non-consensus nucleotides constituting the exon located components of 
the splice sites may also contribute to the decreased intrinsic strength of exon 5. 
Andreadis et al (1995) showed that the context of an alternatively spliced exon can 
influence splicing. Splicing of a small cassette exon was dependent on the presence of a 
pre-spliced upstream exon. Splicing of exon 5 in normal HPRT pre-mRNA does not 
appear to be dependent on the presence of exon 4. Two previously reported deletions of 
exon 4 (see Table 3.2) did not apparently affect exon 5 splicing. There is however, a 
precedent in HPRT for mutations in one exon to affect the splicing of another exon. Two 
in vitro single base nucleotide substitutions within the coding sequence of exon 3 have 
been reported to result in the loss of both exons 2 and 3 in some mRNA transcripts 
(Steingrimsdottir et al, 1992). Mutations which alter the relative strength of an exon 
could alter the pattern of splicing and result in some exons being alternatively spliced. The 
juxtaposition of exon 1 and exon 5 in F75 l may lead to a decrease in the relative strength 
of exon 5 which results in exon 5 being alternatively spliced. Kessler et al (1993) 
observed a highly preferred, non-linear order in the splicing of introns in APRT pre-
mRNA. A similar, preferred order of intron removal may ensure that exon 5 is 
constitutively spliced in normal HPRT pre-mRNA splicing. 
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The two mRNA transcripts identified in F751 result in predicted proteins with a deletion 
of either amino acid residues 10 to 128 or residues 10 to 134 (Figure 3.11). The cDNA 
deletions of exons 2, 3 and 4 common to both transcripts are likely to be the result of a 
structural deletion of the HPR T gene with breakpoints located in intron 1 and intron 5. 
Edwards (1990) points out that 30% of the HPRT gene is composed of repetitive 
sequence elements and it is possible that the structural deletion responsible for the deletion 
of 3 exons in the two transcripts amplified from F751 is associated with two of these 
repetitive elements. It is interesting that more than half the HPRT structural deletions 
defined in somatic cells of new-born infants are due to a deletion of exons 2 and 3 and are 
likely to be the result of inappropriate V(D)J recombinase activity, since the breakpoints of 
the deletions show strong similarity to the consensus sequence for V(D)J recombinase 
(Cariello and Skopek, 1993b ). The breakpoints of the structural deletion in F751 need 
still to be defined, but it will be interesting to see whether at least the 5'-end of the deletion 
in intron 1 is associated with a V(D)J recombinase type recognition sequence. 
In summary, a deletion of exons 2, 3 and 4 leads to alternative splicing of exon 5. Despite 
good homology of the splice sites defining exon 5 to the consensus sequence, exon 5 may 
be an intrinsically weak exon. Constitutive splicing of exon 5 in normal HPRT pre-mRNA 
may be dependent on a preferred order of intron removal. 
3.5 Conclusion. 
All of the mutations in the nine Lesch-Nyhan patients investigated resulted in a truncated 
predicted amino acid sequence and consequent disruption of enzyme structure and 
function. The definition of the molecular defects in these patients enables appropriate 
genetic counselling based on carrier detection within affected families and adds to a 
compendium of mutations 
4. MOLECULAR AND BIOCHEMICAL 
CHARACTERISATION OF FOUR PATIENTS WITH 
PARTIAL HPRT DEFICIENCY. 
4.1 Introduction. 
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Partial HPRT deficiency results in the Kelley-Seegmiller syndrome (Kelley et al, 1969). 
Patients present with hyperuricemia due to purine overproduction, symptoms of gouty 
arthritis and occasionally, mild neurological symptoms. The degree of neurological 
impairment is inversely proportional to the residual HPRT activity measured in intact 
erythrocytes (Page et al, 1981; Fairbanks et al, 1987; Sege-Peterson et al, 1992). Patients 
with partial HPRT activity are spared the symptoms of compulsive self-mutilation 
characteristic of the Lesch-Nyhan syndrome. Partial HPRT deficiency is rare in the gouty 
population and Yu et al (1972) reported a frequency of approximately 1 patient with 
partial HPR T deficiency for every 150 patients with hyperuricemia. 
In vivo mutations at the HPRT locus show marked genetic heterogeneity (Wilson et al, 
1986a; Davidson et al 1989a; Davidson et al, 1991 ; Tarle et al, 1991; Sege-Peterson et al, 
1992; Sculley et al, 1992; Cariello and Skopek, 1993). There is some clustering of 
mutations in exons 3 and exon 5 (Tarle et al, 1991 ; Cariello and Skopek, 1993) which may 
represent functionally important areas of the enzyme or alternatively, a sequence 
dependent predisposition to mutation. 
The definition of the crystal structure of HPRT with bound GMP (Eads et al, 1994) has 
been a major step in understanding HPRT structure and function. However, the derived 
model is static and represents HPRT in a single conformation. 
Nature's experiments in the form of naturally occurring mutations can provide insight into 
the role of individual amino acids in HPRT. Patients with partial HPRT deficiency are 
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particularly important in this regard, since the molecular defect can be correlated with a 
measurable change in enzyme function, providing insight into the function of individual 
amino acids within the enzyme. 
Four patients presenting with the features of partial HPR T deficiency were investigated 
biochemically to confirm partial HPRT deficiency and at the molecular level to determine 
the nature of the defect in the HPR T gene. 
4.2 Materials and Methods. 
4.2.1 Patients. 
Patients (P) are coded in the text by celt line reference numbers (Cell Bank, Department of 
Chemical Pathology, University of Cape Town, South Africa). Cell line numbers prefixed 
by "L" are Epstein Barr virus transformed lymphoblast cultures and cell line numbers 
prefixed by "F" are fibroblast cultures derived from forearm skin biopsies. 
4.2.1.1 Cell line F45 (Patient TK). 
HPR T Cape Town is an unusual biochemical variant of HPR T described from a patient with 
gout. Steyn and Harley (1984) showed that the HPRT enzyme in haemolysates from this 
male patient was subject to marked inhibition by the purine base substrates hypoxanthine 
and guanine. This purine base substrate inhibition was not associated with changes in the 
values of the Km for hypoxanthine, guanine or PRPP, nor in the Vmax. Galloon and Harley 
(1988) showed that the property of substrate inhibition in HPRTeape Town was not restricted 
to the patient's erythrocytes and was also demonstrable in cell free assays of cultured 
lymphoblasts. Purine base inhibition ofHPRT of intermediate character was also shown in 
cell free extracts of erythrocytes and cultured lymphoblasts of the proband's daughter. 
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These results suggested that a mutation in the coding region ofHPRT itself is the basis for 
the unusual kinetics of HPRTcape Town, rather than a defect in post-translational 
modification of the enzyme. 
4.2.1 .2 Cell line L534 (Patient SM). 
Patient SM presented at the age of 38 years at Groote Schuur Hospital, Cape Town, 
South Africa, with recurrent right loin pain since the age of 17 and progressively 
worsening gout since the age of 24. On examination, he had evidence of top hi, severe 
extensive polyarthritis and bilateral knee effusions. Both knees were heavily scarred, 
apparently due to self-inflicted injuries. On questioning, the patient revealed that although 
the injuries were self-inflicted, this was treatment recommended by a traditional healer to 
release "evil spirits" from his painful joints and was not the compulsive self-mutilation 
characteristic of the Lesch-Nyhan syndrome. Further investigations revealed that he had 
moderate renal impairment, with a urea of 18.3 m.rnol/1 (control range 1.7-6.7 mmol/1), 
creatinine of 255 µmol/1 (75-115 µmol/1) , creatinine clearance of 32 ml/min (100-125 
ml/min), an elevated urate of 0.71 mmol/1 (0.12-0.50 mmol/1) and a normal urinary urate 
excretion of 3.3 mmol/day (1.5-4.4 mmol/day). He also had a urinary tract infection, 
evidence on ultrasound of bilateral hydronephrosis and dilated pelvicalyceal system, but no 
discrete stones. The knee effusion yielded negatively birefringent urate crystals. 
4.2.1.3 Cell line L867 (Patients AW) and cell line L868 (Patient GT). 
L867 and L868 were derived from patients in the United Kingdom with biochemical 
evidence of partial HPRT deficiency and were kindly supplied by John Duley and Anne 
Simmonds of the Purine Research Laboratory, Guy's Hospital, London. These cell lines 
were established by The European Collection of Animal Cell Cultures, PHLS Centre for 
Applied Microbiology and Research, Porton Down, Ul( and are stored in this repository 
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under the codes FSOOOl for L867 and FS0002 for L868. Cell lines used as controls had 
no known defect in purine or pyrimidine metabolism. 
4.2.2 Materials. 
Dulbecco's Modified Eagle Medium was purchased from Gibco BRL, Gaithersburg, 
Maryland, USA or from Highveld Biological, Kelvin, South Africa. Foetal calf serum and 
Hanks Balanced Salt solution was purchased from Highveld Biological, Kelvin, South 
Africa. Sterile plastic pipettes, centrifuge tubes, flasks and petri dishes were of tissue 
culture grade. 
[8-14C] hypoxanthine, [8-3H] adenine and L-[2,3,4,5,6-3H] phenylalanine were purchased 
from Amersham International, UK. 5-phosphoribosyl-1-pyrophosphate (sodium salt) and 
hypoxanthine were purchased from Sigma Chemical Corporation, St. Louis, Missouri, 
USA. Bionic-Fluor was from Packard, Downers Grove, Illinois, USA; Biorad reagent 
from Bio-Rad Laboratories, Miinchen, Germany; dTTP from Boehringer Mannheim, 
Germany. 
4.2.3 Methods. 
4.2.3.1 Tissue Culture. 
Fibroblast and transformed lymphoblast cultures were maintained in Dulbecco's Modified 
Eagles medium supplemented with 10% foetal calf serum, in an atmosphere of 10% CO2 
at 3 7°C. Cultures were grown in 250 ml tissue culture flasks without antibiotics and 
screened at intervals for Mycoplasma infection using bisbenzamide fluorochrome stain 
(Hoechst No. 33258), (Chen, 1977). Cultures were fed twice weekly. 
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4.2.3.2 Assay ofHPRT Activity in Erythrocyte Lysates. 
Overview of Method. 
HPRT activity was assayed using a kinetic method described by Wohlhueter (1975) and 
modified according to Steyn and Harley (1984). HPRT activity was measured as the rate 
of [14C] IMP formation from [14C] hypoxanthine. The product, [14C] IMP, was trapped 
on Whatmans DE81 paper which had been treated with EDT A to chelate free magnesium 
and stop the reaction. Unreacted substrate was removed by suspending the strips of anion 
exchange paper in running water and the amount of bound product determined by liquid 
scintillation counting. 
Preparation of Erythrocyte Lysates. 
The huffy coat was removed from 10 ml heparinised blood after centrifugation at 3000g 
for 10 min. The erythrocytes were then washed twice with saline and lysed by the addition 
of 4 volumes of cold distilled water. The stroma was removed by centrifugation and the 
haemolysate dialysed overnight against two 5 1 changes of 50 mM Tris-HCL pH 7.8 
containing 1 mM dithiothreitol. The dialysed haemolysates were stored at -20°C. 
Haemolysates stored at -20°C showed a 10% loss of activity after 4 weeks storage (Steyn, 
1983). 
Preparation ofDE81 Paper. 
Whatmans DESI anion exchange paper was ruled into 2.5x2.5 cm squares, cut into a 2x4 
array and soaked in 20 mM EDTA (pH 8.0). The paper was dried before use. 
Determination ofLysate Protein Concentration. 
Protein concentrations were determined from a standard curve by the method of Bradford 
(1976) using Biorad protein reagent. 
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HPRT Enzyme Assay 
The enzyme assays were performed at 3 7°C in duplicate. Each 100 µl reaction volume 
contained approximately 100 µg of lysate protein, 50 mM Tris-HCL (pH 7.8), 14 mM 
MgCh and [14C] hypoxanthine and PRPP at appropriate concentrations. Assay tubes were 
preincubated for 2 min before the reaction was started by the addition of the lysate. At 
four 1 min timed intervals, 20 µl of the reaction mixture was spotted onto EDT A treated 
DE81 anion exchange paper. Unreacted substrate was removed by suspending the paper 
strips in a 5 l beaker and allowing tap water to flow through at a rate of approximately 1 1 
per minute for 1 hour. The DE81 paper was dipped into absolute ethanol to reduce 
fragility and cut into squares, each square representing a single time point. The squares 
were transferred to scintillation vials, 10 ml of scintillant added and the bound [ 14C] IMP 
determined by scintillation counting using an open window. The rate of [14C] IMP 
formation was estimated from the slope of a linear regression line fitted to the averaged 
duplicate data points using the method of least squares (Instat V2.05a, Graphpad 
Software, San Diego, USA). The reaction was regarded as linear when a correlation 
coefficient of greater than O. 99 was obtained. Counts per minute were converted to dpm 
taking into account the efficiency of the scintillation counter and quenching due to the 
DE81 paper. Units of enzyme activity were defined as 1 U = µmol IMP produced/min/mg 
protein. Kinetic parameters were estimated by fitting the data directly to the Michaelis-
Menten rate equation (1) using a non-linear iterative method of least squares. Preliminary 
estimates of the apparent Km and V max were obtained from Lineweaver-Burk plots. 
v= Vmax [S] (1) 
Km+ [S] 
4.2.3.3 Assay ofHPRT Activity in Cultured Lymphoblasts. 
Lymphoblasts were grown to a density of approximately 106 cells/ml. Approximately 
50 ml of the cell suspension was pelleted at 1 OOOg for 10 min and washed twice in normal 
saline. The cell pellet was resuspended in 100 µl Tris-HCL pH 7.8 and transferred to a 
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microfuge tube. The cells were lysed by 6 freeze-thaw cycles. Cell membranes were 
removed by centrifugation at 10000g for 30 min. The membrane free supernatant was 
passed through a modified Penefsky column (Grubmeyer and Penefsky, 1981) packed with 
Sephadex G50 resin. Enzyme activity in the lysates was assayed immediately. 
The HPRT assay described above was modified by the inclusion of 1.5 mM dTTP in the 
reaction to inhibit 5'-nucleotidase activity present in nucleated cells (Fujimoto and 
Seegmiller (1970); Adams and Harkness, 1976), the activity of which would otherwise 
result in an underestimation of IMP product formation. Shin-Buehring et al (1980) 
reported 5'-nucleotidase activity of 37 - 160 nmol phosphate produced per min per mg 
protein in various tissues as measured by the release of phosphate from IMP during 
conversion to inosine. HPRT assay time points of 15 min, 30 min, 45 min and 60 min 
were used for cell lysates with less than 10% activity. Assay time points for controls were 
at 1 min, 2 min, 3 min and 4 min. The data was analysed as described above. 
4.2.3.4 Heat Stability ofHPRT Activity in Lymphoblast Lysates. 
200 µl aliquots of a prepared lymphoblast lysate from each cell line were incubated for 5, 
10, 15, or 20 min at 75°C and immediately placed on ice until assayed. HPRT activity was 
assayed as described above, with hypoxanthine concentration constant at 100 µM and the 
PRPP concentration at 1. 6 mM. 
4.2.3.5 Double Label Experiments: Uptake of [14C] Hypoxanthine and 
[3H] Phenylalanine by Cultured Fibroblasts. 
Confluent flasks of fibroblasts were trypsinised (0.1% trypsin in 0.5 mmol/1 EDTA in 
phosphate buffered saline) and plated in duplicate into 60 mm diameter tissue culture 
dishes and allowed to recover overnight. The medium was then replaced with 1 ml of 
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Hanks Balanced Salt solution supplemented with 15 mmol/1 Hepes (pH 7.4) 0.5 µCi/ml 
[ 14C] hypoxanthine and 1.5 µCi/ml [3H] phenylalanine. Cells were incubated for 1.25 hr at 
3 7°C without CO2. Each dish was then washed 3 times with 2 ml ice cold 5% 
trichloroacetc acid (TCA), the precipitated material redissolved in 1.3 ml 0.1 N NaOH, 
and neutralised with glacial acetic acid. 1 ml was counted in 10 ml scintillant in a 
Beckman LS6001 C scintillation counter using windows of O to 200 ke V for [3H] and 400 
to 1000 ke V for the [ 14C] label. 
4.2.3.6 Molecular Methods. 
Molecular methods are described in detail in Section 2. 
Briefly, total RNA was extracted from tissue cultured cells, reverse transcribed with AMV 
reverse transcriptase using an oligo dT is primer and amplified using HPRT cDNA specific 
PCR primers. cDNA prepared from F45 and L534 was amplified using primer pair Plb 
and P2, while HPRT cDNA from L867 and L868 were amplified using a nested primer 
system (initial amplification was with primers OPF and OPR, followed by nested 
amplification with primer pair NPF and NPR). PCR products amplified from F45 and 
L534 were purified using Millipore Ultrafree-MC 100 000 NMWL filter units and directly 
sequenced. In order to read sequences close to the 3'-end of the PCR primers, the PCR 
products were also cloned into pUC 18 using the Klenow-Kinase-Ligase method and the 
areas close to the PCR primers sequenced using vector primers. Amplified cDNA from 
L867 and L868 was cloned into pGEM-T and then sequenced. 
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4.3 Results. 
4.3.1 HPRT Activity in Erythrocyte Haemolysates of Patient P534. 
Erythrocytes were available from only one patient, P534. Substrate-velocity curves and 
. 
the derived Lineweaver-Burk plots ofHPRT activity in erythrocyte haemolysates of P534 
and a control are shown in Figure 4.1. With PRPP concentration saturating at 1.6 mM 
and hypoxanthine concentration varied from 5 µM to 90 µM, the Lineweaver-Burk plots 
derived from substrate velocity curves of P534 and the control intersect at the same point 
on the X-axis, but at differing points on the Y-axis. These results are consistent with an 
altered apparent V max, but unchanged apparent Km for hypoxanthine. Similar results were 
obtained when the concentration of PRPP was varied in the range 0.05 to 1.6 mM with 
hypoxanthine at a constant concentration of 200 µM. The Lineweaver-Burk plots of 
patient and control intersect at the same point on the X-axis, but at different points on the 
Y-axis and are consistent with an altered apparent V max, but unchanged apparent Km for 
PRPP. 
The apparent Michaelis constants for P534 and the control are shown in Table 4.1. Each 
value is the mean of duplicate determinations performed on blood specimen drawn on two 
separate occasions. The apparent Km for hypoxanthine of both the patient (mean 5.1 µM) 
and the control (mean 5.2 µM) are within the control range reported by Wilson (1986a) 
and are within the control range of 1.3 µM to 20 µM reported in the literature (Shin-
Buering et al, 1980; Steyn and Harley, 1984; Snyder et al, 1989). The apparent Km for 
PRPP for the patient P534 (0.02 mM) and the control (0.02 mM) are identical and are also 
within the control range of 0.006 mM to 0.25 mM reported in the literature (Shin-Buering 
et al, 1980; Steyn and Harley, 1984; Snyder et al, 1989). However, the apparent Vmax of 
P534 was decreased to 20 to 30% of the control value. 
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Figure 4.1: Substrate-velocity curves and the derived Lineweaver-Burk plots of 
HPRT activity in haemolysates of P534 and a control. (a) Substrate-velocity curve 
with hypoxanthine as the varied substrate. Hypoxanthine concentrations were 10, 15, 25 
and 90 µM with PRPP saturating at 1.6 rnM . The derived Lineweaver-Burk plot is 
shown in ( c ). (b) Substrate-velocity curve with PRPP as the varied substrate. PRPP 
concentrations were 0.05, 0.1 , 0.4, 0.8, and 1.6 rnM with hypoxanthine constant at 
100 µM. The derived Lineweaver-Burk plot is shown in (d). Values are the mean of 
duplicate determinations. 
Table 4.1: Apparent kinetic parameters for HPRT in erythrocyte Iysates of 
patient p534. 
KINETIC PARAMETER CONTROL PATIENT 
Km hypoxanthine (µmol/1) 4.7; 5.5 5.4; 5.0 
PRPP (mmol/1) 0.02; 0.02 0.02; 0.02 
Vmax hypoxanthine (mU) 0.97; 1.10 0.19; 0.21 
PRPP (mU) 0.55; 0.79 0.16; 0.19 
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Patient P534 had received a blood transfusion a day prior to blood being drawn for HPRT 
determination. The possible effects of this blood transfusion on the measurement of 
HPRT activity in haemolysates prepared post-transfusion were assessed by measuring 
HPR T activity in erythrocyte haemolysates prepared from stored blood transfusion units. 
HPRT activity in haemolysates, prepared from units of blood (from different donors) 
stored at 4°C for O days to beyond the expiry date of a unit, were assayed and the results 
are shown in Figure 4.2. There was no appreciable decrease in HPRT activity in blood 
transfusion units stored for up to 36 days. On the contrary, HPRT activity in blood stored 
with citrate, phosphate, glucose and adenine as an anticoagulant appeared to increase with 
time. 
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Figure 4.2: HPRT activity in blood transfusion units stored for up to 36 days. 
Hypoxanthine concentration was constant at 100 µM with PRPP saturating at 1.6 mM. 
Values are the mean of duplicate determinations. 
4.3 .2 The Incorporation of [14C] Hypoxanthine Relative to [3H] Phenylalanine 
by Fibroblasts Cultured from P534. 
The incorporation of [14C] hypoxanthine relative to [3H] phenylalanine by fibroblasts 
cultured from P534 was compared to a Lesch-Nyhan cell line (F526) and two control cell 
lines and is shown in Table 4.2. The values shown are the means of duplicate 
determinations. The ratio of [14C] hypoxanthine to [3H] phenylalanine in the cell line F534 
was approximately 30% of control values, which supported the finding of partial HPRT 
deficiency in the erythrocytes of this patient. 
Table 4.2: Ratio of [14C] hypoxanthine to [3H] phenylalanine incorporation by 
cultured fibroblasts. 
Fibroblast cell line Ratio 
Control 1 0.07 
Control 2 0.07 
F526 (Lesch-Nyhan) <0.0001 
F534 0.026 
Values are the mean of duplicate determinations. 
4.3.3 HPRT Activity in Cultured Lymphoblast Lysates. 
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Transformed lymphoblast cultures were available from patients P534, P867 and P868. 
The substrate-velocity curves and derived Lineweaver-Burk plots of HPRT activity in 
lymphoblast lysates with hypoxanthine as the varied substrate are shown in Figure 4.3. 
The substrate-velocity curve and Lineweaver-Burk plots derived when the concentration 
of PRPP was varied are shown in Figure 4. 4. The apparent kinetic parameters calculated 
by fitting the data to the Michaelis-Menten equation are shown in Table 4.3 . 
Table 4.3: Apparent kinetic parameters for HPRT in cultured lymphoblast 
Iysates. 
HYPOXANTHINE 
Patient Km Vmax 
(µmol/1) (mU) 
control 16.6+/-7.0* 3.34+/-0.76* 
L534 
L867 
L868 
* 
** 
12.9+/-7.6** 3.83+/-0.95** 
27.9: 33.9 0.07: 0.09 
20.3: 10.3 0.07: 0.06 
Mean+/- ISD from 3 control cell lines, each assayed in 
duplicate in 2 independent experiments. 
Mean+/- I SD from duplicate values of 3 experiments 
PRPP 
Km Ymax 
(µmol/1) (mU) 
59.7+/-9.0* 3.54+/-0.91 * 
52.9: 38.8 4.25 : 2.21 
49.1: 52.4 0.07: 0.06 
42.7: 50.7 0.03 : 0.09 
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Figure 4.3: Substrate-velocity curves, with hypoxanthine as the varied substrate, of 
HPRT activity in lymphoblast lysates of L534, a control, L867 and L868. 
Hypoxanthine concentrations were 5, 10, 15, 25 and 100 µM with PRPP saturating at 1.6 
mM. (a) and (c) Substrate-velocity curve and derived Lineweaver-Burk plot ofL534 and 
a control. (b) and (d) Substrate-velocity curve and derived Lineweaver-Burk plot of 
L867 and L868. Values are the mean of duplicate determinations. 
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Figure 4.4: Substrate-v.elocity curves, with PRPP as the varied substrate, of 
HPRT activity in lymphoblast lysates of L534, a cpntrol, L867 and L868. PRPP 
concentrations were 0.05, 0.1, 0.4, 0.8 and 1.6 mM with hypoxanthine concentration 
constant at 100 µM. (a) and (c) Substrate-velocity curve and derived Lineweaver-Burk 
plot ofL534 and a control. (b) and (d) Substrate-velocity curve and derived Lineweaver-
Burk plot ofL867 and L868. Values are the mean of duplicate determinations. 
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Figure 4.5: Heat stability of HPRT in lymphoblast lysates of L534, L867, L868 
and controls. HPRT activity was assayed with hypoxanthine and PRPP concentrations at 
100 µMand 1.6 mM respectively. HPRT activity at each time point was determined in 
duplicate. Data points for the controls represent the mean (+/-1SD) of duplicate 
determinations ofHPRT activity in three control lymphoblast cell lines. 
HPRT activity in lymphoblast lysates of the cell lines L867 and L868 were less than 2% of 
the mean of the control range, while the apparent Km for hypoxanthine and PRPP were 
normal. The Vmax and apparent substrate affinities for L534 were normal, a result which 
contradicted the finding of a decreased V max in erythrocyte lysates and the decreased 
incorporation of [14C] hypoxanthin~ by fibroblasts. Apparent Km values for HPRT 
determined in lymphoblast lysates showed greater variability than in erythrocytes, which is 
consistent with the experience of other investigators (Adams and Harkness, 1976). 
HPRT activity in lymphoblast lysates of L867 and L868 showed marked heat !ability 
(Figure 4.5). Enzyme activity in both cell lines had a half-life of 10 min at 75°C compared 
to a mean half-life of 23 min for the controls. HPRT activity in L534 showed a similar 
heat stability profile to that of controls, with a half-life of 37 min. 
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4.3.4 Results of the Molecular Investigations. 
Amplification of HPRT cDNA prepared from F45 and L534 using primers Plb and P2, 
yielded a single PCR product of approximately the predicted size of 725 bp (Figure 4. 6c, 
L534 not shown). Amplification of HPRT cDNA from L867 and L868 using the nested 
primer system yielded PCR products of approximately the predicted size with both outer 
primers (798 bp) and nested primers (741 bp) (Figure 4.6a and 4.6b respectively) . 
The entire coding region of HPRT cDNA amplified from each of the three patient cell 
lines was sequenced. An A to G transition at nt 307 due to a Tag polymerase error was 
found in a single clone ofL867 HPRT cDNA. This nucleotide transition was distinguished 
from a true mutation by the presence of a normal base at the same position in two other 
clones. 
DNA sequencing of cloned PCR products amplified from HPRT cDNA ofL867 showed a 
G to T transversion at nt 481 in two independent clones (Figure 4.7a). The mutation 
resulted in an Alal61 to Ser amino acid substitution (the methionine coded by the ATG 
start codon is numbered as residue 1). Interestingly, a C to G transversion at the adjacent 
nucleotide nt 482, was found in L868. This mutation alters the same amino acid Ala161 but 
to Gly instead of Ser. 
Direct sequencing of cDNA amplified from F45 showed a G to A transition at nt 403, 
which resulted in the amino acid substitution of Asn for Asp135 (Figure 4.7b). 
The entire coding region of HPRT cDNA amplified from L534 was sequenced directly. 
PCR products were also cloned and sequenced. No mutations within the coding region of 
the HPRT cDNA in this patient were found. 
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Figure 4.6: HPRT cDNA amplified from L867, L868 and F45. (a) and (b) Nested primer 
amplification of HPRT cDNA from L867 and L868. (a) Amplification with outer primers OPl and 
OP2 at different MgCh conceQtrations. Amplification was optimal at 1.5 and 2 mM MgCli . (b) 
Nested primer amplification of L867 and L868 HPRT cDNA with nested primers NPl and NP2 at a 
MgCl2 concentration of 1.5 mM. I µI of the outer primer PCR reaction was amplified with primers NPI 
and NP2.in a PCR reaction containing 1.5 mM MgCh . Lane OP BL, a PCR reaction blank carried 
through both outer and nested PCR. Lane NP BL, nested PCR reaction blank. Lane m, lambda DNA 
digested with DraI, the 696 bp and 533 bp pair bands are indicated. (c) HPRT cDNA amplified from 
F45 with primers Plb and 2, lane labelled F45. A PCR blank is shown in the lane Blank . Lambda 
DNA digested with HindIII was used as a molecular weight marker in lane m. The 564 bp and 2027 bp 
bands of the marker are indicated. 
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A F45 Control A 
A G A T C G A T C A 
lie T T lie 
A A 
T T 
Asn A A Asp 
A G 
A A 
Glu A \ ~Glu G 
G 
T 
397 - G G-397 
J 
Figure 4.7: The molecular defect in L867, L868 and F45. (a) In L867, a G to T 
transversion at nt 481 alters the codon for Ala16 1 to Ser. In L868, a C to G transversion 
at nt 482 alters the codon for Ala161 to Gly. (b) The molecular defect in F45 is a G to A 
transition at nt 403 which results in the substitution of Asp135 by Asn. 
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4.4 Discussion. 
The recent determination of the crystal structure of HPR T with GMP bound (Eads et al, 
1994) is a major advance in the understanding of HPRT structure. The model however, 
characterises the enzyme in a single conformation, with GMP bound. In vivo mutations 
causing partial HPRT deficiency thus present an opportunity to gain insight into the role of 
individual amino acids within the functioning protein. 
A survey of in vivo amino acid substitutions reported in HPRT is shown in Table 4.4 and a 
graphical representation of this data is shown in Figure 4.8. The linear representation of 
the HPRT protein shows a distinct clustering in the occurrence of amino acid 
substitutions. The clusters of amino acid substitutions rriay point to either functionally 
important region of the enzyme, or provide evidence for mutational hot spots at the DNA 
level. Clustering of mutations at the DNA level in exon 3 and exon 5 have been noted by 
Tarle et al (1991) and Cariello and Skopek (1993) respectively. 
A clustering of amino acid substitutions occurs between amino acid residues 40 and 60. 
These residues are within a helix A2 of the crystal structure defined by Eads et al, 1994 
(see Figure 4.9). This large helix is located away from the catalytic site of the enzyme and 
appears to have a structural function. It is possible that this clustering of amino acid 
substitutions which are encoded by exon 3, represent a DNA sequence predisposition to 
mutation. However, 8 of the 12 amino acid substitutions reported have occurred only 
once at residues within this region. This heterogeneity would suggest functional 
sensitivity of the protein to amino acid substitutions in a helix A2 rather than a nucleotide 
sequence susceptibility to mutation. 
In contrast, the amino acid substitutions clustered at residue 70 to 73, also encoded by 
exon 3, are more likely to have resulted from a DNA sequence predisposition to mutation. 
G to A transitions at nucleotide G20s or the adjacent G209 both alter the codon for Gly70 
and these two mutations have occurred independently in five patients. 
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Mutations at Gm and G212 have resulted in differing amino acid substitutions in two 
patients at residue Gly71 • The occurrence of seven amino acid substitutions due to 
mutations within the run of G nucleotides between nt 207 and nt 212, may reflect a DNA 
mutational hot spot. Five of the seven mutations are G to A transitions and it is possible 
that guanine nucleotides within mono-nucleotide runs may have an increased propensity 
for this type of mutation. Amino acid residues 70 to 73 occur within a loop of residues 
connecting the B strand B3 and a. helix A3 and are in close proximity to the catalytic site 
of HPRT. Mutations at these residues may thus be the result of an increased DNA 
sequence susceptibility to mutation which affects functionally important residues of the 
protein. The substitution of Phe14 by Leu in four apparently independent patients are due 
to C222 to A transversions. These four identical mutations are the most common of the 
amino acid substitutions reported in HPRT. The high rate of identical mutations at 
nucleotide C222 suggests that a DNA sequence dependent cause for the observed increase 
in mutations cannot be excluded. 
Exon 5 (nt 385 to nt 402) codes for the amino acid residues 129 to 135. These residues 
form part of the conserved PRPP binding motif (residues 129 to 140). Amino acid 
substitutions occur at four of the six residues encoded by exon 5, but these substitutions 
are probably a reflection of the functional importance of these residues in the catalytic site 
(discussed in more detail below), rather than a DNA sequence predisposition to increased 
rates of mutation. Similarly, substitutions in the 30 amino acids at the carboxyl terminal of 
the protein are evenly spaced and point to a heterogeneous mutational origin in a 
functionally important region of the enzyme. 
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Table 4.4: A review of in vivo mutations in HPRT which result in amino acid 
substitutions. 
Variant cDNA Predicted Change Comment Reference 
Change in Protein 
HPRT Gravesend G 20to A Gly7 to Asp partial, McKeran et al, 1975; 
(FamilyD} 0.9% activi!,y Davidson et al, 1991 
HB T23 to G Val 8 to Gly partial, Sege-Peterson et al, 
6.9% activi!,y 1992 
HPRT UraDIIBD G46toA Gly 16 to Ser partial, Keough et al, 1988; 
(GL) <0.1 % activity Sculley et al, 1991 
0.7%CRM 
FG G47 to A Gly 16 to Asp Lesch-Nyhan Sege-Peterson et al, 
1.4% activi!,y 1992 
HPRTMashad A 59 to T Asp 20 to Val partial, 0.7% activi!,y Davidson et al, 1991 
JS C69toG Cys23 to Trp partial, 30% activity Sege Peterson et al, 
1992 
HPRTy= C 73 to A Pro 25 to Thr partial, Tohyama et al, 1994 
4.2% activity, 
normalmRNA 
HPRTnetroit T 122 to C Leu 41 to Pro Lesch-Nyhan Davidson et al 1989a 
HPRT 00 A 124 to T Ile 42 to Phe Lesch-Nyhan Burgemeister et al, 
(KM) 0.37 to 3.2 % 1995 
residual activi!,y 
HPRTH~ T 125 to C Ile 42 to Thr activi!,y not reported Davidson et al, 1991 
HPRT Salamanca T 128 to G Met 43 to Arg Partial, Sege-Peterson et al, 
(AA) G 130 to A Asp 44 to Asn 7.5% activity, 1992 
Km for hx increased 
2 amino acid 
substitutions in same 
atient 
RJK 2163 (TD) G 134 to A Arg45 toLys Lesch-Nyhan Gibbs et al, 1990 
AG G 143 to A Arg48 to His partial, 20% activity Sege-Peterson et al, 
DD same mutation in 2 1992 
tients 
LW G 148 to C Ala 50 to Pro partial, 1.6% activity Sege-Peterson et al, 
1992 
1265 C 149 to T Ala 50 to Val Lesch-Nptan Tade et al, 1991 
HPRT Toronto C 151 toG Arg 51 to Gly partial, 33% activity Wilson et al, 1982c; 
(LP) normalmRNA Kelley and Wilson, 
52%CRM, 1982; 
normal Km Wilson et al, 1983b; 
Wilson et al, 1983c; 
Wilson et al, 1986a 
HPRTBanbwy G 152 to C Arg 51 to Pro Lesch-Nyhan Gibbs et al, 1986; 
Family 2 Davidson et al, 1991 
HPRT E<linb!!!Bl! A 155 to G AsE 52 to Gly Eartial Lightfoot et al, 1992 
TE G 157 to A Val 53 to Met partial, 20% activity Sege-Peterson et al, 
1992 
MG T 158 to C Val 53 to Ala partial, 15% activity Sege-Peterson et al, 
1992 
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Variant cDNA Predicted Change Comment Reference 
Change in Protein 
JaEan 1 A 160 to C Met 54 to Leu Lesch-Nyhan Igarashi et al, 1989 
HPRTMontreal T 170 to C Met 57 to Thr Lesch-Nyhan Skopek et al, 1990 
HPRT TOOWODjP; Gl72toA Gly 58 to Arg partial, 10% activity Keough et al, 1988; 
(PH) normalmRNA Sculley et al, 1991 
49%CRM 
Case2 G 190 to C Ala 64 to Pro Lesch-Nyhan Yamada et al, 1992 
<1% activir.y 
HPRT Utrecht G208 to A Gly70 to Arg Lesch-Nyhan Bowens-Rombouts et 
(K-Kindred) same mutation in 2 al, 1993; 
Case 1 patients Tohyama et al, 1994 
normalmRNA 
HPRTNewHaven G 209 to A Gly 70to Glu Lesch-Nyhan Wilson et al, 1986a; 
(DG) Normal mRNA Davidson et al, 
50% CRM, same 1989a; 
1510 mutation in 3 Tarle et al, 1991 
955-2 different Qatients 
HPRTya10 G 211 to C Gly 71 to Arg Lesch-Nyhan Wilson et al, 1986a; 
(KT) normalmRNA Fujimori et al, 1989 
92%CRM 
HPRTMadrid G 212 to T Gly 71 to Val partial Bowens-Rombouts et 
(S-Kindred} al, 1993 
HPRTSeou1 A215 to G Tyr72 to Cys partial, Choi et al, 1993 
<0.2% activi!,y 
HPRTF!int C 222 to A Phe 74 to Leu Lesch-Nyhan Wilson et al, 1986a: 
(AC, RJK 892) nomRNA Davidson et al, 
noCRM 1988b; 
HPRTpertb Same mutation in 4 Gibbs et al, 1989; 
different patients Sculley et al, 1991 ; 
1522 Tarle et al, 1991; 
DW Sege-Peterson et al, 
1992 
HPRTswan C 232 to G Leu 78 to Val partial, 10% activi!,y Sculley et al, 1991 
Case 3 T 233 to A Leu 78 to Gln Lesch-Nyhan Yamada et al, 1992 
2% activi 
HPRTAr1in,o;ton A 239 to T Asp 80 to Val partial Davidson et al, 
(MSandWB} 1989a 
HPRTMunich A310toG Ser 104 to Arg partial, 3% activity Wilson et al, 1982c; 
(IV) normal mRNA Kelley and Wilson, 
79%CRM 1982; 
increased Km for bx, Wilson and Kelley, 
decreased V max 1984; 
Wilson et al, 1986a 
HPRTLondon C 329 to T Ser 110 to Leu partial, 59% to 69% Wilson et al, 1982c; 
(GS) activity Kelley and Wilson, 
normalmRNA 1982; Wilson et al, 
DB 35% to 52% CRM, 1983a; Wilson et al, 
increased Km for bx, 1986a; Davidson et 
same mutation in 2 al, 1988c 
different patients 
107 
Variant cDNA Predicted Change Comment Reference 
Change in Protein 
HPRT Midland T 389 to A Val 130 to Asp Lesch-Nyhan Wilson et al, 1986a; 
(JH, RJK 896) Nonna! mRNA Davidson et al , 
noCRM 1988a, 1989a; 
same mutation in 2 Gibbs et al, 1989; 
375 different patients Tarle et al, 1991 
RJK 1784 T 392 to C Leu 131 to Ser Lesch-Nyhan Gibbs et al, 1989 
HPRTRuncom T 395 to C Ile 132 to Thr activi!X not reported Davidson et al, 1991 
HPRT Ann Arbor T 396 to G Ile 132 to Met 10% activity Wilson et al 1982c; 
(KC and TC) increased Km for hx Kelley and Wilson, 
and PRPP, normal 1982; 
Vmax Wilson et al, 1986a; 
normalmRNA Fujimori et al, 1988 
11%CRM 
HPRTcape Town G403 A Asp 135 to Asn substrate inhibition, Steyn and Harley, 
(TK) nonnal Km for hx 1984; 
(P45} andPRPP this study 
HPRTTokyo G419toA Gly 140 to Asp Lesch-Nyhan Fujirnori et al, 1992 
YY (WR 194} 
HPRT Milwaukee G481 toT Ala 161 to Ser partial, 1.4% activity Wilson et al, 1986a; 
(JM, RJK 949) nonnalmRNA Davidson et al, 
3%CRM 1989a; Gibbs et al, 
P867 <2% activity, normal 1989; 
(AW) Km, decreased V max this study 
same mutation in 2 
different patients 
P868 C 482 to T Ala 161 to Gly <2% activity, nonnal this study 
(GT) Km, decreased V max 
HPRT Farnham C 486 to G Ser 162 to Arg activi!X not reported Davidson et al, 1991 
HPRTBrisbane C 503 toT Ile 168 to Thr partial, !0% activity Gordon et al, 1987b; 
(FC) KmforPRPP Keough et al, 1988; 
increased Gordon et al, 1990 
normal mRNA, 
26%CRM 
HPRTMarlow C 527 to T Pro 176 to Leu 0.8% activi!X Davidson et al, 1991 
RJK 2185 G 529 to T AsE 177 to Tyr Lesch-Nyhan Gibbs et al, 1990 
Japan2 T 536 to G Val 179 to Gly partial Igarashi et al, 1989 
and and two mutations in 
G 538 to A Gly 180 to Arg same Eatient 
1734 T 548 to C Ile 183 to Thr partial, 8% activity Tarle et al, 1991 
(JF) Sege-Peterson et al, 
1992 
Case 1 T 563 to C Val 188 to Ala 5%activi!X Yamada et al, 1992 
HPRT.Kinston G 580 to A Asp 194 to Asn Lesch-Nyhan Wilson et al, 1982c; 
(ES, RJK 2188) normalmRNA Kelley and Wilson, 
72%CRM 1982; Wilson et al, 
increased Km for bx 1986a 
andPRPP 
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Variant cDNA Predicted Change Comment Reference 
Change in Protein 
HPRT Moose Jaw C582 to G Asp 194 to Glu partial 5 to 12% Lightfoot et al, 1994 
activity, Km for hx 
and PRPP increased 
HPRTNew Briton T 595 to G Phe 199 to Val Lesch-Nyhan Wilson et al, 1986a; 
(EC, RJK 950 normalmRNA Davidson et al, 
noCRM 1989a; Gibbs et al, 
1989 
RB G601 to A Asp 201 to Asn 60% activity Sege-Peterson et al, 
1992 
GM G601 toT Asp 201 to Tyr Lesch-Nyhan Sege-Peterson et al, 
1992 
HPRTAshville A602 to G Asp 201 to Gly Partial <0.1 % Wilson et al, 1986a; 
(PC) increased Km for hx Davidson et al, 
andPRPP, 1989b 
normalmRNA 
4%CRM 
RJK 1874 C610G His 204 to Asp Lesch-Nyhan Gibbs et al, 1989; 
RJK.2079 same mutation in 2 Gibbs et al, 1990 
different Qatients 
779 A611 toG His 204 to Arg Lesch-Nyhan Tarle et al, 1991 
RJK 1727 G 617 to A Cys 206 to Tyr Lesch-Nyhan Gibbs et al, 1989; 
HPRT Reading same mutation in 2 Watts et al, 1982; 
(Patient 6, different patients Gibbs et al, 1986; 
FamilI 7l Davidson et al, 1991 
HPRT cDNA is numbered with the A of the ATG start codon numbered as base 1. The amino acid 
sequence is numbered with the Met residue coded by the start codon as residue 1. 
Abbreviations: hx, hypoxanthine; crm, HPRT imunoreactive material. Partial, partial HPRT deficiency; 
normal mRNA, normal mRNA size and levels. · 
In contrast, only three amino acid substitutions, one at residue Ser104 and two at Ser110, 
have been reported in the 50 amino acid run from residue 81 to the start of the PRPP 
binding domain at residue 129. These substitutions occur in partial HPRT variants with 
altered affinity for the substrate hypoxanthine. This mutationally silent region corresponds 
to the flexible loop region linking strand B4 with B5. Both Ser104 and Ser110 are located 
close to the catalytic site of the enzyme. The paucity of amino acid substitutions in the 
flexible loop region suggests that this structure may be fairly tolerant of amino acid 
substitutions. 
In summary, a review of mutations causing amino acid substitutions in HPRT suggests 
that the majority of mutations are not the result of DNA mutational hotspots, but reflect 
instead, structurally and functionally important regions of the protein. There is however, 
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evidence to support the existence of two DNA mutation hotspots, the first at the run of G 
nucleotides encoding amino acid residues 70 and 71 , and the second at nucleotide C222. 
4.4.1 The Biochemical Genetics ofL867 and L868. 
The differences found in the values for the apparent Km of hypoxanthine and PRPP 
between control haemolysates and control lymphoblast lysates do not reflect tissue specific 
isoforms ofHPRT. Differing Km values in different tissue has been well described (Adams 
and Harkness 1976; Shin-Buehring et al 1980) and probably reflect differences in the 
metabolism of the substrates hypoxanthine and PRPP, or the product IMP, by other 
enzymes present in the crude lysate preparations. 
The kinetic characteristics of HPRT in L867 and L868 were similar with essentially 
normal substrate affinities for hypoxanthine and PRPP, but a severely decreased V max, 
The similarity between the two HPR T variants extended to the nature of the genetic 
defect, with single base substitutions affecting adjacent nucleotides in the codon for Ala161. 
The Gm to T transversion and the resulting Ala161 to Ser amino acid substitution found in 
L867 occur within the context of a CpG dinucleotide on the non-coding strand. CpG 
dinucleotides represent potential sites of cytosine methylation in mammalian cells (Wolf 
and Migeon, 1985) and spontaneous deamination of 5-methylcytosine to thymine (Ehlrich, 
1990) has been reported to lead to the occurrence of a disproportionate number of C to T 
transitions at these sites (Rideout et al, 1990; Skandalis et al, 1994). The Gm to T 
transversion in L867 could not have occurred by spontaneous deamination of a 5-
methylcytosine residue on the non-coding strand, as this mechanism would have led to a 
G4s1 to A transition on the coding strand and a change in the codon GCA (Ala) to ACA 
(Thr). 
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The identical G481 to T transition and resulting Ala161 to Ser substitution has been 
described in an apparently unrelated patient with gout (Patient JM of Davidson et al 
(1989a), cell line RJK 949 derived from JM of Gibbs et al, 1989). Davidson et al (1989a) 
named the variant HPRTMitwaukee- In the original description of JM, Wilson et al (1986a) 
reported 1.4% residual HPRT activity in cultured lymphoblasts, but did not measure any 
kinetic parameters. The level of HPRT immunoreactive protein was decreased to 3% of 
control values. 
The C4s2 to G transition and the resulting Alal61 to Gly amino acid substitution found in 
P868 is a novel mutation. 
With the exception of the PRPP binding domain, the phosphoribosyltransferases show 
little amino acid sequence homology between enzymes. However, a comparison ofHPRT 
amino acid sequences from various organisms shows that Ala161 occurs within an 
evolutionary conserved region of HPRT and is absolutely conserved in organisms as 
diverse as the rat, Schistosoma mansoni and Plasmodium falciparum and is conserved in 
character in Leishmania donovani (Figure 4.9). 
150 160 170 180 
Human1 KTMQTLLSLV RQYNPKMVKV ASLLVKRTPR SVGYKPDFVG 
L867 . . . . . . . . . . . . . . . . . . . . s ......... . ......... 
L 8 68 . . . . . . . . . . . . . . . . . . . . G ••••• • ••• . ......... 
Mouse2 . . . . . . . . . . K •• S •••••• . ....... s . . •.• R ••••• 
Hamster3 . . . . . . . . . . KR •• L •...• . ....... s . • ••• R ••••• 
Rat4 . . . . . . . . . . K .. S .....• . . . . . . . . s . . ••• R ••••• 
s. . 5 manson1. . • ITK. I. HL DSLST.S .•• ••..••.• SP RND. R •.•.• 
P. f al ciparum6 • • LVKFCEYL KKFEI. T .AI • C. FI •••• L WN.F.A •••• 
L. donovani 7 I.L.Y.MRFM LAKK.ASL.T VV . . D. PSG. K.EVLV.YPV 
Figure 4.9: A between species comparison of the amino acid sequence of HPRT 
from residue 141 to 180. Numbering is according to the human sequence with the 
methionine coded by the ATG start codon numbered as residue 1. Only amino acids 
which differ from the human sequence are shown. Sequences were aligned using DAPSA 
(Harley, 1994). References: 1Jolly et al, 1983; 2•3 Konecki et al, 1982; 4Chiaverotti et al, 1991; 5Craig 
et al, 1988; 6Vasanthakumar et al, 1989; 7 Allen et al, 1993 . 
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Figure 4.10: Ribbon diagram of human HPRT structure with GMP bound 
(reproduced from Eads et al, 1994). 
The exact position of Ala161 within the crystal structure ofHPRT was determined by using 
the shareware programme RasMol v2.S (Sayle, 1994) to view the X-ray diffraction data 
lodged by Eads et al (1994) in the Brookhaven Protein Data Base. 
Ala161 is located near the end of the B strand B6, which together with strand BS, a helix 
AS and strand B7 comprise the second half-sheet of the core of the enzyme. Strand B6 
ends with Ser162, then leads into a distinct bend followed by a short secondary strand B6' 
(Figure 4.10). Ala161 is some distance from the active site and appears to have a structural 
role. 
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It is generally recognised that protein secondary structure prediction models based on 
local amino acid sequence information which do not take into account global effects, 
rarely produce a predictive score of greater than 65% (Nishikawa and Noguchi, 1991). 
Nevertheless, where the local structure predicted by singlet-type methods such as Chou 
and Fasman (CF) (Chou and Fasman, 1978) and the quasi-doublet method of Gamier et al 
(1978) (GOR method) are in agreement with the structure defined by X-ray 
crystallography, simple models such as CF and GOR can prove useful in modelling the 
effects of an amino acid substitution on the predicted local structure. 
Secondary structure predictions using the programmes PepPlot (Gribskov and Devereux, 
1986), PeptideStructure and PlotStructur~ (Wolf et al, 1988) which form part of the 
Sequence Analysis Software Package (Genetics Computer Group) were used to predict 
the local structure about the residue Ala161 in the normal protein, as well as the affect on 
the predicted normal sequence of the amino acid substitutions, Ala161 to Ser in P867 and 
Ala161 to Gly in P868. Secondary structure predictions based on the GOR method differed 
from structures derived using the CF method. The GOR method predicted that Ala161 falls 
within an a helix. The substitution of Ala161 by either Ser or Gly resulted in the predicted 
loss of an a helix and the gain of a B strand. 
Conflicting predictions were obtained using CF based methods which predicted Ala161 to 
fall within a short B strand (Figure 4.11). This prediction is consistent with the model of 
HPRT structure derived from the crystal structure of OPRT by Scapin et al (1994) as well 
as the position of Ala161 within the crystal structure of HPRT as defined by Eads et al 
(1994). This support for the local secondary structure predicted by the CF method lends 
credibility to the use of CF secondary structure predictions in the analysis of the effects of 
amino acid substitutions at Ala161-
150 
Control 
P867 150 
200 
P868 150 
Al a1 61 to GI y -t"itt-~e,,..~ 
200 
0 ¢ 
- -113 
KD Hydrophilicity >=1.3 . 
KD Hydrophobicity >=1.3 · 
COOH 
COOH 
COOH 
Figure 4.11: Effect of substituting Ser or Gly for Ala161 on the predicted local 
secondary structure of HPRT. PeptideStructure and PlotStructure (Wolf et al, 1988) were used to 
predict the local structure aboµt the rest.due Ala161. a-Helices are shown with a sine wave, f3-strands with 
sharp saw-tooth waves, turns with 180 degree turns and coils with dull saw- tooth waves. 
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The substitution of the non-polar hydrophobic Alal61 residue by a polar hydrophilic Ser in 
P867 may affect packing within the hydrophobic core of the enzyme and also raises the 
possibility of changes in the secondary structure through the potential of Ser to form 
hydrogen bonds with other amino acid residues brought into close proximity by the change 
in secondary structure. 
These disruptions to the structure of the enzyme may lead to partial unfolding. Partially 
unfolded proteins are thought to have higher rates of proteolytic degradation in vivo 
(Goldberg and St. John, 1976). The marked decrease in immunoreactive HPRT protein 
reported in HPRTMitwaukee (Wilson et al, 1986a) and the decreased thermal stability of 
HPRT noted in L867, are evidence of increased enzyme degradation in vivo. The normal 
apparent substrate affinities found in L867 supports the view that the defect in 
HPRTMilwaukee and L867 affects a structurally important amino acid residue with no direct 
role in substrate binding or catalysis. 
In HPRT of L868, Ala161 is substituted by Gly. The effect of the substitution on 
secondary structure predictions using the CF method (Figure 4 .11) was identical to those 
predicted for the Ala161 to Ser mutation. A predicted B turn and B strand are lost and 
replaced by an a helix. Ala161 to Gly is a relatively conservative amino acid change in that 
both Gly and Ala are hydrophobic non-polar amino acids. However, Gly differs from Ala 
by the absence of a methyl side chain, resulting in greater conformational freedom, a 
decreased hydrophobic surface relative to Ala and an intrinsic capacity to destabilise both 
a helix (Chou and Fasman, 1978; Lyu et al, 1990; Horovitz et al, 1992; Blaber et al, 1994) 
and B strand structures (Minor and Kim, 1994). 
Substituting Gly near the end of strand B6 could result in premature termination of the B 
strand, increasing flexibility in the bend linking B6 and B6' and possibly allowing the bend 
to fall into an a helix. Increased flexibility in the bend could allow B6 to float and may 
possibly have an effect on strand B6'. Lys166 is located in B6' and interacts with GMP 
through side chain hydrogen bonding to the purine base, whilst the main chain oxygen is 
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hydrogen bonded to the side chain oxygen of Thr16s, presumably stabilising this region of 
the enzyme (Eads et al, 1994). The normal apparent substrate affinities found in L867 and 
L868 suggests that the destabilising effects of both the Gly and Ser substitutions at Ala161 
do not significantly affect strand B6' and the position of Lys166 within the active site. The 
effect of both substitutions at Ala161 appears to be focused on the B strand structural 
element B6. 
Two HPR T variants have been reported with amino acid substitutions in the immediate 
vicinity of Ala161 {Table 4.4). Davidson et al (1991) reported the substitution of Ser162 by 
Arg in HPRTFamham· No residual activity was detected in this enzyme variant using a gel-
based assay system, but the sensitivity of this assay in detecting low levels of residual 
activity was not discussed and it was not reported whether the variant resulted in the 
Lesch-Nyhan phenotype. The substitution of the small neutral, polar, mildly hydrophilic 
residue side chain of Ser162 by the bulky, highly hydrophilic, positively charged side chain 
of Arg has the potential for a major disruption of the core structure of the enzyme. The 
substituted Arg side chain would probably disrupt the bend between B6 and B6'. The 
effect could be transmitted to the nearby residue Lys166 affecting substrate binding within 
the active site. The non-conservative nature of the amino acid substitution and the 
consequent disruption to the core of the enzyme, as well as the potential for displacement 
of residues with side chains located within the active site, are consistent with a possible 
complete loss of enzyme activity in HPRTFamham- Eads et al (1994) discussed the effect of 
the Thr16s to Ilu substitution found in a partially deficient HPRT variant, HPRTBrisbane 
(Gordon et al, 1990) and pointed out that the mutation would be expected to interfere 
with the hydrogen bond between Thr16s and Lys166 leading to an increased Km for the 
purine base substrates. Contrary to expectations, the reported Km for guanine was normal · 
while that ofPRPP was elevated fivefold (Keough et al (1988). 
The three mutations affecting Ala161 described in L868, HPRTMilwaukee and the identical 
mutation in L867, as well the mutation at Ser162 found in HPRTFamham, suggest that the end 
of B strand B6 and the bend between strand B6 and B6' are key structural elements within 
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the core of HPR T. The severe impact on residual activity of the two relatively 
conservative amino acid substitutions in L867 and L868, and the absence of any effect on 
substrate affinities, provides further evidence that Alal61 plays a crucial role in maintaining 
the integrity ofHPRT structure. 
4.4.2 The Molecular Defect in HPRTcape Town• 
The molecular defect in HPRTeape Town results in the substitution of Aspm by Asn. 
Secondary structure predictions using the CF and GOR methods predicted no changes in 
local secondary structure as a result of the residue substitution. Aspm is located at the 
center of the highly conserved PRPP binding motif which in HPR T comprises the residues 
129-VLIVEDIIDTGK-140 (Wilson et al, 1983d; Hove-Jensen et al 1986). The character 
of the motif has been conserved through all known phosphorybosyltransferases, in species 
as diverse as humans and E. coli and is also identifiable in PRPP synthetase (Table 4.5). 
Asp135 is the only amino acid within the PRPP binding motif which is absolutely 
conserved. 
Within the HPRT crystal structure, Eads et al (1994) described the PRPP binding motif as 
starting with the hydrophobic residues of strand BS within the core of the enzyme (Figure 
4.10). These hydrophobic residues have no direct interactions with the active site. The B 
strand makes a sharp tum at Aspm and leads into a loop composed of residues Asp138 to 
Thr142 which encircle the phosphate group of GMP. The carboxylate side chains of Glu134 
and Aspm are located below the ribose in HPRT, as are the equivalent amino acids in the 
crystal structure of OPRT (Scapin et al, 1994). 
The kinetics of HPRTcape Town in haemolysates has been described in detail by Steyn and 
Harley (1984). This unusual HPRT variant has normal substrate affinities and Vmax. 
However, at hypoxanthine concentrations above 70 µM, enzyme activity decreased with 
increasing purine base substrate concentration. 
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The pattern of inhibition was uncompetitive and was characteristic of an ordered 
sequential reaction, with PRPP binding before hypoxanthine. On the basis of double 
inhibition studies (using the inhibitory substrate hypoxanthine and the product PPi) Steyn 
and Harley proposed the reaction mechanism shown in Figure 4.12. In both the normal 
enzyme and HPRTeape Town, PRPP binds before hypoxanthine. Catalysis occurs and IMP is 
released. In the normal enzyme PPi is released. But in HPRTeape Town, before PPi is 
released, hypoxanthine binds to the enzyme pyrophosphate intermediate forming a dead 
end product-substrate-enzyme complex. 
HPR T Cape Town is a unique HPR T variant and no other variant phosphoribosyltransferase 
characterised by substrate inhibition has been previously reported. However, a similar 
pattern of apparent substrate inhibition to that found in HPRTeape Town was reported in rat 
liver by Wohlhueter (1975). There is no evidence for tissue specific HPRT isoenzymes in 
the rat or any other species and it seems likely that the apparent substrate inhibition shown 
by Wolhueter in rat liver may be a consequence of using crude undialysed enzyme 
preparations. The assay method used by Wolhueter did not include TTP as an inhibitor of 
5'-nucleotidase and it is possible that this may have contributed to the decreased product 
formation at high substrate concentrations in the crude rat liver preparation. 
Early models of phosphoribosyltransferase structure suggested that the two carboxylate 
residues at the center of the PRPP binding motif in HPRT (Busetta, 1988) and OPRT 
(Ashton et al, 1989) play a role in binding the pyrophosphate moiety of the PRPP-Mg2+ 
substrate complex. 
The absence of PPi or PRPP in the crystal structures of HPR T and OPR T has resulted in 
difficulties in clarifying the functional role of the two conserved carboxylate residues. 
Eads et al (1994) and Scapin et al (1994) showed no direct interaction between the 
carboxylate residue of Aspm in HPRT (and the equivalent residue in OPRT) and the 
ribose of the bound mononucleotide. 
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PRPP Hx IMP Hx 
E I I I E 
E PRPP 
E Hx E IMP 
PRPP PPi 
E PPi - Hx 
E Hx 
PPi 
Figure 4.12: Proposed reaction mechanism of catalysis in HPRTcape Town - In the 
reaction mechanism proposed by Steyn and Harley (1984), PRPP binds to the enzyme (E) 
before hypoxanthine (Hx). Catalysis occurs and IMP is released. In HPRTcape Town 
hypoxanthine then binds to the enzyme pyrophosphate intermediate forming a dead end 
product-substrate-enzyme complex. 
This is consistent with the normal substrate affinities described in HPR T cape Town by Steyn 
and Harley (1984), since direct interaction between Asp135 and the ribose of PRPP would 
be expected to result in an increased Km for PRPP with a change to Asn135. 
Both Eads et al (1994) and Scapin et al (1994) speculate that the two carboxylate residues 
may be involved in stabilising the transition state of oxocarbonium character which is 
believed to develop during phosphoribosyl transfer. A weak positive charge is expected to 
develop on the ribose. Scapin et al (1994) speculated further that in OPRT, the two 
carboxylate residues may act as a Mg2+-PPi binding site. Although the distance between 
the nucleoside and the possible PPi binding site is greater than expected for nucleophilic 
displacement, Scapin et al (1994) suggested that during the transition state, the bond 
length between the ribose group and the incoming nucleophile or leaving base during 
group (ribosyl) transfer may lengthen, bringing the Mg2+ -PPi complex and the nucleotide 
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into close proximity. Alternatively, PPi may bind to one of the conserved basic residues 
found within the active site of both HPRT and OPRT. 
Thus there are two proposed roles for Aspm and the neighbouring carboxylate residue in 
HPRT: either stabilising the oxocarbonium transition state, or acting as a 
Mg2+ -pyrophosphate binding area, or both. 
An alternative mechanism of substrate inhibition in HPRTcape Town based on the assumption 
that Asp135 is not involved in PPi binding, takes into account the Recovery Model of 
substrate inhibition proposed by Kuhl (1994). The model postulates that after the catalytic 
act, an obligatory recovery phase is necessary before the new operation cycle can start. 
The recovery phase has a fixed finite time t of negligible variance. At high concentrations 
of substrate, inappropriate binding of substrate to the refractory state of the enzyme may 
occur. Binding of a substrate molecule during this recovery phase gives rise to substrate 
inhibition. It is possible that the negative charge associated with Aspm may play a role in 
the enzyme recovery phase of HPRT. Such a mechanism would be consistent with the 
placement of Aspm within the crystal structure ofHPRT below the ribose ring of bound 
IMP with no direct interaction with PPi. However, this model does not explain Steyn and 
Harley's (1984) observation that hypoxanthine and PPi are not independent inhibitors of 
HPRTeape Town-
The proposed formation of a dead-end hypoxanthine-enzyme-PPi complex in 
HPRTeape Town (Steyn and Harley, 1984) suggests that Asp135 interacts in some way with 
PPi. The release of the products IMP and PPi by the normal enzyme has been reporled to 
be ordered sequential by Krenitsky and Papaioannou (1969), while Giacomello and 
Salemo (1978) proposed a random sequential release of products based on assays of the 
reverse reaction. Both mechanisms would result in an EPPI intermediate. The bond 
lengthening during the transition state may place PPi within close proximity to the 
negatively charged area of Glun4 and Aspm. The release of PPi from the active site of 
HPR T would then be hastened by repulsion between the carboxylate residues and the 
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negatively charged PPi. The substitution of the carboxylate residue Aspm by neutral Asn 
could reduce the leaving impetus of pyrophosphate, increasing the time spent by PPi 
within the active site and allowing the purine base substrates to bind to form a dead-end 
product-substrate-enzyme complex. This proposed model thus includes some elements of 
the Recovery model. 
A number of mutations affecting the conserved PRPP binding motif have been reported 
(Table 4.4). The Val130 to Asp in the Lesch-Nyhan variant HPRTMidiand (Davidson et al 
1988a) and the Leum to Met in partially deficient HPRTAnn Arbor (Wilson et al 1986a) are 
both in the B strand BS at the core of the enzyme. Both variants have decreased 
intracellular levels of HPRT protein. The Val130 to Asp substitution would destabilise the 
entire core structure, while the substitution in HPRTAnn Arbor is more conservative, but 
could result in altered residue packing within the hydrophobic core of the enzyme (Eads et 
al, 1994). The implication of the Gly140 to Asp substitution in the Lesch-Nyhan variant 
HPRTrokyo (Fujimori et al, 1992) is also discussed by Eads et al (1994). The substitution 
would be expected to alter the conformation and charge of the phosphate binding loop 
affecting the binding of the 5'-phosphate ofPRPP. 
It is tempting to speculate that the phenomenon of substrate inhibition due to the Asp135 to 
Asn in HPRTeape rown can be generalised to other phosphoribosyltransferases. De Boer 
and Glickman (1991) reported the equivalent mutation in an APRT variant isolated from a 
Chinese hamster ovary cell line. Although the enzyme was not characterised kinetically, it 
is interesting that this variant APRT showed 10% residual activity. 
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4.4.3 Patient P534. 
The clinical presentation of patient P534 was consistent with partial HPRT deficiency. 
The "self-mutilation" reported by the clinicians is of anecdotal interest and should not be 
confused with the compulsive self-mutilation characteristic of the Lesch-Nyhan syndrome. 
The self-inflicted injuries observed in the patient represented a cognitive attempt by the 
patient at treatment as recommended by a traditional healer. 
The results of the biochemical and molecular investigations of patient P534 are 
contradictory: HPRT assays on two independently blood specimens were typical of a V max 
variant, but kinetic parameters and the heat stability profile of HPRT in lymphoblast 
lysates were normal. 
It is possible that the decreased HPRT activity in haemolysates of P534 is artifactual. As 
Fairbanks et al (1987) pointed out, the assay of HPRT activity in haemolysates may 
dramatically underestimate the amount of residual HPR T activity as measured in intact 
erythrocytes. Similar, but as yet undefined factors, may have contributed to an 
underestimation of normal HPRT activity in haemolysates of P534. The interpretation of 
the decreased haemolysate HPRT activity in P534 is complicated by the blood transfusion 
the patient had received a day prior to blood being drawn for HPR T determination. There 
have been reports of a blood transfusion restoring HPRT activity in a Lesch-Nyhan infant 
(Simmonds, 1994) and this is in line with the finding that HPRT activity in blood 
transfusion units was stable to beyond the expiry date of the units. It seems unlikely that 
the blood transfusion could have led to the decreased HPRT activity seen in haemolysates 
of the patient, as evidence suggests that a blood transfusion would have led, on the 
contrary, to an increase and consequent overestimation ofHPRT activity in P534. 
The double label experiment on intact cultured fibroblasts appeared to support a diagnosis 
of partial HPRT deficiency, but only a single experiment with two control cell lines was 
performed and no confirmed partial HPRT fibroblast cell lines were available for the study. 
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Baumgarten and Harley (1995) stressed the variability of purine label incorporation 
between experiments by cultured fibroblasts and predicted that the results of a single 
experiment with few control fibroblasts cell lines, could result in an erroneous diagnosis of 
partial HPRT deficiency. These reservations are of general relevance and were 
substantiated by the double label studies on cultured lymphoblasts, which included the cell 
lines L534, L867 and L868, described in Section 5. In this study, L534 was not 
significantly different in [14C] hypoxanthine incorporation from the partially HPRT 
deficient lymphoblast cell lines L867 and L868, but was significantly lower than three of 
the six control cell lines. These results are also ambiguous and may be taken to support 
either the hypothesis that P534 has a partial deficiency in HPRT, or that P534 is normal. 
The genetic status of P534 remains uncertain. No mutations could be found in the coding 
region of L534 HPRT cDNA. It is possible that a mutation in a HPRT gene regulatory 
element could result in decreased transcription and consequently, decreased HPRT activity 
predominantly in erythrocytes. A lower than normal rate of HPRT enzyme synthesis in 
nucleated cells could be compensated by the stability of the enzyme and it is conceivable 
that normal or near normal levels of the enzyme can be maintained. The mature 
erythrocyte on the other hand, has lost the capacity for protein synthesis. An impaired 
rate of HPRT enzyme synthesis in the nucleated red cell precursor could result in 
decreased HPR T enzyme levels in the mature erythrocyte. Without evidence of decreased 
levels ofHPRT mRNA however, the defect in P534 remains speculative. 
124 
4.5 Conclusion. 
Ala161 has an important structural role in maintaining the integrity of HPRT enzyme 
structure. The biochemical effects of mutations at this residue have not been previously 
defined. Three mutations have now been reported to affect this residue. The Alal61 to Ser 
substitution in L867 is identical to HPRTMi1waukec, while the Ala161 to Gly substitution in 
L868 is a novel mutation. 
The role of the extremely conserved residue Aspm in the PRPP binding motif remains 
uncertain. The Aspm to Asn substitution in HPRTeape Town is associated with substrate 
inhibition and a proposed dead-end hypoxanthine-PPi-enzyme complex. This suggests 
that role of Aspm in HPRT lies in the expulsion of PPi from the catalytic site of the 
enzyme. 
The defect in P534 remains unclear. A defect in a HPRT gene regulatory element would 
be consistent with the profile of impaired enzyme activity in haemolysates and normal 
activity in lymphoblast lysates. 
5. 
5.1 
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VARIATION IN PURINE LABEL METABOLISM BY 
CULTURED LYMPHOBLASTS: [14C] HYPOXANTHINE 
INCORPORATION AS A PREDICTOR OF PARTIAL 
HPRT DEFICIENCY. 
Introduction. 
A number of investigators have suggested that a single measure of HPR T activity is not 
sufficiently reliable to diagnose partial HPRT deficiency. Reservations have been 
expressed about the accuracy of assay methods based on the incorporation of [ 14 C] 
hypoxanthine by cultured fibroblasts (Willers et al, 1984), or intact erythrocytes (Gordon 
et al, 1987) and the direct assay of HPRT activity in erythrocyte lysates (Fairbanks et al, 
1987). Our experience with the patient P534 has confirmed that reliance on a single 
diagnostic system such as the measurement of HPR T activity in haemolysates, may prove 
misleading. 
Rozen et al ( 1977) pioneered the use of a double label approach to the diagnosis of inborn 
errors of metabolism in fibroblasts. The activity of the pathway under investigation can be 
determined by measuring the incorporation of a [ 14C] labelled substrate into the product of 
the pathway relative to a [3H] substrate which is incorporated into a separate, unrelated 
pathway. The incorporation of the [3H] substrate by the unrelated pathway serves as a 
control for cell viability and cell number in the assay system. Rozen was able to 
demonstrate severely decreased [14C] hypoxanthine incorporation relative to normal [3H] 
thymidine incorporation by fibroblasts derived from a Lesch-Nyhan patient. The value of 
a similar double label approach, using the ratio of [14C] hypoxanthine incorporation to the 
control substrate [3H] phenylalanine, in demonstrating complete HPRT deficiency in 
Lesch-Nyhan patients was shown in Section 3. 
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Recently our laboratory defined the components of the major physiological variation found 
in the uptake of the purine bases adenine and hypoxanthine by human and other 
mammalian fibroblasts (Baumgarten and Harley, 1995; Vreede, 1994)). Although cell 
lines partially deficient in HPR T were not included in these studies, the finding of a large 
variation in the uptake of labelled hypoxanthine between individual fibroblast cell lines 
within the same experiment over a time scale of a few days, has cast doubt on the validity 
of using the incorporation of labelled hypoxanthine by nucleated cells as a means of 
diagnosing partial HPRT deficiency. 
Cultured lymphoblasts are an easily obtainable, renewable source of patient material and 
are often, as in the case of P867 and P868, the only material available for investigation by 
a reference laboratory. Little is known of the components and extent of variation of whole 
cell purine base uptake in these cells. The validity of an intact lymphoblast double label 
assay as a method of diagnosing partial HPR T deficiency in nucleated cells merited further 
investigation. 
Two label pairs were assessed as predictors of HPRT deficiency: [14C] hypoxanthine and 
[ 3H] phenylalanine and in a modification of the method described by Rozen et al (1977), 
[ 14C] hypoxanthine and [3H] adenine. In the first label pair, PH] phenylalanine enters an 
independent control pathway and serves as a measure of cell viability within the assay 
system and corrects for variables such as cell number. In contrast, the salvage of [3H] 
adenine and [14C] hypoxanthine are not independent. The salvage pathways of 
hypoxanthine and adenine converge at AMP. The first step of both salvage pathways are 
catalysed by a phosphoribosyltransferase which requires PRPP as a co-substrate. 
APR T activity has been reported to be increased in erythrocytes of partially and 
completely HPRT deficient patients (Kelley et al, 1967, 1969; Seegmiller et al, 1967; 
Shin-Buehring, 1980; Snyder et al, 1984), while Zoref et al (1978) showed increased 
adenine salvage in intact fibroblasts from a patient with partially deficient HPRT activity. 
However, APRT activity in fibroblast lysates (Kelley, 1971) and lymphoblast lysates 
127 
(Snyder et al 1989) was found to be normal. In an analogous approach to a whole cell 
double label method, Stout et al (1985) used the ratio of HPRT activity to APRT activity 
in cell free chorionic villus material in the prenatal diagnosis of the Lesch-Nyhan 
syndrome. The measure of APR T activity served as an internal control. 
On the basis of increased APRT activity reported in HPRT deficiency, we postulated that 
if [3H] adenine was used instead of the traditional [3H] phenylalanine or [3H] thymidine as 
a measure of the control pathway, the dynamics of [14C] hypoxanthine and [3H] adenine 
uptake by a partially deficient lymphoblast cell line could act to increase the differential in 
the uptake of [14C] hypoxanthine relative to the control pathway label. An analysis of 
variance was used to define the components of variation within the two assay systems, and 
a pair-wise comparison of patients and controls was used to test the predictive power of 
both label pairs in detecting partial HPR T deficiency in cultured lymphoblasts. 
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5.2 Methods. 
5.2.1 Cell Lines. 
The transformed lymphoblast cell lines used in the d<'>uble label experiments are shown in 
Table 5 .1. All cell lines were free of Mycoplasma contamination. 
Table 5.1: 
CELL LINE 
L516 
L517 
L634 
L844 
L863 
L864 
L534 
L867 
L868 
Transformed lymphoblast cell lines used in the double label 
experiments. 
DEFECT 
obligate heterozygote variegate porphyria 
obligate heterozygote variegate porphyria 
acute intermittent porphyria 
possible porphyria 
normal individual 
normal individual 
possible partial HPR T deficiency 
partial HPR T deficiency 
partial HPR T deficiency 
5.2.2 Incorporation of [14C] Hypoxanthine Relative to [3H] Adenine or 
[3H] Phenylalanine by Cultured Lymphoblasts. 
Lymphoblast cultures were fed twice weekly with 20 ml of DMEM supplemented with 
10% foetal calf serum. Experiments were timed to occur the day after the cells were fed . 
All experiments were performed in triplicate. Cell densities of lymphoblast cultures were 
estimated on a Coulter Model Z cell counter (Coulter Electronics, Florida, USA). A 
volume of the cell suspension equivalent to 1x106 cells was transferred to a centrifuge tube 
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and the cells pelleted at 1 OOOg for 10 min. The medium was discarded and replaced with 
normal saline, the cells pelleted and then resuspended in 1 ml of a labelling medium 
consisting of 15 mM Hepes buffered Hanks Balanced Salt solution (pH 7.4) supplemented 
with 0.2 µCi [14C] hypoxanthine and 0.8 µCi [3H] phenylalanine or [3H] adenine. The 
cells were then incubated with shaking at 3 7°C without CO2 for 2 hours. After labelling, 
the cells were pelleted at 1 OOOg for 10 min and the cell pellet washed with 4 ml ice cold 
saline. The cells were pelleted again, the saline discarded and the tubes allowed to drain 
for a few moments in an inverted position on absorbent paper to remove as much of the 
saline as possible. 200 µl of ice cold 5% trichloroacetic acid (TCA) was then added to the 
cell pellet and the precipitate trapped on Whatman GF IC glass microfibre filters (Whatman 
International, Maidstone, England) mounted in a Millipore vacuum manifold. The filters 
were washed twice under vacuum with 4 ml ice cold 5% TCA. Care was taken to rinse 
the edges of the filters after removal of the sealing gasket of the vacuum manifold. Each 
filter was transferred to a scintillation vial and 200 µl water and 10 ml Bionic-Fluor 
scintillant added. The vials were counted the next day using windows of O to 200 ke V for 
[3H] and 400 to 1000 ke V for the [14C] label. The efficiency of counting of each isotope 
in each window is shown below: 
[3H] in the [3H] window 
[3H] in the [14C] window 
[ 14C] in the [3H] window 
[ 14C] in the [14C] window 
34% efficiency 
0% efficiency 
5% efficiency 
54% efficiency 
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5.2.3 Statistical Analysis. 
5.2.3.1 Analysis of Components of Variance of Labelled Substrate Incorporation 
by Cultured Lymphoblasts. 
The double label experiments have a nested design. Replicate determinations are nested 
within individual cell lines which are nested within experiments performed on different 
occasions. Determinations are influenced by random factors derived from each 
experimental level. The experimental system fits a random effects model with three stages 
of sampling as shown in Table 5.2. The general structure of the model and formulae for 
calculations are as described by Snedecor and Cochran (1980). 
The kth observation of the jth cell line in the ith experiment has the structure 
X ··k=µ+A ·+B ·· +e ··k lj l lj lJ 
µ = general mean 
Ai = random effect of experiments 
Bij = random effect of individual cell lines 
eijk = random effect of replicate determinations. 
with i = l , .. ,a; j = l , .. ,b: k = l , .. ,n; 
and Ai = N(O,cra 2); Bij = N(O,crb 2); eijk = N(O,cre 2). 
The variables Ai, Bij and eijk are all assumed independent. 
Table 5.2: Structure of double label experiments. 
Experiment, i 
i=I, ... ,a 
Cell Line, ij 
j=I, ... ,b 
1 
a 
1 
2 
b 
1 
b 
Total size= abn 
Calculations of Sum of Squares (SS): 
a = number of experiment; b = number of cell lines; 
n = number of replicate 
C = (X..)2/(abn) 
Total SSdeterminations = t X2 ijk - C 
Total SScel/ lines= t X 2ij_ln - C 
Total SSexp = t x\. / bn - C 
SSind (individual cell lines of same experiment) 
= SScell lines - SSexperiment 
SSerr (Replicate in same cell line in same experiment) 
= SSdeterminations - SScel/ lines 
Replicates, ijk 
k=I, ... ,n 
X111 
Xm 
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Xa1n 
132 
An ANOVA table was constructed as shown below (Table 5.3). 
Table 5.3: Form of ANOV A tables. 
Source of 
Variation ss df MS Parameters Estimated 
Experiment SSexp (a-1) SSexp cre" + ncrB" + bncrA" 
(a-1) 
Individual SSind a(b-1) SSind CTe" + ncrB" 
a(b-1) 
Replicate SSerr ab(n-1) SSerr cre" 
ab(n-1) 
Estimation of the Components of Variance. 
Unbiased estimates of the three components of variance were calculated from the mean 
squares as shown below: 
Variance due to replication error: 
2 
Se = MSerr estimates cre 2 
Variance due to individual cell lines within an experiment: 
2 
SB = (MSind - MSerr)/n estimates crB2 
Variance due to experiments: 
2 
SA = (MSexp - MSind)/nb • 2 estimates cr A 
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Hypothesis Testing. 
2 
H0: a A = 0, there is no significant difference in the incorporation of a labelled substrate 
F = MSexp 
MSind 
by a cell line between experiments. 
estimates ae 2 + n as 2 + bn al'-
2 2 
a e + n as 
with degrees of freedom v = (a-1),a(b-1) 
At large values ofF, reject Ho and accept H1 that there is a significant difference in the 
incorporation of a labelled substrate by a cell line between experiments. 
Ho: as 2 = 0, there is no significant difference in the incorporation of a labelled substrate 
by individual cell lines within the same experiment. 
F =MSind 
MSerr 
estimates a e 2 + nai 
a/ 
with degrees of freedom v = a(b-1),ab(n-l) 
At large values of F, reject Ho and accept H 1 that there is a significant difference in the 
incorporation of a labelled substrate between individual cell lines within an experiment. 
5.2.3.2 Analysis of Variance and Multiple Comparison Testing Between Patients 
and Control Cell Lines. 
An analysis of variance was used to determine whether there were significant (p<0.05) 
differences between the population means of individual cell lines. Replicate data from 
three experiments for both patient and control cell lines were pooled and analysed with the 
aid of a statistical computing programme (Instat V2.05a, Graphpad Software, San Diego, 
USA). If the overall p value was <0.05, a multiple comparison between cell lines was 
performed using the Student-Newman-Keuls multiple-range test. 
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Interpretation of results: 
p>0.05 ns not significant 
p<0.05 * significant 
p<0.01 ** very significant 
p<0.0001 *** extremely significant 
5.3 Results. 
5.3.1 Time Course ofLabelled Substrate Incorporation. 
The incorporation of [14C] hypoxanthine by a control lymphoblast cell line relative to 
either [3H] adenine or [3H] phenylalanine, over a time course of 150 min is shown in 
Figure 5. 1. The rate of incorporation of all three labelled substrates was approximately 
linear between 90 min and 150 min and is shown in Table 5.4. The rate of 
[ 14C] hypoxanthine uptake was not affected by the nature of the second [3H] label. 
The trend of the ratio with time of each substrate pair is a reflection of the rate of the 
incorporation of each label. The incorporation of [14C] hypoxanthine and [3H] 
phenylalanine showed a marked lag phase between 30 min and 90 min, during which the 
labelled substrates were incorporated into acid precipitable material at a slower rate than 
between 90 and 150 mm. As a result, the ratio of [14C] hypoxanthine to [3H] 
phenylalanine showed an increasing trend with time (Figure 5 .1 c ). The rate of 
incorporation of [14C] hypoxanthine was similar to the rate of [3H] adenine uptake which 
was relatively constant (Figure 5 .1 b). The slope of the regression line fitted to the ratio of 
[ 14C] hypoxanthine to [3H] adenine versus time was not significantly different from zero. 
Table 5.4: The rate of incorporation of labelled substrate by cultured 
lymphoblasts. 
LABEL PAIR 
[ C] Hypoxanthine 
3H Adenine 
[ C] Hypoxanthine 
3 Phen lalanine 
CONCENTRATION 
IN MEDIUM 
nM 
3750 (0.2 µCi/ml) 
38.1 0.8 Ci/ml 
3750 (0.2 µCi/ml) 
6.5 0.8 Ci/ml 
RATE OF 
INCORPORATION* 
d m/min/1 o6cells 
102.0 
115.4 
105 .9 
60.2 
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* calculated from the slope of a regression line fitted to the data shown in Figure 5. 1 for 
the interval 90 min to 150 min. 
5.3.2 Analysis of Variance of Double Label Incorporation by Cultured 
Lymphoblasts. 
The Standard Experiment. 
Lymphoblasts at a density of lxl06 cells/ml were incubated for 2 hours in 1 ml medium 
containing either, 0.2 µCi [14C] hypoxanthine and 0.8 µCi [3H] phenylalanine or 0.2 µCi 
[ 14C] hypoxanthine and 0.8 µCi [3H] adenine. The study included 6 control cell lines and 
the partially HPRT deficient cell lines L867 and L868. The results of the biochemical and 
molecular studies on L534 (Section 4) did not confirm an HPRT deficiency in this cell line. 
In an attempt to determine whether HPRT deficiency in this patient could be demonstrated 
in vivo, L534 was included in the double label study. 
Three levels of experimental variation were analysed: 
EXPERIMENT: Between experiment variance (variation of 
individual control cell lines between experiments). 
INDIVIDUAL: Between individual variance (variation 
between control cell lines within the same experiment). 
REPLICATE: Between replicate variation (variation 
between triplicate values for an individual control 
cell line within an experiment). 
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Figure 5.1: Double label time course of [14C] hypoxanthine incorporation relative 
to the incorporation of either [3H] phenylalanine or [3H] adenine by a normal 
cultured lymphoblast cell line. (a) Time course of incorporation of [14C] hypoxanthine 
and [3H] phenylalanine. (b) Time course of incorporation of [ 14C] hypoxanthine and [3H] 
adenine. (c) Change in the ratio of [14C] hypoxanthine relative to either [3H] phenylalanine 
or [3H] adenine over time. Values are the mean of triplicate determinations. 
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The results of the analysis of variance of three experiments on six control cell lines for 
each labelled substrate pair are shown in Tables 5.5 to 5.10, and summarised in 
Table 5.11. 
Table 5.5: 
SOURCE 
Experiment 
Individual 
Replicate 
Total 
SOURCE 
Experiment 
Individual 
Analysis of variance of the ratio of (14C] hypoxanthine to 
[3H] phenylalanine incorporation by six control lymphoblast cell lines 
in three experiments. 
ss df MS % OF VARIANCE 
17.732 2 8.8860 72.9 
4.636 15 0.3091 10.1 
3.988 36 0.1108 17.0 
26.356 53 100.0 
FVARIANCE df Fvl,v2 LEVEL OF 
RATIO (V1 ,V')) (1%) SIGNIFICANCE (o) 
2.87 2.15 6.36 ns 
1.16 15.36 2.58* ns 
* Value between F 14,36 and F 16,36 estimated by linear interpolation. 
Table 5.6: 
SOURCE 
Experiment 
Individual 
Replicate 
Total 
SOURCE 
Experiment 
Individual 
Analysis of variance of [14C] hypoxanthine (with [3H] phenylalanine 
as the second label) incorporation by six control lymphoblast cell lines 
in three experiments. 
ss df MS % OF VARIANCE 
2.666E+09 2 1.333E+09 51.5 
2.126E+09 15 1.417E+08 30.9 
8.l 15E+08 36 2.254E+07 17.6 
5.604E+09 53 100.0 
FVARIANCE df Fvl,v2 LEVEL OF 
RATIO (Vl,V?) (1%) SIGNIFICANCE ( o) 
1.25 2 15 6.36 ns 
184.87 15.36 2.58* <0.001 
* Value between F 14, 36 and F 16,36 estimated by linear interpolation. 
Table 5.7: 
SOURCE 
Experiment 
Individual 
Replicate 
Total 
SOURCE 
Experiment 
Individual 
Analysis of variance of [3H] phenylalanine incorporation by six 
control lymphoblast cell lines in three experiments. 
ss df MS % OF VARIANCE 
7.238E+09 2 3.619E+09 34.4 
1.192E+ 10 15 7.947E+08 54.3 
1.861E+09 36 5.169E+07 11.3 
2.102E+l0 53 100.0 
FVARIANCE df Fvl,v2 LEVEL OF 
RATIO (Vl,V'J) (1%) SIGNIFICANCE ( o) 
0.61 2 15 6.36 ns 
6.41 15 36 2.5-8* <0.001 
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* Value between F 14,36 and F 16,36 estimated by linear interpolation. 
Table 5.8: 
SOURCE 
Experiment 
Individual 
Replicate 
Total 
SOURCE 
Experiment 
Individual 
Analysis of variance of the ratio of [14C) hypoxanthine to [3H] adenine 
incorporation by six control lymphoblast cell lines in three 
experiments. 
ss df MS % OF VARIANCE 
0.4137 2 0.2069 30.8 
0.7793 15 0.0520 58.2 
0.1107 36 0.0031 11.0 
1.3037 53 100.0 
FVARIANCE df Fvl,v2 LEVEL OF 
RATIO (v1 ,V? ) (1%) SIGNIFICANCE ( o) 
0.53 2.15 6.36 ns 
7.04 15,36 2.58* <0.001 
* Value between F14,36 andF16,36 estimated by linear interpolation. 
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Table 5.9: Analysis of variance of [14C] hypoxanthine (with [3H] adenine as the 
second label) incorporation by six control lymphoblast cell lines in three 
experiments. 
SOURCE ss df MS % OF VARIANCE 
Experiment 3.325E+08 2 1.663E+08 47.2 
Individual 3.647E+08 15 2.431E+07 46.3 
Replicate 3.897E+07 36 1.083E+06 6.5 
Total 7.362E+08 53 100.0 
SOURCE FVARIANCE df Fvl,v2 LEVEL OF 
RATIO (v1.v,.,) (1%) SIGNIFICANCE (p) 
Experiment 0.91 2.15 6.36 ns 
Individual 9.36 15,36 2.58* <0.001 
* Value between F 14,36 and F 16,36 estimated by linear interpolation. 
Table 5.10: Analysis of variance of [3H] adenine incorporation by six control 
lymphoblast cell lines in three experiments. 
SOURCE ss df MS % OF VARIANCE 
Experiment 4.836E+08 2 2.418E+08 36.7 
Individual 5.564E+08 15 3.709E+07 28.1 
Replicate 3.929E+08 36 1.091E+07 35.2 
Total 1.433E+09 53 100.0 
SOURCE FVARIANCE df Fvl,v2 LEVEL OF 
RATIO (v1 ,V?) (1%) SIGNIFICANCE (o) 
Experiment 0.87 2.15 6.36 ns 
Individual 1.42 15,36 2.58* ns 
* Value between F14,36 and F16,36 estimated by linear interpolation. 
140 
A summary of the components of variance within the double label experiments is shown in Table 
5.11. For the ratio [14C] hypoxanthine / [3H] phenylalanine, variation of cell lines between 
experiments showed the greatest variance in the experimental system. This is in contrast to the 
label pair [14C] hypoxanthine / [3H] adenine, where variation between experiments is less than half 
the between experiment variance of the [14C] hypoxanthine / [3H] phenylalanine label parr. 
Variation between replicate determinations in both double label systems was low. 
Table 5.11: 
% Component 
of variance 
Experiment 
Individual 
Replicate 
Summary of the components of variance in six control cell lines in three 
double label experiments with either [14C] hypoxanthine and [3H] 
phenylalanine, or [14C] hypoxanthine and [3H] adenine as the labelled 
substrate pair. 
Labelled Substrate Pair Labelled Substrate Pair 
f14Cl Hx f3Hl Phe Ratio f14Cl Hx f3Hl Ad Ratio 
51.5 34.4 72.9 47.2 36.7 30.8 
30.9 54.3 IO.I 46.3 28.1 58.2 
17.6 11.3 17.0 6.5 35.2 11.0 
The significance of the variance of control cell lines between experiments and within an experiment 
are shown in Table 5.12. The variance of substrate incorporation by individual control cell lines 
and of the ratio between substrates was not significant between experiments. However, low 
replicate variance resulted in significant differences between cell lines, when cell lines are 
compared within an experiment. 
Table 5.12: Summary of the significance of control cell line variance between three 
experiments and within an experiment with either [14C] hypoxanthine and 
[3H] phenylalanine, or [14C] hypoxanthine and [3H] adenine as the labelled 
substrate pair. 
Labelled Substrate Pair Labelled Su )Strate Pair 
Variation 
Between: f14Cl Hx f3Hl Phe Ratio f14Cl Hx f3Hl Ad Ratio 
Experiment ns ns ns ns ns ns 
Individual ** ** ns ** ns ** 
ns not significant, p>0.05 
* * significant at the 1 % level 
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Significant variation between control cell lines within an experiment suggested that a pair-wise 
comparison between individual control cell lines and patient cell lines within a single experiment, 
would be unable to discriminate control from patient cell lines with a genuine HPRT deficiency. 
Triplicate data for each patient and control cell line over three experiments were combined in an 
analysis of variance. The data is shown graphically in Figure 5.2 and Figure 5.3. A summary of 
the analysis of variance of combined patients and controls is compared to that of control cell lines 
alone and is shown in Table 5 .13 . 
Table 5.13: Significance of the variation between experiment of six control cell lines 
excluding patients and six control cell lines including patients with either [14C] 
hypoxanthine and [3H] phenylalanine, or [14C] hypoxanthine and [3H] 
adenine as the labelled substrate pair. 
Labelled Substrate Pair 
Variation 
Between: f14Cl Hx f3Hl Phe 
Controls ns ns 
Controls 
+ Patients *** ns 
ns 
* 
** 
*** 
not significant, p>0.05 
significant, p<0.05 
very significant, p<O.01 
extremely significant, p<0.0001 
Labelled Substrate Pair 
Ratio f14Cl Hx f3Hl Ad Ratio 
ns ns ns ns 
* ** ** *** 
Between experiment variance for control cell lines was not significant for either of the labelled 
substrate pairs. When patient cell lines were included in the analysis, significant variance between 
cell lines was detected. 
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Figure 5.2: The incorporation of [14C] hypoxanthine relative to [3H] phenylalanine by 
control and patient cultured lymphoblast cell lines. Triplicate values for each cell line from 3 
experiments were pooled and are shown as the mean +/-ISD. (a) Ratio of [14C] hypoxanthine to 
[
3H] phenylalanine incorporation. (b) Incorporation of [14C] hypoxanthine. (c) Incorporation of 
[3H] phenylalanine. 
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Figure 5.3: The incorporation of [14C] hypoxanthine relative to [3H] adenine by control 
and patient cultured lymphoblast cell lines. Triplicate values for each cell line from 3 
experiments were pooled and are shown as the mean +/-ISO. (a) Ratio of [14C] hypoxanthine to 
[3H] adenine incorporation. (b) Incorporation of [14C] hypoxanthine. (c) Incorporation of [3H] 
adenine. 
5.3.3 Multiple Pairwise Comparison Between Patient and Control Cell Lines 
Using the Student-Newman-Keuls Multiple-Range Test. 
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An analysis of variance determines whether there are differences among the population 
means of the cell lines being compared, but does not define which cell lines, if any, differ 
from the others. The Student-Newman-Keuls multiple-range test was used to compare 
cell lines if the p value was <O. 05 as determined by the analysis of variance. The results 
are shown in Table 5.14. 
Table 5.14: Student-Newman-Keuls multiple-range test: comparison between 
control and patient cell lines using replicate data pooled from three 
experiments. 
LABEL PAIR [1,.Cl HYPOXANTHINE AND [-'H PHENYLALANINE 
Cell ['"C] HYPOXANTHINE 
Line L516 L517 L634 L844 L863 L864$ L534 L867 L868 
L534 ns ns ns ** ns *** - ns ns 
L867 ns ns ns * ns *** ns - ns 
L868 ns ns ns * ns *** ns ns -
[~H] PHENYLALANINE 
No significant difference between patients and controls. 
RATIO 
No significant difference between patients and controls. 
LABEL PAIR r·'fc HYPOXANTHINE AND rm ADENINE 
Cell [ 1"C] HYPOXANTHINE 
Line L516 L517 L634 L844 L863 L864 L534 L867 L868 
L534 * ns ns ** ns ns - ns * 
L867 ** ns ** ** ns ns ns - ** 
L868 ** ns ns ** ns ns * ** -
[~H] ADENINE 
No significant difference between patients and controls. 
Cell RATIO 
Line L516 L517 L634 L844 L863 L864 L534 L867 L868 
L534 * ns ns ** ns ** 
- ns ns 
L867 *** ** ** *** * ** ns - ns 
L868 *** * ** *** * ** ns ns -
ns not s1gruficant, p>0.05 
* significant, p<0.05 
* * very significant, p<O. 0 I 
* * * extremely significant p<O. 000 I 
$ L864 was significantly higher than all control and patient cell lines. 
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The tritriated label entering the control pathway showed no significant differences between 
patient and control cell lines for both labelled substrate pairs. The incorporation of [14C] 
hypoxanthine was not a reliable predictor of partial HPRT deficiency. The ratio [14C] 
hypoxanthine / [3H] phenylalanine failed to statistically distinguish the partial HPRT 
deficient cell lines from control cell lines. However, the ratio [14C] hypoxanthine / [3H] 
adenine was a powerful predictor of partial HPRT activity, with significant differences 
between the confirmed HPRT partially deficient cell lines L867 and L868 and all control 
cell lines. Of note is that L534 was not significantly different from the two partially HPRT 
deficient cell lines, L867 and L868. 
5.4 Discussion. 
5.4.1 The Incorporation of [14C] Hypoxanthine as a Single Measure of HPRT 
Activity in Cultured Lymphoblasts. 
The incorporation of [ 14C] hypoxanthine by intact lymphoblasts as a single measure of 
HPRT activity was not able to accurately allocate a particular cell line to either the control 
or partially HPRT deficient groups. Similar results were found in cultured :fibroblasts by 
Zoref et al (1978) who showed an overlap in the range of [14C] hypoxanthine 
incorporation by control cell lines and cell lines partially deficient in HPRT. 
5.4.2 The Ratio of [14C] Hypoxanthine Relative to [3H] Phenylalanine 
Incorporation as a Measure ofHPRT Activity. 
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The use of [3H] phenylalanine as an independent metabolic control substrate is in line with 
the traditional design of double label experiments (Rozen et al 1977). It was surprising 
that the ratio of incorporation of [14C] hypoxanthine relative to the control substrate [3H] 
phenylalanine, was unable to discriminate between lymphoblast cell lines partially deficient 
in HPR T activity and control cell lines. 
Factors which may have contributed to this unexpected lack of sensitivity in detecting 
partial HPRT deficiency are discussed in Section 5.4.4. below. 
5.4.3 The Ratio of C4C] Hypoxanthine to [3H] Adenine Incorporation as a 
Measure ofHPRT Activity. 
The use of [3H] adenine as a control substrate differs from the traditional double label 
assay of a metabolic pathway (Rozen et al, 1977). The incorporation of [14C] 
hypoxanthine and [3H] adenine are not metabolically independent, since both salvage 
reactions are catalysed by phosphoribosyltransferases and share a substrate in PRPP. 
Ultimately, both [14C] hypoxanthine and [3H] adenine are incorporated into the same acid 
precipitable product, nucleic acid. 
The incorporation of [ 14C] hypoxanthine relative to [3H] adenine proved to be an accurate 
measure of partial HPRT activity and was able to correctly identify the two cell lines L867 
and L868 as being partially HPR T deficient. The interpretation of the double label results 
obtained for the cell line L534 remains problematical. The ratio for L534 showed no 
significant differences when compared to L867 and L868, which would be consistent with 
a diagnosis of partial HPRT deficiency in this cell line. However, the ratio for L534 was 
significantly lower than only three of the six control cell lines, which suggests that L534 
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may represent the lower extreme of normal physiological variation in purine substrate 
metabolism. The absence of a mutation within the coding region of HPRT cDNA 
amplified from L534, the normal activity of HPRT in lymphoblast lysates and the 
ambiguous results of the double label experiments suggests that any defect in L534 is not 
the result of an abnormal HPRT enzyme. 
The ratio of [ 14C] hypoxanthine to [3H] adenine incorporation may be a better measure of 
functional HPRT activity (and phenotype) than the measurement of HPRT activity in 
lymphoblast lysates. The mean of the ratio of [14C] hypoxanthine to [3H] adenine 
incorporation over three experiments for L867 and L868 were 27% and 33% respectively 
of the control mean, while the ratio for L534 was 58% of the control mean. Although 
these values do not give an indication of the population variance (the ratio mean for L534 
falls within the 1 SD control range), they are nevertheless an indication that functional 
residual HPRT activity in intact cultured lymphoblasts of L867 and L868 was markedly 
higher than the less than 2% residual activity measured in lymphoblast lysates. These 
results are equivalent to studies by Fairbanks et al (1987) who reported that intact 
erythrocyte assays of HPRT are a better indicator of residual HPRT activity and hence 
phenotype, than HPRT assays on haemolysates. However, it would appear that cell free 
enzyme assays are still a better method of confirming a genuine HPRT enzyme deficiency. 
5.4.4 Sources of Variation. 
Mycop/asma infection may lead to increased purine incorporation by infected cell lines 
(Harley et al, 1970) and could result in an overestimation of residual HPRT activity 
(Willers et al, 1984). Extreme care was taken to monitor cell lines used in these 
experiments for the presence of Mycoplasma contamination and this is an unlikely source 
of either variation or increased labelled purine incorporation in the experimental system. 
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Increased [ 14C] hypoxanthine incorporation due to unrecognised Mycoplasma infection in 
control cell lines, could give rise to a misdiagnosis of partial HPRT deficiency when 
compared to uninfected cell lines. Any cell lines used in whole cell assays for the 
diagnosis of an inborn error of metabolism should be rigorously screened for the presence 
of Mycoplasma. Regular screening of cultured cell lines will reduce the risk of 
Mycoplasma metabolic processes interfering with the pathway under investigation and the 
possibility of a misdiagnosis. 
Baumgarten and Harley (1995) showed low replicate variance in the incorporation of [14C] 
hypoxanthine and [3H] adenine by cultured fibroblasts. Similarly low replicate variance 
was foun9 in this study in the incorporation of the two pairs of labelled substrates by 
cultured lymphoblasts. A consequence of low replicate variance in both double label 
systems was that within a single experiment, a pair-wise comparison between control cell 
lines and between control and patient cell lines, resulted in significant differences between 
nearly all the cell lines. A single experiment was not sufficient to reliably predict whether 
a cell line was normal or partially deficient in HPRT. It was necessary to pool the results 
of the three experiments to obtain a statistically significant measure of the differences 
between patient and control cell lines. 
The contribution of the three levels of variation to the variance of the ratio of [ 14C] 
hypoxanthine to [3H] adenine in lymphoblasts was strikingly similar to that found by 
Baumgarten and Harley (1995) in fibroblasts. The largest component of variance in 
lymphoblasts was between individual cell lines within the same experiment, which was 
double the variance of cell lines between experiments. The smallest component of 
variance was between replicates. 
The pattern of variation was different for the [14C] hypoxanthine / [3H] phenylalanine label 
pair. This ratio showed the largest between experiment variance, double the between 
experiment variance of the [14C] hypoxanthine / [3H] adenine substrate pair. Whilst low 
replicate variance led to unacceptably high sensitivity in detecting differences between cell 
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lines, the large between experiment variance in the ratio [14C] hypoxanthine / [3H] 
phenylalanine resulted in a complete loss of discriminatory power and no significant 
differences between patient and control cell lines could be seen against the background of 
between experiment variation. 
A possible explanation for the large variability between experiments of the [14C] 
hypoxanthine / [3H] phenylalanine ratio lies in the observation that the rate of 
incorporation of [14C] hypoxanthine and [3H] phenylalanine varied over time, with a non-
linear lag phase apparent between 30 and 90 min. As a result, the ratio of [14C] 
hypoxanthine to [3H] phenylalanine showed an increasing trend over time. Any difference 
between experiments which affects the duration of the lag phase and/or alters the rate of 
incorporation of one of the labelled substrates, could result in a difference in the ratio and 
contribute to between experiment variation. 
Growth stimulation of lymphoblasts has been reported to rapidly alter HPR T mRNA levels 
and HPRT enzyme activity in human lymphocytes (Steen et al, 1991). In an effort to 
reduce the possibility of variation in the metabolism of the labelled substrates due to 
growth stimulation as a result of medium changes, care was taken to feed cultures twice 
weekly and maintain lymphoblast cultures at approximately the same cell density. In 
addition, experiments were timed so as to always occur after a medium change. 
[ 14C] Hypoxanthine and [3H] adenine are incorporated at approximately the same rate into 
the same acid precipitable product, nucleic acid. Once the two substrate salvage pathways 
converge at AMP, they share the same pathways and metabolic fates. This may account 
for the observations that the ratio of incorporation of these two substrates showed no 
significant trend over time and that between experiment variance was less than half that of 
the [14C] hypoxanthine / [3H] phenylalanine label pair. 
At the between experiment level, the ratio of the labelled purine substrates proved to be a 
powerful and accurate predictor of partial HPRT deficiency. A pair-wise comparison 
150 
between cell lines showed no significant differences between any of the six control cell 
lines, but significant differences between all six control lines and the two confirmed HPR T 
variant cell lines, L867 and L868. An increase in adenine incorporation predicted on the 
basis of increased PRPP pools in partial HPRT activity was, however, not detectable 
above the background of experimental variation. 
5.5 Conclusion. 
The double label approach to the diagnosis of partial HPR T deficiency was successful in 
identifying two HPR T variant cell lines, but the method should be used and interpreted 
with caution. On the basis of the results described above, a candidate HPRT deficient cell 
line should be significantly lower than all control cell lines in at least three independent 
experiments. All defects should be confirmed at the genetic level. 
Perhaps the greatest value of the [14C] hypoxanthine / [3H] adenine double label approach 
is to provide an estimate of functional residual HPRT activity and a more precise 
prediction of phenotype. 
6. 
6.1 
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BIOCHEMICAL INVESTIGATIONS IN PATIENTS 
WITH PRIMARY IDIOPATHIC GOUT DUE TO URATE 
OVERPRODUCTION. 
Introduction. 
Gout has been recognised as a clinical entity for more than two thousand years and is 
characterised by recurrent attacks of acute inflammation in one or more joints (the clinical 
presentation of gout is comprehensively reviewed by German and Holmes, 1986; Pallela 
and Fox, 1989; Roubenoff, 1990; Cameron et al, 1993). Crystals of monosodium urate 
monohydrate are demonstrable in leukocytes of synovial fluid during acute attacks and 
may accumulate in dense deposits (tophi) in or around the joints of extremities. Only a 
minority of patients with hyperuricemia may develop gout and then only after 20 to 30 
years of sustained hyperuricemia (Pallela and Fox, 1989). 
Gout is the most common inflammatory joint disease in men over the age of 40, with 
estimates of incidence for males ranging from 5/1000 to 86/1000 (Roubenoff, 1990). The 
incidence of gout in urban Caucasian South Africans has been estimated at 13/1000 for 
males and 3/1000 for women (Beighton et al, 1977). 
6.1.1 Classification ofHyperuricemia. 
Hyperuricemia and gout have traditionally been classified into two major groups on the 
basis of either, increased metabolic uric acid production (urate overproduction) or, 
decreased renal uric acid excretion (urate underexcretion). A further distinction between 
primary and secondary gout is made on the basis of whether the principal metabolic 
abnormality is an elevation of serum urate due to a genetic defect, or whether the 
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increased serum urate can be ascribed as secondary to a defined pathological entity or the 
effects of a pharmacological agent. 
6.1.1.1 Hyperuricemia due to Urate Overproduction. 
Hyperuricemia due to urate overproduction has been reported to occur with a frequency 
of about 10% in the gouty population (Palella and Fox, 1989). Potential causes of primary 
overproducing gout have been reviewed by Pallela and Fox (1989) and Henderson (1993) 
and are discussed below. 
6.1.1.2 Increased Purine Breakdown. 
In humans, uric acid synthesis occurs primarily in the liver and to a lesser extent in the 
intestinal mucosa (Palella and Fox, 1989). A possibility that can not be excluded is that 
decreased inhibition of hepatic AMP deaminase, the rate limiting step of purine catabolism 
in the liver, could result in an increased rate of purine breakdown and urate 
overproduction. 
Any condition which leads to decreased ATP synthesis such as tissue hypoxia, ischemia 
and hypophosphatemia will lead to increased rates of purine degradation and ultimately, 
increased uric acid production. 
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6.1.1.3 L-Glutamine in Primary Hyperuricemia and Gout. 
Together with PRPP, L-glutamine concentration is potentially rate limiting for purine de 
novo synthesis (Palella and Fox, 1989). At present, no specific defect in either glutamine 
or glutamate metabolism has been implicated in the pathogenesis of primary 
overproducing hyperuricemia. 
6.1.1.4 Decreased Reutilisation ofHypoxanthine. 
Decreased salvage or reutilisation of hypoxanthine could act in concert with increased 
PRPP levels to lead to purine overproduction by a mechanism similar to that which causes 
hyperuricemia in HPRT deficiency (Palella and Fox, 1989). . 
6.1.1.5 Accelerated Rates of Purine Biosynthesis. 
PRPP occupies a central role in purine metabolism (see section 1). The link between 
increased PRPP levels due to PRPP synthetase overactivity or HPR T deficiency and 
hyperuricemia have been described in sections 1 and 3. Briefly, increased PRPP 
concentrations in these two enzymopathies activates arnidophosphoribosyltransferase, 
leading to an increased flux through the purine de novo synthetic pathway and to increased 
punne production. As PRPP levels are usually below the Km for 
amidophosphoribosyltransferase, the increase in flux through de novo purine synthesis is in 
direct proportion to the increase in PRPP levels. 
PRPP metabolism has been implicated in the pathogenesis of idiopathic pnmary 
overproducing gout. Increased rates of PRPP turnover in patients with idiopathic primary 
overproducing gout have been reported in vivo (see references in Palella and Fox, 1989), 
while increased levels of PRPP have been reported in cultured fibroblasts (Becker, 1976). 
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Measurements of PRPP levels in erythrocytes of gouty overproducers have produced 
contradictory results. No perturbation in erythrocyte PRPP levels of primary gouty 
overproducers were found in studies by Fox and Kelley (1971) and Becker et al (1973). 
These results however, are in conflict with a later study on patients with primary 
overproducing gout (Becker, 1976), which showed some correlation between increased 
levels of PRPP in fibroblasts and increased erythrocyte PRPP levels. In the latter study, 
four out of six patients with overproducing gout and no apparent defect in either HPR T or 
PRPP synthetase, showed increased levels of PRPP in both fibroblasts and erythrocytes. 
There is thus some evidence to suggest that disturbances in PRPP metabolism are 
implicated in the pathogenesis of primary overproducing idiopathic hyperuricemia and that 
these disturbances may be detected in erythrocytes. 
6.1.2 The Use of Intact Erythrocytes in the Detection of Abnormalities in PRPP 
Metabolism in Patients with Overproducing Gout. 
The intact erythrocyte represents a simple model for the study of the dynamics of PRPP 
metabolism in primary overproducing gout. Our laboratory has developed a sensitive 
assay to measure rates of PRPP accumulation in intact erythrocytes. The assay is based 
on the erythrocyte oxypurine cycle described by Berman et al (1988). 
In 1967 and 1969, Hershko et al demonstrated that rabbit and human erythrocytes 
incubated in a high phosphate medium accumulated PRPP. Berman et al (1988) defined 
the precise conditions under which PRPP accumulates in intact erythrocytes (Figure 6.1). 
Briefly, incubation of intact erythrocytes under conditions of pathophysiologically low pH 
(pH 7.0) and a high concentration of external inorganic phosphate (10 mM) leads to a rise 
in intracellular Pi. The increase in intracellular Pi at low pH is largely due to the fall in 
steady state 2,3-bisphosphoglycerate (2,3-DPG) levels induced by acidification. 
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Figure 6._1: . The erythrocyte oxypurine cycle. (a) conditions of acid pH, low Po2 , 
and high external Pi concentration. (b) conditions of neutral or alkaline pH, high Po2, and 
low external Pi concentration. DPG, 2,3-bisphosphoglycerate; Hb, hemoglobin; Hx, 
hypoxanthine: R5P, ribose-5-phosphate; X-P, phosphorylated glycolytic intermediates 
including 2,3 DPG. Reproduced from Berman et al (1988). 
The high level of intracellular Pi inhibits the activity of 5'-nucleotidase and stimulates 
PRPP synthetase activity. In the absence of any of the phosphoribosyltransferase 
substrates, PRPP will accumulate. When an excess of [ 14C] labelled hypoxanthine is 
added to the medium, hypoxanthine enters the erythrocyte and is rapidly salvaged in a 
reaction catalysed by endogenous HPRT to form [14C] IMP. Erythrocytes lack 
adenylosuccinate synthetase, an enzyme needed m the convection of 
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IMP to AMP. If conditions of extracellular low pH and high phosphate are maintained, 
the salvaged [14C] hypoxanthine will remain trapped within the erythrocyte as [14C] IMP. 
The amount of [14C] IMP formed from [14C] hypoxanthine is related in a 1: 1 stoichiometry 
to the concentration of PRPP which had previously accumulated in the intact erythrocyte. 
A preliminary study in our laboratory (P. Cole, 1988) used an assay based on these 
principles to measure the rate of accumulation of PRPP in the erythrocytes of patients 
with gout. These provisional results suggested that in 3 patients with overproducing gout, 
PRPP accumulated at an increased rate. 
The aim of the present study was twofold. Firstly, to determine whether the parameters of 
low pH and high phosphate which promote PRPP accumulation in erythrocytes in vitro 
promote PRPP accumulation in erythrocytes in vivo. Patients with physiologically high 
serum phosphate levels and low blood pH represent an in vivo model of the assay system 
and are predicted to have intrinsically higher levels of PRPP in their erythrocytes. Patients 
in chronic renal failure fulfil the criteria of low blood pH and high phosphate and were 
chosen as a group likely to have increased erythrocyte PRPP levels in vivo. Secondly, the 
methodology of the pilot study was refined and the patients noted in that study to have 
increased rates of PRPP accumulation in erythrocytes, were re-evaluated. The study was 
broadened to include a larger control group and more patients with gout were included. 
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6.2 Materials and Methods. 
6.2.1 Patient Groups. 
All patients and controls were adult males. Informed consent from each patient was 
obtained before entry into the study. Four gmups of patients were selected: normal 
controls, gouty underexcretors, possible gouty overproducers and patients with chronic 
renal failure. 
Individuals were selected as normal controls on the basis of no clinical or family history of 
gout and a normal serum urate. Patients with gout were classified as gouty 
underexcretors on the basis of clinical gout, documented hyperuricemia and a decreased 
fractional excretion of urate CF'Eur) compared to the normal control group (Calabrese et al, 
1990). Patients with clinical gout, hyperuricemia and a normal FEur were classified as 
being likely to have gout due to urate overproduction. The calculation of the FEur is 
shown below: 
FEur = U-urate x P-creatinine x 100 
P-urate x U-creatinine 
Where U-urate is urinary urate (mmol/1), P-urate is plasma urate (mmol/1), P-creatinine is 
plasma creatinine (mmol/1) and U-creatinine is urinary creatinine (mmol/1). 
Patients with chronic renal failure were on regular dialysis at the Dialysis Unit, Groote 
Schuur Hospital, Cape Town, South Africa and had no prior history of hyperuricemia or 
clinical gout. Plasma creatinine in these patients ranged from 823 µmol/1 to 1413 µmol/1 
(mean I 093 µmol/1) . All assays were performed on blood drawn before the start of a 
dialysis session. 
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6.2.2 Methods 
6.2.2.1 Determination of Plasma and Urinary Uric Acid and Creatinine. 
Plasma and urinary uric acid were determined by an automated uricase method. The pH 
of urine specimens was adjusted to pH 8 before levels of urate were estimated. Plasma 
and urinary creatinine were measured by an automated method based on the Jaffe reaction. 
Plasma inorganic phosphate was measured by the acid-molybdate method of Fiske and 
Subbarow. Whole blood pH was determined on a Radiometer blood gas and pH analyser. 
6.2.2.2 Assay of the Rate of PRPP Accumulation in Intact Erythrocytes. 
Heparinised blood (10 ml) was centrifuged at 3000g for 10 min, the huffy coat and plasma 
were removed and the erythrocytes washed twice in cold normal saline. The packed 
erythrocytes were resuspended in ice cold incubation buffer (10 mM NaH2P04, 10 mM 
glucose, 130 mM NaCl, 50 mM Hepes, pH to 7.0 with NaOH) to a haematocrit of 
approximately 30%. Duplicate tubes were incubated at 37°C. At time zero, 1 hr and 2 hr, 
300 µl of the suspension was transferred to a prewarmed microfuge tube at 37°C 
containing 100 µ1 [14C] hypoxanthine at a specific activity of 6 to 24 dpm/pmol and 
incubated for a further 5 min. The final concentration of [14C] hypoxanthine in the assay 
was 200 µM. The reaction was stopped by the addition of 400 µl ice cold 5% TCA. The 
precipitated protein was removed by centrifugation (5 min at 12000g). The supernatant 
was transferred to a clean microfuge tube and neutralised by repeated extractions with 
water saturated ether. 
The product of the reaction, [ 14C] IMP, was separated from unincorporated 
[14C] hypoxanthine by reverse phase HPLC (System Gold, Beckman Instruments, 
Fullerton, California, USA). 100 µl of the deproteinised and neutralised supernatant was 
loaded onto a Beckman Ultrasphere ODS 5 µm 25 cm reverse phase column. The column 
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was eluted with a buffer containing I mM KHP04 pH 5 .2 in 5% MeOH at a flow rate of 
1.2 ml/min. Under these isocratic conditions, IMP typically eluted at 3 .2 min, while 
hypoxanthine eluted at 5. 6 min. In initial experiments, the column eflluent corresponding 
to the IMP peak were collected in 30 sec fractions directly into scintillation vials, IO ml of 
Bionic-Fluor scintillation fluid (Packard Instrument Company, Meriden, Connecticut, 
USA) was added and radioactivity determined by liquid scintillation counting using an 
open window. Counts per minute were converted to dpm using appropriate factors to 
correct for quenching by the eluting buffer and the efficiency of the counter. In later 
experiments, a Radiomatic Flo-One Beta Series A-100 inline radiochemical detector 
(Radiomatic, Tampa, Florida, USA) equipped with a 2.5 ml flow cell was used to quantify 
radioactivity eluted from the column. Scintillant (Flo-Scint IV, Radiomatic, Tampa, 
Florida, USA) was used at a flow rate four times that of the HPLC buffer. The efficiency 
of the radiochemical detector was determined by adding a known amount of [ 14C] label to 
the scintillant as a standard and monitoring cpm during an HPLC run. This factor was 
used to convert [14C] IMP cpm to dpm. The results obtained on duplicate specimen using 
the two different radiochemical detection methods were identical. 
The conversion of [14C] hypoxanthine to [14C] IMP consumes a single molecule of PRPP. 
The rate of PRPP formation in intact erythrocytes was calculated as the difference 
between the I and 2 hr PRPP values and expressed as pmol/hr/106 red blood cells (RBC). 
Data was analysed usmg a statistical computing package, Instat V2.05a (Graphpad 
Software, San Diego, USA). 
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6.3 Results. 
6.3 .1 Development of a Standard Method for the Measurement of the Rate of 
PRPP Accumulation in Intact Erythrocytes. 
The influence of extracellular pH and inorganic phosphate on the conversion of 
[ 14C] hypoxanthine to [14C] IMP by intact erythrocytes (an indirect measure of 
intracellular PRPP levels) has been documented by Berman et al (1988). On the basis of 
this data, a pathophysiologically low pH of 7. 0 and a nonphysiologically high 
concentration of inorganic phosphate (IO mM) were chosen so as to maximise PRPP 
formation in intact red blood cells. 
The following variables were identified as potentially having an effect on the experimental 
system: 
i) The concentration of the substrate [ 14C] hypoxanthine. 
ii) The linearity of PRPP accumulation over time. 
iii) The effect of specimen age on PRPP accumulation. 
i) The concentration of the substrate [ 14C] hypoxanthine. 
The optimal concentration of the added [1 4C] hypoxanthine was determined by incubating 
red blood cells for 1 and 2 hours at pH 7.0 with 10 mM Pi in order to prime the 
erythrocytes with PRPP. [14C] Hypoxanthine was then added to the incubation medium to 
give a final concentration of between 50 and 250 µM. 
The amount of [14C] hypoxanthine converted to [14C] IMP was maximal at hypoxanthine 
concentrations above 50 µM (Figure 6.2a(i)). However, after 2 hours PRPP priming 
followed by incubation with 50 µM [14C] hypoxanthine, more than 60% of the [14C] 
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hypoxanthine had been converted to [14C] IMP (Figure 6.2a(ii)). This suggested that in 
patients with high erythrocyte PRPP levels, [1 4C] hypoxanthine could become limiting, 
which could result in an underestimation of the rate of PRPP accumulation. At a 
concentration of 100 µM [14C] hypoxanthine, approximately 30% of the label was 
converted to [ 14C] IMP in two hour primed erythrocytes. Labelled hypoxanthine at this 
concentration was used throughout this study. 
ii) Linearity of PRPP Accumulation Over Time. 
Erythrocytes were primed at low pH and high phosphate for up to 5 hours and the amount 
of PRPP determined. After a short initial lag phase, the accumulation of PRPP was 
effectively linear between 1 hour and 3 hours (Figure 6.2b). 
The difference between the 1 hr and the 2 hr PRPP levels (within the linear range of the 
assay) was used as an estimate of the rate of PRPP accumulation and the results expressed 
as pmol PRPP formed per hour per 106 erythrocytes. 
iii) The Effect of Specimen Age on PRPP Accumulation. 
The effect of specimen age on the rate of PRPP accumulation was determined by leaving 
whole blood specimens at room temperature for up to 3 hr. Levels of PRPP accumulated 
by erythrocytes prepared and assayed 3 hr after venipuncture, were approximately 50% 
less than the level of PRPP accumulated by erythrocytes prepared and assayed 
immediately after venipuncture (Figure 6.2c). 
Based on these results, the time between venipuncture and the start of the assay was 
standardised. All specimen were prepared and assayed within 1 hour of blood being 
drawn from the patient. 
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Figure 6.2: Optimisation of tbe erythrocyte PRPP accumulation assay. (a)(i) The 
effect of [14C] hypoxanthine concentration on [14C] IMP formation after either 1 hr or 2 hr 
PRPP priming . (ii) Percent conversion of [14C] hypoxanthine to [14C] IMP after either 
1 hr or 2 hr PRPP priming. (b) The linearity of PRPP accumulation over time. ( c) The 
effect of specimen age on PRPP accumulation. 
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6.3.2 PRPP Accumulation in Patients with Chronic Renal Failure. 
The elevated levels of plasma phosphate and mild acidosis associated with chronic renal 
failure, represent a model to test the validity of the hypothesis that PRPP could 
accumulate in erythrocytes in vivo under conditions of physiologically high phosphate and 
low pH. The initial PRPP level measured in erythrocytes at time O hr is an estimate of the 
in vivo PRPP levels. 
The initial erythrocyte PRPP concentration was measured and correlated with plasma 
phosphate concentration or blood pH (Figure 6.3). Erythrocyte PRPP levels showed an 
increasing trend (r=0.81) with increasing plasma phosphate. Only two of the patients had 
plasma phosphate levels within the reference range of 0.96 to 1.45 mM, with the highest 
level of plasma phosphate recorded at 2.90 mM. 
The relationship between blood pH and erythrocyte PRPP levels showed a similar but 
negative correlation (r=-0.85). Higher erythrocyte PRPP levels occurred in patients with 
the lowest blood pH. However, blood pH values of only three patients fell outside the 
reference range of pH 7.35 to 7.45. 
The positive relationship between high initial erythrocyte PRPP levels and high plasma 
phosphate and the negative correlation of initial PRPP levels with blood pH, thus appear 
to support the prediction that PRPP will accumulate in vivo under physiological conditions 
of low pH and high phosphate. However, as a group, the PRPP content of erythrocytes of 
the chronic renal failure patients at time zero were not significantly different from controls 
(two sided t-test). The PRPP accumulation rate in erythrocytes of the eight patients in 
chronic renal failure are shown in Figure 6.4 and were not significantly different from the 
control group (two sided t-test). 
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Figure 6.3: Correlation of initial erythrocyte PRPP levels with plasma Pi or whole 
blood pH in eight patients with chronic renal failure. (a) Initial levels of erythrocyte 
PRPP were positively correlated with plasma inorganic phosphate. (b) Erythrocyte PRPP 
levels were negatively correlated with whole blood pH. 
6.3.3. PRPP Accumulation in Erythrocytes of Patients with Gout. 
The mean plasma urate concentration and the FEur of the control and gouty underexcretor 
groups are shown in Table 6.1. The concentration of PRPP in erythrocytes at time zero 
and the rate of accumulation ofPRPP for each group are shown in the lower part of Table 
6.1. The rate of PRPP accumulation of patients in each group are shown graphically in 
Figure 6.4. 
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Table 6.1: A comparison between plasma urate (P-urate), fractional urate 
excretion (FEur), initial erythrocyte PRPP concentration and the rate 
of erythrocyte PRPP accumulation of controls and patients with gout 
due to urate underexcretion. Values are the mean+/-1SD, with the 
range shown in parenthesis. Patients on treatment for gout were 
excluded from the mean and range. 
Normal controls Underexcretors 
P-Urate 0.28+/-0.02 *0.45+/-0.10 
(mmol/1) (0.19-0.36) (0.32-0.62) 
n=22 n=13 
FEur 8.33+/-3 .35 **4.06+/-1.46 
(%) (4.20 to 13 .50) (2.00 to 5.60) 
n=lO n=8 
Initial 0.58+/-0.50 0.63+/-0.43 
PRPP (0.05-1.65) (0.05-1.30) 
I ( pmol/106 RBC) n=22 n=13 
PRPPRate 5.48+/-1.15 ***4.34+/-1. 71 
(pmol/hr/106 RBC) (3.40 to 8.30) (2.00 to 7.67) 
n=22 n=13 
n: number of individuals. 
* Serum urate values of the urate underexcretion group was significantly different (higher) than the 
control group (two sided t-test, p<0.001). 
** FEur ofunderexcretors was significantly different (lower) than the normal control group (two sided t-
test, p<0.01). 
*** The rate of PRPP accumulation in the urate underexcretion group was significantly different (fower) 
than the control group (two sided t-test, p<0.05). 
There was no significant difference in the mean of the initial PRPP level in erythrocytes of 
the control and underexcretor groups. There was however, a significant difference in the 
rate of PRPP accumulation between the two groups, with the underexcretor group being 
significantly lower than the control group (p<0.05, two sided t-test). 
The slopes of linear regression lines fitted to the patient data for FEur versus initial 
concentration of PRPP in erythrocytes, were not significantly different from zero for either 
the control or underexcretor group. This suggests that there is no correlation between the 
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fractional excretion of urate and erythrocyte PRPP levels in either group. Similar results 
were obtained when FEur was plotted against the erythrocyte PRPP accumulation rate, 
with no correlation found between measures of urate excretion and the rate of PRPP 
accumulation in either of the two groups. 
Four patients were provisionally identified as gouty overproducers and are listed in Table 
6.2. One patient, KAT, was identified in the present study, while three other patients were 
originally identified in the pilot study (Cole, 1988) and were recalled for the present study. 
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Figure 6.4: The rate of erythrocyte PRPP accumulation in controls, orate 
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Table 6.2: 
Patient 
KAT 
JT* 
NL* 
EL* 
Patients identified as possible orate overproducers. The values 
determined in the pilot study are shown in parentheses. 
P-urate U-urate U-creat. F£ur 
mmol/1 mmol/1 mmol/1 % 
0.53 3.7 11.6 7.64 
2.7 6.91 
3.7 8.39 
16.2 15.2 
12.02 
5.00 
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Abbreviations: plasma urate (P-urate), urinary urate (U-urate), plasma creatinine (P-creat.) urinary 
creatinine (U-creat.), fractional urate excretion CFEur). 
* patients identified as urate overproducers with increased rates of erythrocyte PRPP accumulation in the 
pilot study. 
NL was on allopurinol during current study. 
El was on oestrogen therapy for cancer of the prostrate, no specific treatment for gout. 
Patient NL was on allopurinol treatment during the present study, but was not on 
treatment during the pilot study. On the basis of a FEur of 15.2% determined in the pilot 
study, this patient was classified as a urate overproducer. Patient IT is unlikely to be an 
underexcretor with a FEur of 6. 91 % determined in this study and 8 .3 9°/o determined in the 
pilot study. The patient is not on treatment and is well controlled, with no attacks of gout 
in the last 6 years. Patient EL is an elderly male with cancer of the prostrate for which he 
is on oestrogen therapy. Gout in this patient is of three years duration and could be 
secondary to his cancer. The FEur of 5.00% determined in the pilot study has more than 
doubled in the present study (12.02%). 
The initial erythrocyte PRPP concentration and the rate of PRPP accumulation for the 
four possible gouty overproducers KAT, IT, NL and EL are shown in Table 6.3 and in 
Figure 6.4. 
Table 6.3: 
Patient 
KAT 
JT 
NL 
EL 
The initial erythrocyte PRPP concentration and rate of erythrocyte 
PRPP accumulation in patients with possible overproducing gout. 
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The rate of erythrocyte PRPP accumulation determined in the pilot study is 
shown in parentheses. 
Initial PRPP PRPPRate 
(pmol/106 RBC) (pmol/hr/106 RBC) 
0.71 4.06 
0.33 8.21 (12.59) 
0.33 7.10 (10.33) 
0.51 12.52 (15.10) 
The rate ofPRPP accumulation (4.06 pmol/hr/106 RBC) measured in erythrocytes of KAT 
fell below the mean of the control range. The rate of PRPP accumulation determined in 
the pilot study for IT, NL and EL, are all increased by a similar margin compared to the 
rate of PRPP accumulation determined in this study. This is probably due to differences in 
the methodology between the two studies, notably the higher [14C] hypoxanthine 
concentration used in this study (100 µM compared to 60 µMused in the pilot study). 
Nevertheless, the rate of PRPP accumulation of 8.21 and 7.10 pmol/hr/106 RBC 
determined for IT and NL respectively in this study, are at the upper end of the control 
range and are greater than 1 SD from the control mean. The rate of erythrocyte PRPP 
accumulation of 12.52 pmol/hr/106 RBC determined in EL is double the control mean and 
above the upper limit of the control range. 
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6.4 Discussion. 
Erythrocytes lack the capacity to synthesize purines de novo and represent a simple system 
for the study of components of the purine metabolic pathways. A generalised defect in 
purine metabolism which is reflected in erythrocytes may be easier to recognise because of 
the absence of complicating components of a metabolic pathway. The absence of a de 
novo purine synthetic pathway however, potentially limits the usefulness of erythrocytes as 
a model system. Any defect in purine de novo synthesis which leads to purine 
overproduction, with the exception of defects in PRPP synthetase, cannot be studied. 
PRPP synthetase is active in the mature erythrocyte and the erythrocyte represents a 
convenient, easily manipulated model for the study of this highly regulated enzyme. 
Erythrocytes also represent a significant pool of purines within the body and it is possible 
that an intrinsic defect in erythrocyte purine metabolism may well play a role in the 
pathogenesis of overproducing gout. 
The increased levels of IMP together with normal levels of PRPP reported by Mansell et al 
(1981) in patients with chronic renal failure, are of particular interest in view of the results 
of the present study. In the present study, erythrocyte PRPP levels in patients with 
chronic renal failure were also found to be within the control range. However, PRPP 
levels appeared to be inversely correlated with blood pH and positively correlated to 
plasma phosphate levels. No increase in the rate of erythrocyte PRPP accumulation could 
be detected. These findings are consistent with those of Mansell et al (1988) who 
reported normal activity of PRPP synthetase and normal levels of PRPP in the 
erythrocytes of patients with chronic renal failure. 
Berman et al (1988) in their description of the erythrocyte oxypurine cycle, speculated that 
the reason for the increased levels of erythrocyte purine nucleotides reported in patients 
with chronic renal failure lies in the interplay between intracellular pH, phosphate and 2,3-
DPG. Under the conditions of low blood pH and high Pi characteristic of patients in 
chronic renal failure, the entry of Pi into the cell is enhanced. At low pH, the 
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concentration of free 2,3-DPG is reduced and Pi derived from the degradation of 2,3-DPG 
adds to the increased levels of Pi in the erythrocyte. The net conversion of 2,3-DPG to 
lactate results in the conversion of 2 ADP molecules to 2 ATP molecules. While the 
production of ATP from 2,3-DPG may contribute to the increase in ATP levels noted in 
the erythrocytes of chronic renal failure patients, this will not lead to an increase in total 
adenine nucleotide levels. The inhibitory effect of high intracellular levels of free 
phosphate and the decreased stimulatory effect of a reduced 2,3-DPG level on 5'-
nucleotidase activity (Bontemps, 1988) are likely to contribute to the maintenance of the 
increased intracellular nucleotide pool. Partial inhibition of 5'-nucleotidases may result in 
a decreased flux through the first step of the purine nucleotide degradation pathways and 
despite the increased activities of PNP and adenosine deaminase reported by Mansell et al 
(1981), the rate of endogenous hypoxanthine production may be reduced. Erythrocyte 
HPRT activity in chronic renal failure is increased (Mansell et al, 1981) and combined with 
a possibly decreased flux of purine nucleotides to hypoxanthine, may result in enhanced 
salvage of hypoxanthine leading to the notable increase in IMP in these patients. IMP is 
trapped in the "Berman cycle" and should not contribute to an increase in adenine 
nucleotide levels. 
The normal erythrocyte PRPP levels noted in this study and by Mansell et al ( 1981) are an 
anomaly. Under conditions of low pH and high phosphate, PRPP levels are expected to 
increase (Berman et al, 1988). However, the modulation of intracellular erythrocyte Pi 
and hydrogen ion concentration in vivo is dependent on a myriad of factors and may not 
exactly parallel the in vitro model. In vivo, the salvage of endogenous hypoxanthine and 
other phosphoribosyltransferase substrates are continuously depleting PRPP. In addition, 
inhibition of 5'-nucleotidase may not be complete in the range of plasma Pi concentrations 
present in chronic renal failure. It is likely that there is some cycling between 
hypoxanthine and IMP within the erythrocyte. This cycling would consume PRPP in the 
salvage reaction and could account for the normal levels of PRPP described in the 
erythrocyte of renal failure patients. 
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In summary, although erythrocyte levels of PRPP in patients with chronic renal failure are 
within the control range, there does appear to be a correlation between blood pH or Pi 
concentration and erythrocyte PRPP levels in vivo. 
There was no significant difference in the time zero erythrocyte PRPP levels between 
controls and gouty underexcretors. An unexpected finding was a significant difference in 
the rate of PRPP accumulation between the control group and the gouty underexcretor 
group. The reason why erythrocytes ofunderexcretors should show a lower rate of PRPP 
accumulation than controls, is difficult to explain. It is possible that the difference 
between the two groups is a consequence of the small underexcretor sample size. If a 
significant difference between the two groups still persists with an increased underexcretor 
sample size, this may be evidence of a generalised defect of anion transport across 
membranes and the rate and regulation of Pi transport into the erythrocyte would warrant 
further investigation. 
The identification of patients with purine overproduction was problematical. All of the 
patients entered into the study had not been previously evaluated by the attending 
clinicians as to whether they were overproducers or underexcretors. This strategy is based 
on the belief, supported in the literature (Peters and Ball, 1992), that in the majority of 
adult patients with gout, such a classification would not influence the treatment decisions. 
Emmerson ( 1991) recommended the following protocol in order to distinguish 
underexcretors from overproducers. Urinary urate is determined on two consecutive 24-
hour urine collections with the patient on a normal diet. The patient is then placed on a 
seven day purine restricted diet and a further two 24-hour urine specimens are collected 
on days 5 and 6. On a purine restricted diet, underexcretors excrete less than 2 mmol of 
uric acid in 24 hours, while overproducers excrete more than 4. 5 mmol/24 hours. In 
patients with hyperuricemia due to excessive purine consumption, dietary purine 
restrictions should lead to a fall in serum urate of at least 0,06 mmol/l and a fall of at least 
1.2 mmol in 24 hour urinary urate excretion. We believed that the restrictions of this 
protocol would discourage patients from entering the study and in addition, patient 
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adherence to the protocol would be difficult to control outside of the hospital 
environment. 
Our strategy was therefore to base initial classification of hyperuricemic patients on 
estimates of urate clearance relative to creatinine clearance determined from untimed urine 
specimen (Calabrese et al, 1990). 
Four patients were classified as gouty overproducers on this basis and were shown to have 
a FEur within the control range. The patients were not on a purine restricted diet and the 
estimations of urate excretion should be interpreted with this fact in mind. The initial 
PRPP erythrocyte concentrations in all four patients were within the normal range. The 
rate of PRPP accumulation in one patient fell within I SD of the control mean, while two 
patients fell within the upper limits of the control range. The highest rate of PRPP 
accumulation, above the control range, was found in EL. This 88 year old patient has had 
gout for three years and is on oestrogen treatment for cancer of the prostrate. There is no 
evidence of widespread malignancy in the patient and cancer as a cause of gout in EL is 
possible, but seems unlikely. 
Although the presentation of gout in EL is not typical of primary gout, the increased rate 
of PRPP accumulation observed in this patient is a phenomenon which warrants further 
attention. The effect of oestrogen therapy on PRPP metabolism is not known. However, 
it is known that females have a higher FEur (until the menopause) than males. The increase 
in the FEur of EL in the current study may be due to the effects of oestrogen therapy on 
urate excretion. 
More urate overproducing patients will need to be identified to determine whether there is 
a statistical difference in the rate of PRPP accumulation between controls and urate 
overproducers. 
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The PRPP accumulation assay relies on endogenous erythrocyte HPRT activity to convert 
[14C] hypoxanthine to [14C] IMP. Unfortunately, no patients with partial HPRT deficiency 
were available to test the effect of HPRT deficiency on the erythrocyte PRPP 
accumulation assay. A deficiency of HPRT could result in a lower rate of PRPP 
consumption in the salvage reaction and would appear in our assay, to represent a marked 
decrease in the rate of PRPP accumulation. Conversely, PRPP synthetase overactivity 
should lead to increased rates of PRPP synthesis in vivo, which would be reflected as an 
increased PRPP level at time zero and an increased rate of PRPP accumulation in vitro. 
The metabolic basis of the erythrocyte PRPP assay suggests that the assay has validity as a 
screening method for defects in both HPR T and PRPP synthetase. The assay may also 
prove useful in screening primary urate overproducers for these two specific enzyme 
defects. 
Although only four candidate patients with overproducing gout have so far been 
identified, a phenomenon of an increased rate of PRPP accumulation in the erythrocytes of 
three of these patients has been demonstrated. In the group of urate underexcretors, an 
unexpected, statistically significant decrease in the mean rate of erythrocyte PRPP 
accumulation was found. The results of the study are sufficiently provocative to warrant 
continuation and expansion of the study. Studies on phosphate and acid/base transport 
across the erythrocyte and other cell membranes, could probe for logical mechanisms 
which might explain the basis of both urate overproducing and underexcreting gout. 
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